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Summary 
I 
Summary 
Toll-like receptors (TLRs) belong to the pattern-recognition receptors (PRR) expressed 
mainly by cells of the innate immune system and recognize conserved structures derived 
from microbes. Stimulation of TLRs by their respective TLR ligands induces the 
production of proinflammatory cytokines, chemokines, and maturation of dendritic cells 
(DCs), which plays a crucial role in the induction of adaptive immunity. Strinkingly, we 
and others have shown that the systemic exposure to TLR ligands suppresses the 
generation of adaptive T cell immunity towards subsequent infections. Our group has 
recently observed that the systemic injection of single-stranded RNA (ssRNA), which is 
recognized by endosomal TLR7, inhibited antigen-specific cytotoxic T lymphocyte (CTL) 
responses in the spleen in a type I interferon (IFN) dependent manner. Whereas the 
immunostimulatory effects of TLR stimulation and type I IFNs are well described, it 
remains poorly understood how the suppression of adaptive immune responses is mediated 
by TLR ligands and type I IFN, respectively. In this thesis, the underlying mechanisms of 
ssRNA- and type I IFN-mediated inhibition of adaptive immunity were investigated.  
The results presented demonstrate that the systemic administration of ssRNA leads to the 
suppression of CTL responses against subsequent infections with viral and bacterial 
pathogens, which was attributed to an impaired expansion and activation of antigen-
specific CD8 T cells. Furthermore, we detected that the proliferation and cytokine 
production of antigen-specific CD4 T cells was impeded, which was associated with a 
downregulation in MHC class II molecule expression on ssRNA-preactivated splenic DCs. 
These results clearly indicate that a systemic injection of ssRNA inhibited the generation 
of CD4 T cell help, which contributed to the suppression of antigen-specific 
CTL responses. This interpretation was supported by the observation that ssRNA-induced 
CTL suppression was circumvented in the presence of effector or memory antigen-specific 
CD4 T helper cells. The generation of T cell immunity was not impaired if ssRNA was 
targeted to the cytoplasm by complexation with the carrier in vivo-jetPEI
TM
, thereby 
avoiding the recognition by TLR7. TLR7-mediated recognition of systemic ssRNA 
stimulated the production of type I IFNs, which were essential in ssRNA-induced 
CTL suppression. We identified plasmacytoid DCs (pDCs) to respond immediately to 
ssRNA stimulation by releasing early type I IFNs. Based on our experiments in LysM-
specific IFNAR1 deficient, STAT1 deficient, and IRF7 deficient mice, we assume that 
ssRNA-induced early type I IFNs are amplified via the JAK-STAT pathway in splenic 
macrophages. The resulting secretion of substantial amounts of IFN affected splenic DCs, 
which were impaired in their ability to cross-prime antigen-specific CD8 T cells, thus 
contributing to the lack of antigen-specific cytotoxicity. 
A clinical relevance of RNA-mediated immune suppression was shown in a combinatorial 
anti-tumor therapy model, mimicking small-interfering RNA (siRNA) application and 
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induction of tumor-specific CTL responses. We could demonstrate that, depending on the 
carrier used, systemic in vivo siRNA application interfered with an adenoviral-based 
melanoma vaccination due to the lack of a tumor-specific CTL response. 
Moreover, we revealed that CTL suppression was not restricted to the application of 
synthetic RNA oligoribonucleotides. Infection with an Influenza virus impeded the 
generation of the CTL response against a subsequent adenovirus infection, which was 
ascribed to the production of type I IFNs. This observation implies that type I IFN-
triggering viruses in general might inhibit adaptive immune responses in a similar fashion 
as we observed with systemic ssRNA.  
Taken together, our results point out that ssRNA- and virus-induced type I IFNs cannot 
only stimulate, but also inhibit antigen-specific T cell responses in the spleen. Furthermore, 
we indicate that a therapeutic siRNA application in vivo, e.g. in tumor therapies, might lead 
to undesired off-target effects, such as immune suppression, due to the recognition of 
siRNA by nucleic acid receptors such as TLR7.  
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Zusammenfassung 
Toll-like Rezeptoren (TLRs) gehören zu den Muster-Erkennungsrezeptoren (Pattern-
recognition receptors, PRR), welche hauptsächlich auf den Zellen des innaten 
Immunsystems exprimiert werden. Sie dienen der Erkennung von bestimmten 
konservierten Strukturen, die ausschließlich auf oder in Pathogenen vorkommen. Die 
Stimulation von TLRs durch Bindung ihrer spezifischen TLR Liganden induziert die 
Produktion von proinflammatorischen Zytokinen, Chemokinen und Reifung von 
dendritischen Zellen (DCs). Dieser Prozess spielt eine entscheidende Rolle bei der 
Aktivierung der adaptiven Immunität. Jedoch haben wir und andere Gruppen gezeigt, dass 
die systemische Gabe von TLR Liganden nachfolgende T Zell Antworten supprimieren 
kann. Wir haben kürzlich beobachtet, dass die systemische Applikation von 
einzelsträngiger RNA (ssRNA), welche vom endosomalen TLR7 erkannt wird, antigen-
spezifische zytotoxische T Lymphozyten (ZTL) Antworten in der Milz inhibieren. Diese 
Hemmung der ZTL Antwort war von der Induktion von Typ I Interferonen (IFN) 
abhängig. Während die immunstimulatorischen Eigenschaften von TLR Liganden und 
Typ I IFN gut beschrieben sind, ist es noch unzureichend verstanden, wie TLR Liganden 
beziehungsweise Typ I IFN die Suppression von adaptiven Immunantworten vermitteln. 
Ziel dieser Arbeit war es, die zugrunde liegenden Mechanismen der ssRNA- und 
Typ I IFN-induzierten Hemmung der adaptiven Immunität zu untersuchen.  
Die Ergebnisse dieser Arbeit zeigen, dass eine systemische Gabe von ssRNA zu einer 
Suppression der ZTL Antworten führt, die gegen nachfolgende Infektionen mit viralen und 
bakteriellen Pathogenen gerichtet sind. Die fehlende antigen-spezifische zytotoxische 
Aktivität konnte auf eine gestörte Expansion und Aktivierung von antigen-spezifischen 
CD8 T Zellen zurückgeführt werden. Des Weiteren konnten wir aufzeigen, dass die 
antigen-spezifischen CD4 T Zellen hinsichtlich ihrer Proliferation und Zytokinproduktion 
beeinträchtigt waren, was mit einer verringerten Expression von MHC Klasse II Molekülen 
auf ssRNA-aktivierten Milz-DCs verbunden war. Diese Daten weisen deutlich darauf hin, 
dass die vorherige Gabe von ssRNA die Generierung der CD4 T Zell Hilfe verhindert, was 
zur Suppression einer antigen-spezifischen ZTL Antwort beiträgt. Die T Zell Antworten 
waren nicht beeinträchtigt, wenn die ssRNA durch Komplexierung in in vivo-jetPEI
TM
 in 
das Zytoplasma gelenkt wurde, wodurch die Erkennung durch TLR7 umgangen wurde. 
Die TLR7-vermittelte Erkennung führte zur Produktion von Typ I IFN, die eine essentielle 
Rolle in der ssRNA-induzierten Suppression von ZTL Antworten spielten. Wir zeigten, 
dass plasmazytoide dendritische Zellen (pDCs) unmittelbar auf die Stimulation mit ssRNA 
reagierten, indem sie „frühes“ Typ I IFN ausschütteten. Basierend auf unseren 
Experimenten in IFNAR1 defizienten, STAT1 defizienten und IRF7 defizienten Mäusen 
nehmen wir an, dass das ssRNA-induzierte „frühe“ Typ I IFN durch den JAK-STAT 
Signalweg in Milz-Makrophagen amplifiziert wird. Die daraus resultieren Mengen an 
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sezerniertem IFN beeinträchtigen Milz-DCs in ihrer Funktion, antigen-spezifische 
CD8 T Zellen zu aktivieren (cross-priming), was letztendlich zum Fehlen einer antigen-
spezifischen ZTL Antwort beiträgt.  
Eine klinische Bedeutung der RNA-vermittelten Immunsuppression wurde anhand eines 
Modells zur kombinatorischen Anti-Tumor Therapie gezeigt, in dem wir die Verwendung 
von „small-interfering RNA“ (siRNA) und die Induktion einer tumor-spezifischen 
ZTL Antwort nachahmten. Wir konnten zeigen, dass die systemische in vivo Applikation 
von siRNA, abhängig vom verwendeten Komplexierungsreagenz, eine Adenovirus-
basierte Tumorvakzinierung beeinträchtigte, indem die Induktion einer tumor-spezifischen 
ZTL Antwort verhindert wurde.  
Des Weiteren konnten wir aufzeigen, dass die Suppression einer ZTL Antwort nicht nur 
durch die systemische Gabe von synthetischen RNA Oligonukleotiden erfolgt. Vielmehr 
führte auch eine Infektion mit Influenza Virus dazu, dass die Generierung einer 
ZTL Antwort gegen eine nachfolgende Adenovirusinfektion aufgrund der Produktion von 
Typ I IFN verhindert wurde. Diese Beobachtung weist darauf hin, dass Typ I IFN-
induzierende Viren eine adaptive Immunantwort in einer ähnlichen Art und Weise, wie wir 
sie für systemische ssRNA beobachtet haben, unterdrücken können. 
Zusammenfassend konnte in dieser Arbeit gezeigt werden, dass ssRNA- als auch Virus-
induziertes Typ I IFN nicht nur antigen-spezifische T Zellantworten in der Milz 
stimulieren, sondern auch hemmen kann. Darüber hinaus weisen wir darauf hin, dass eine 
systemische in vivo Behandlung mit siRNA, z.B. in Tumortherapien, zu ungewünschten 
„Off-target“ Effekten, wie Immunsuppression, führen kann. Aufgrund dieser Daten ist es 
unerlässlich, die therapeutische Anwendung von siRNA sorgfältig zu überdenken, um 
unerwünschte Nebenwirkungen zu vermeiden.  
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1 Introduction 
1.1 The immune system 
 
Vertebrates are constantly threatened by the invasion of microorganisms, such as viruses, 
bacteria, or parasites and have evolved multiple mechanisms of immune defense, which 
ensure the elimination of infective pathogens in the body. The mammalian immune system 
is comprised of two branches:  
(1) The innate immune system is the first line of host defense against intruding pathogens. 
(2) The aquired (adaptive) immune system, which is characterized by high specificity, is 
involved in the elimination of pathogens in the late phase of infection and generation of 
immunological memory.   
 
 
1.1.1 The innate immune system 
 
The innate immune system is an evolutionary conserved (Hoffmann et al., 1999) and 
ancient form of host defense that serves to limit infection in the first minutes to hours after 
exposure to microorganisms. The major components of the innate immune system include: 
(1)  Physical epithelial barriers, such as the skin as well as the mucosal epithelia of the 
respiratory, gastrointestinal, and reproductive tracts, prevent the intrusion of 
microbes into the organism. 
(2)  Phagocytes, such as macrophages and neutrophils, ingest and eliminate microbes 
from the blood or tissue. 
(3)  Soluble molecules, such as antimicrobial peptides (e.g. defensins), complement, 
acute-phase proteins, chemokines, and cytokines are released by a variety of cells 
and contribute to innate immune protection as well as initiation of adaptive 
immunity.   
 
Central to host protection – according to the hypothesis postulated by Charles Janeway in 
1989 - is the ability to discriminate between “noninfectious self” and “infectious nonself” 
in order to initiate appropriate defense responses (Janeway, 1989, 1992; Medzhitov and 
Janeway, 2002). The innate immune system recognizes microorganisms via a limited 
number of germline-encoded, nonclonal, and broadly expressed pattern-recognition 
receptors (PRRs). PRRs sense conserved microbial pathogen-associated molecular patterns 
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(PAMPs), which are unique to microbes and absent from the host. Furthermore, PAMPs 
are often essential for the survival and pathogenicity of the microorganism, thus limiting 
the ability of the microorganism to evade innate immune recognition through mutation of 
these molecules (Akira et al., 2006; Janeway and Medzhitov, 2002; Medzhitov, 2007; 
Medzhitov and Janeway, 2000; Medzhitov and Janeway, 1997, 2002; Palm and Medzhitov, 
2009). Stimulation of PRRs, mainly expressed on professional antigen-presenting cells 
(APCs), results in APC activation, which subsequently leads to T cell priming and 
initiation of acquired immunity. Critical mediators of this process are dendritic cells (DCs), 
which are specialized in their function to translate innate recognition into adaptive 
immunity (Banchereau and Steinman, 1998; Iwasaki and Medzhitov, 2004; Reis e Sousa, 
2001, 2004). Thus, the innate and adaptive immune systems do not act independently, but 
these two branches interact at several points to ensure an optimal protection of the host.  
 
 
1.1.2 The adaptive immune system 
 
The adaptive immune response is divided into a B lymphocyte-mediated humoral and a 
T lymphocyte-mediated cellular immune response. The main distinction between the 
innate and adaptive immune system lies in the mechanisms and receptors used for immune 
recognition. The T cell receptor (TCR) and the B cell receptor (BCR) are not encoded in 
the germline but are generated somatically during the development of T and B cells. This 
process, which is called somatic recombination, is characterized by the rearrangement of 
genes encoding for the receptor, which finally endows every cell with a structurally unique 
receptor. In that way, an extremely diverse repertoire of receptors is provided, which 
allows the recognition of a nearly infinite number of antigens (Goldrath and Bevan, 1999; 
Medzhitov and Janeway, 2000; Thompson, 1995). Extracellular pathogens and their toxins 
as well as soluble proteins are targets of the humoral immune response mediated by 
antibodies, the secreted form of the BCR. In contrast, infections with intracellular 
pathogens are cleared by T cells, which are the mediators of the cell-mediated immune 
response. Different from the BCR, which recognizes foreign antigens as such, the TCR 
only recognizes processed antigenic peptides that are presented on major 
histocompatibility molecules (MHC) expressed by APCs. Upon activation, 
B and T lymphocytes proliferate and differentiate into effector cells, which clear the 
present infection. Importantly, the adaptive immune response is involved in the generation 
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of long-lived immunological memory, which ensures an immediate and strong antigen-
specific immune response upon re-encounter with the pathogen.  
However, cells of the adaptive immune system cannot reliably discriminate between 
infectious microorganisms and innocuous environmental antigens or self-antigens due to 
their random receptor specificities. Activation of the adaptive immune system can be 
deleterious to the host when antigens are self or environmental antigens, leading to 
autoimmune diseases and allergies. Therefore, adaptive immune responses must be 
educated and tightly controlled by the innate immune system, which is able to sense 
intruding microbes via the detection of PAMPs by PRRs expressed on APCs. In that way, 
an adaptive immune response is only initiated in case of a pathogenic infection (Medzhitov 
and Janeway, 2000; Medzhitov and Janeway, 1998; Palm and Medzhitov, 2009).  
 
 
1.2 Pathogen recognition via pattern-recognition receptors 
 
The innate immune system uses a variety of pattern-recognition receptors (PRRs), which 
are specialized to detect conserved structures of pathogens. PRR-expressing cells are 
primarily professional APCs, such as DCs, macrophages, and B cells. Upon stimulation of 
the respective PRR, APCs mature and immediately perform their effector functions, 
namely secretion of pro-inflammatory cytokines and chemokines, increased expression of 
surface molecules as well as activation of adaptive immune response. PRRs are expressed 
on the cell surface, in intracellular compartments, or secreted into the blood stream and 
tissue fluids. Secreted PRRs function as opsonins by binding microbial cell walls and 
flagging them for recognition by the complement system and phagocytes (Janeway and 
Medzhitov, 2002; Medzhitov and Janeway, 2000). The best-characterized secreted form of 
PRRs is the mannan-binding lectin, which binds microbial carbohydrates to initiate the 
lectin-pathway of the complement cascade (Epstein et al., 1996; Fraser et al., 1998). 
Endocytic PRRs expressed on the cell surface are involved in the uptake and delivery of 
the pathogen into the lysosome. Examples of endocytic PRRs are the mannose receptor and 
the scavenger receptor, both expressed by macrophages, which are essential for the 
clearance of bacteria from the circulation (Fraser et al., 1998; Pearson, 1996; Thomas et 
al., 2000). Intracellular PRRs are present in endosomal compartments and the cytoplasm. 
Examples of intracellular PRRs are the retinoic acid-inducible gene I (RIG-I) and the 
melanoma differentiation-associated gene 5 (MDA5). Both are expressed in the cytoplasm 
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and are specialized for the recognition of double-stranded RNA viruses (Kato et al., 2006; 
Yoneyama et al., 2004). Intracellular bacteria can be detected by the nucleotide-binding 
oligomerization domains (Nod1, Nod2), which sense bacterial cell wall components (Fritz 
et al., 2007; Kaparakis et al., 2007; van Beelen et al., 2007). The most familiar PRRs are 
the family of Toll-like receptors (TLRs), which play an essential role in the activation of 
host immunity. 
 
 
1.2.1 Toll-like receptors 
 
TLRs are evolutionary conserved from the worm Caenorhabditis elegans to mammals 
(Akira and Takeda, 2004; Akira et al., 2006; Janeway and Medzhitov, 2002). Toll, the 
founding member of the TLR familiy, was initially identified as a component of a 
signaling pathway that controls dorsoventral polarity in Drosophila embryos (Hashimoto et 
al., 1988). Later studies performed in Toll-deficient mutants demonstrated that Toll is 
critically involed in antifungal responses of flies (Lemaitre et al., 1996). TLRs are 
type I membrane glycoproteins with a trimodular structure, which are characterized by an 
extracellular domain containing varying numbers of leucine-rich-repeat motifs that are 
responsible for the detection of PAMPs and a cytoplasmic domain homologous to the 
cytoplasmic region of the IL-1 receptor, known as the Toll/IL-1 receptor (TIR) domain. 
This intracellular domain is required for the interaction and recruitment of various adaptor 
molecules to activate the downstream signaling pathway (Kawai and Akira, 2007; Kumar 
et al., 2009). TLRs are expressed on various immune cells, including DCs, macrophages, 
and B cells. But expression can vary depending on the activation status or the cell subset. 
TLR expression has been even identified on non-immune cells, such as fibroblasts and 
epithelial cells (Akira et al., 2006; Iwasaki and Medzhitov, 2004). To date, 11 TLRs in 
humans and 13 TLRs in mice have been identified, with each receptor recognizing distinct 
PAMPs derived from various pathogens, including bacteria, viruses, protozoa, and fungi. 
TLRs are expressed in distinct cellular compartments: TLR1, TLR2, TLR4, TLR5, TLR6, 
and TLR11 (only found in mice) are expressed on the cell surface, whereas TLR3, TLR7, 
TLR8, and TLR9 are located in the endosome (Figure 1.1).  
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1.2.2 Toll-like receptor ligands 
 
TLRs can be classified into several groups based on the types of PAMPs - also known as 
TLR ligands - they recognize (Figure 1.1).  
TLRs sense mainly components of the bacterial cell wall and nucleic acids expressed by 
microbes. They dimerize to homo- or heterodimers upon ligation. TLR4, together with its 
coreceptors MD-2 and CD14, recognizes lipopolysaccharide (LPS) from gram-negative 
bacteria (Lien et al., 2000; Poltorak et al., 1998). TLR2 forms heterodimers with TLR1, 
TLR6, and non-TLRs such as CD36 to discriminate a wide variety of TLR ligands, 
including peptidoglycan, lipopeptides, and lipoproteins of gram-positive bacteria, 
mycoplasma lipopeptides and fungal zymosan. In particular, TLR1/2 and TLR2/6 are able 
to discriminate triacyl- and diacyl-lipopeptide, respectively (Akira et al., 2006). Flagellin 
from flagellated bacteria is recognized by TLR5 (Hayashi et al., 2001), whereas mouse 
TLR11 senses yet unknown structures of uropathogenic bacteria (Zhang et al., 2004) and 
profilin-like protein of the protozoan parasite Toxoplasma gondii (Yarovinsky et al., 2005).  
 
 
Figure 1.1   Toll-like receptors and their ligands. 
Toll-like receptors (TLRs) are expressed on the cell surface or in intracellular compartments, such 
as the endosome. TLRs are specialized to recognize distinct conserved pathogen-associated 
molecular patterns (PAMPs), which are also known as TLR ligands. Upon TLR stimulation, 
intracellular adaptor molecules are recruited and intracellular signaling pathways are initiated that 
activate NFB and IRF dependent target genes resulting in the expression of proinflammatory 
cytokines and type I interferons (IFN). 
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Intracellular TLRs, expressed in the endosome, are involved in the recognition of bacterial- 
and viral-derived nucleic acids. TLR3 recognizes double-stranded RNA (dsRNA), which is 
generated during replication of many viruses. PolyI:C is a synthtetic ligand of TLR3 
(Alexopoulou et al., 2001). TLR7 senses synthetic imidazoquinoline-like molecules, 
guanosine analogues such as loxoribine, single-stranded RNA (ssRNA), and small 
interfering RNA (siRNA) (Diebold et al., 2004; Heil et al., 2004; Hornung et al., 2005). 
Human TLR8, with highest homology to TLR7, participates in the detection of 
imidazoquinolines and ssRNA, whereas in mice the function and ligands of TLR8 remain 
elusive. TLR9 is responsible for the recognition of CpG-DNA motifs present in bacterial 
and viral genomes (Hemmi et al., 2000). Furthermore, it was shown to sense non-nucleic 
acid structures, such as hemozoin from the malaria parasite (Coban et al., 2005). 
TLRs as PRRs are critically involved in the discrimination between “self” and “non-self”. 
However, it has been shown that TLRs, especially TLR4, TLR7/8, and TLR9 are able to 
sense endogenous ligands. TLR4 recognizes heat shock protein 60 (HSP60) and 
fibronectin (Ohashi et al., 2000; Okamura et al., 2001), whereas immunocomplexed “self-
RNA” or “self-DNA” can act as agonists for TLR7/8 or TLR9, respectively (Barrat et al., 
2005). These findings support the “danger” model postulated by Polly Matzinger (Barrat et 
al., 2005; Matzinger, 1994, 2002). According to her theory, the immune system does not 
solely tend to discriminate between “self” and “foreign”, but is rather activated by 
“danger” signals derived from damaged and stressed tissue. Thus, stimulation of TLRs by 
endogenous ligands may activate the immune system under certain conditions, e.g. stress, 
and promote the development of autoimmiune diseases. 
 
 
1.2.3 TLR signaling 
 
Upon binding of PAMPs, TLRs undergo conformational changes and a set of intracellular 
TIR-domain-containing adaptors, including MyD88, TIRAP (also known as MAL), TRIF 
(also known as TICAM1), and TRAM (also known as TICAM2), are recruited via TIR-
TIR interactions. MyD88 is a universal adaptor that is shared by all TLRs except for TLR3 
(Akira and Takeda, 2004). TLR1, TLR2, TLR4, and TLR6 recruit TIRAP, which serves as 
a linker molecule between the TIR domain of TLRs and MyD88. TRIF is recruited to 
TLR3 and TLR4, where TLR4 uses TRAM as a linker molecule to bind TRIF.  
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Stimulation of the MyD88-dependent pathway used by all TLRs except for TLR3 leads to 
the recruitment of MyD88 and IRAK familiy of protein kinases, which results in the 
activation of TRAF6. TRAF6 induces the activation of TAK1, which in turn results in the 
activation of NFB and AP-1 through the IKK complex and the MAP kinase pathway 
(Figure 1.1, simplified illustration).  
The TRIF-dependent pathway, which is initiated by TLR3 and TLR4, activates NFB via 
two independent pathways. The N-terminal domain of TRIF interacts with TRAF6, 
whereas the C-terminal domain interacts with RIP1. Activated TRAF6 and RIP1 
subsequently activate NFB and MAP kinases via TAK1. Type I interferon (IFN) 
production is induced by interaction of TRIF with TRAF3, which in turn activates the 
IKK-related kinase, TBK1 and IKKi. In consequence, the transcription factors IRF3 and 
IRF7 are activated, translocate into the nucleus, and induce the transcription of type I IFNs 
(Figure 1.1, simplified illustration).  
Stimulation of TLR7 and TLR9 are able to activate NFB and MAP kinases via the 
MyD88-dependent pathway resulting in the production of inflammatory cytokines. To 
trigger the production of type I IFNs, MyD88 associates with the IRAK family of proteins, 
where IRAK1 and IKK activate IRF7. IRAK1 also binds to TRAF3 leading to the 
activation of IRF7 (Figure 1.1, simplified illustration) (Akira and Takeda, 2004; Kawai and 
Akira, 2007; Kumar et al., 2009).  
Taken together, stimulation of TLRs by their respective TLR ligand results in the 
activation of intracellular signaling pathways that trigger the induction of proinflammatory 
cytokines, such as TNF, IL-6, IL-12, and IL-1. Furthermore, several TLRs are capable 
to induce type I IFNs. TLR signaling also initiates the upregulation of costimulatory 
molecules on APCs, an essential step for the induction of adaptive immune responses.  
 
 
1.3 T cell activation by APCs 
 
All T cells originate from hematopoietic stem cells in the bone marrow. Progenitors 
derived from hematopoietic stem cells populate the thymus and develop into immature 
thymocytes. In the thymus, thymocytes undergo developmental processes known as 
positive and negative selection. Only those T cells leave the thymus, which are able to 
recognize “self-MHC molecules” (positive selection) and which do not react with “self-
peptides” presented on MHC (negative selection). About 98% of thymocytes die during the 
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development processes in the thymus by failing either positive selection or negative 
selection, whereas only 2% survive and leave the thymus as naive CD4 or CD8 T cells 
(Schwarz and Bhandoola, 2006; von Boehmer and Kisielow, 1990).  
Naive T cells populate the T cell areas of secondary lymphoid organs, such as the lymph 
nodes or the spleen, until they are activated by mature APCs presenting the TCR-specific 
peptide. The most potent APCs are DCs, which are sparsely but widely distributed cells 
specialized in antigen capture, transport, processing, and presentation. Immature DCs act 
as sentinel cells in peripheral tissues, continuously sampling the environment. Upon 
encounter with a pathogenic stimulus, e.g. recognition of PAMPs by PRRs, DCs undergo a 
maturation process that is characterized by phenotypical and functional changes of the DC. 
Following activation, DCs loose their ability to phagocytose and process antigen from the 
environment, while they upregulate the surface expression of MHC molecules and the 
costimulatory molecules CD80, CD86, as well as CD40, important signals required to 
activate T cells (Banchereau and Steinman, 1998). In addition, DCs migrate towards 
secondary lymphoid organs. DC migration is mediated by the downregulation of 
chemokine receptors (CCRs) involved in the homing to peripheral tissues, whereas CCR7 
is upregulated facilitating the migration and entry into T cell areas of the secondary 
lymphoid tissues, where the CCR7 ligands CC-chemokine ligand 19 (CCL19) and CCL21 
are expressed (Mebius and Kraal, 2005; Sallusto et al., 1998; Sozzani et al., 1998). 
Intimate contact between antigen-presenting DCs and naive T cells in the T cell areas of 
the spleen and lymph nodes plays a central role in the induction of adaptive immunity. 
 
 
1.3.1 Antigen presentation on MHC molecules 
 
T cells expressing the  TCR are incapable to recognize foreign antigens as such. Instead 
T cells only recognize their antigen, if it is processed and presented as antigenic peptides 
on MHC molecules on the cell surface. There exist two different classes of MHC 
molecules involved in antigen presentation, namely MHC class I and MHC class II 
(Germain, 1994).  
MHC class I molecules are expressed on all nucleated cells and function mostly in the 
presentation of endogenous peptides to antigen-specific cytotoxic T cells expressing the 
CD8 co-receptor. Intracellular cytosolic proteins are degraded into peptides by the 
proteasome present in all cells. Recognition of MHC class I-presented peptides by 
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cytotoxic CD8 T cells is a crucial mechanism in viral defense, as viral-derived peptides are 
presented on MHC class I molecules upon intracellular virus replication. In this way, 
activated antigen-specific cytotoxic CD8 T cells are able to lyse and eliminate infected 
cells (Wong and Pamer, 2003). 
In contrast, MHC class II molecules are exclusively expressed on professional APCs, such 
as DCs, macrophages, and B cells, and present exogenous derived antigenic peptides to 
CD4 positive T cells. Exogenous antigens are internalized by APCs and shuttled into 
endosomes or phagosomes, respectively. Upon fusion with lysosomes, uptaken antigen is 
enzymatically degraded and loaded onto MHC class II molecules, which are recruited to 
the lysosome from the endoplasmatic reticulum (ER). Peptide-loaded MHC class II 
molecules translocate to the cell surface, where they present the antigenic peptide to 
antigen-specific CD4 T cells (Wolf and Ploegh, 1995).  
Activation of T cells can only be achieved by APCs. However, APCs are not always 
infected themselves. Therefore presentation of exogenous antigens on MHC class I 
molecules, a process called cross-presentation, is important for mounting antigen-specific 
CD8 T cell immunity. APCs acquire antigen for cross-presentation by taking up soluble 
antigens or cell-associated antigens derived from apoptotic or virally infected cells. 
Internalized antigens are shuttled into the cytoplasm, processed via the proteasome, loaded 
onto MHC class I molecules, and presented to cytotoxic CD8 T cells (Bevan, 1976, 2006; 
Heath et al., 2004; Heath and Carbone, 2001). Moreover, cross-presentation of exogenous 
self-antigens contributes to the elimination of autoreactive CD8 T cells, a process known 
as cross-tolerance (Kurts et al., 1997). 
  
 
1.3.2 T cell activation and differentiation into effector cells 
 
T cell activation follows a so-called “two signal” model provided by mature APCs 
(Janeway and Bottomly, 1994). According to this theory, signal 1 is delivered by the TCR 
recognizing the cognate antigen presented on MHC molecules. Signal 1 is not sufficient to 
induce the development into effector T cells. Naive T cells receiving signal 1 only become 
anergic, meaning they are inactive and unresponsive (Schwartz, 1996, 1997). T cells 
require a second signal, which is provided by mature APCs, mainly DCs, expressing the 
co-stimulatory molecules CD80 (B7.1) and CD86 (B7.2) (Collins et al., 2005). CD80/86 
expression is upregulated upon DC maturation and binds to CD28 expressed by naive 
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T cells. Stimulation of the TCR together with CD28 induces an intracellular signaling 
cascade that leads to clonal expansion and differentiation of T cells (Acuto and Michel, 
2003; Shaw and Dustin, 1997; Viola and Lanzavecchia, 1996). In addition, signaling via 
CD28 induces the production of proinflammatory cytokines, such as IL-2, and expression 
of CD25, the -chain of the IL-2 receptor (Acuto and Michel, 2003). IL-2 acts in an 
autocrine manner and promotes the proliferation of T cells (Malek, 2008). Furthermore, 
costimulation via CD28 augments T cell survival through the induction of Bcl-XL (Acuto 
and Michel, 2003; Boise et al., 1995). 
Full activation of CD8 T cells and development of effector functions requires a third signal 
in addition to TCR engagement (signal 1) and costimulation (signal 2). Signal 3 is 
provided by IL-12 or type I IFNs (Cousens et al., 1999; Curtsinger et al., 2003b; Curtsinger 
et al., 1999; Curtsinger et al., 2005), which is produced by DCs upon TLR stimulation or 
CD40 ligation. CD40 expressed by matured DCs interacts with CD40L, which is expressed 
on activated CD4 T helper cells. In that way, CD4 T cell help licenses the DC to stimulate 
an efficient and long-lasting cytotoxic CD8 T cell response (Bennett et al., 1998; 
Schoenberger et al., 1998; Toes et al., 1998). Moreover, CD4 T cell help is crucial for the 
generation of long-lived and functional CD8 T cell memory (Janssen et al., 2003; Shedlock 
and Shen, 2003; Sun and Bevan, 2003; Williams and Bevan, 2007).  
 
T cells differentiate into CD4 or CD8 T effector cells upon priming by mature APCs. 
CD4 T cells develop into T helper cells (TH), which are subdivided into TH1, TH2, and 
TH17 cells (Bettelli et al., 2008; Moser and Murphy, 2000). TH1 cells produce mainly IFN 
upon IL-12 secretion by DCs and are essential for the protection against a variety of 
intracellular infections. TH2 responses are characterized by the production of IL-4 and are 
directed against certain extracellular pathogens (Moser and Murphy, 2000). Recently 
identified TH17 cells synthesize large quantities of IL-17 and play a role in the clearance of 
extracellular pathogens, which have not been efficiently eliminated by TH1 or TH2 cells. 
Furthermore, they are potent inducers of autoimmunity and tissue inflammation (Bettelli et 
al., 2008). As already mentioned before, CD4 T helper cells are critically involved in 
providing CD4 T cell help to DCs (Bevan, 2004; Castellino and Germain, 2006; Williams 
and Bevan, 2007). 
CD8 T cells differentiate into cytotoxic T lymphocytes (CTL), which recognize their 
specific peptide presented on MHC class I molecules of infected cells in the tissue. CTLs 
induce apoptosis of infected cells by three distinct pathways, namely (1) the granule-
dependent exocytosis pathway, (2) the Fas-FasL intercellular linkage-mediated pathway, 
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and (3) cross-linking of TNF and TNFR type I. In the granule-dependent exocytosis 
pathway granules or lysosomes are formed within the CTL. Upon contact with the infected 
target cell, stored lytic molecules such as perforin, granzymes, and granulysin are released. 
Perforins penetrate the target cell membrane leading to the formation of pores, through 
which granzymes and granulysin enter the cell to induce apoptosis. In addition, CTLs 
express Fas ligand (FasL; CD178), whereas target cells express Fas receptor (CD95;    
Apo-1). Binding of Fas to FasL induces trimerization and the formation of the death-
inducing signaling complex (DISC), which transduces a downstream signaling cascade 
resulting in apoptosis. Binding of TNF, secreted by activated cells, to the TNF receptor 
type I results in receptor multimerization and formation of DISC, which in consequence 
activates the apoptosis cascade (Chavez-Galan et al., 2009). CTLs secrete additionally 
effector cytokines such as IFN, which contribute to the elimination of pathogens. 
 
 
1.3.3 T cell memory 
 
The adaptive immune system is able to generate a long-lived immunological memory. 
Memory T cells mediate rapid and strong recall responses upon re-encounter with a given 
pathogen, which provides an enhanced protection of the host (Sprent and Surh, 2001, 
2002). 
Upon clearance of the pathogen during the effector phase (comprising 1-2 weeks post 
infection), the majority (90-95%) of effector cells die. During this contraction phase, a pool 
of memory T cells is left behind, which are stably maintained in the absence of antigen for 
a long time. One can differentiate between two different subtypes of memory T cells: 
Central memory (TCM) and effector memory (TEM) T cells, which can be distinguished by 
their phenotype and function. Generally, TCM cells reside in the lymphoid organs, do not 
exert immediate effector functions, express high levels of CD62L and are positive for 
CCR7. In contrast, TEM cells are found in non-lymphoid tissues, display lytic activity, 
express low levels of CD62L, and are CCR7 negative (Williams and Bevan, 2007). It is 
controversially discussed whether TEM and TCM cells represent interconnected or distinct 
lineages. Three models of differentiation have been proposed, with the first being that TCM 
cells provide a continuous source of TEM cells (Lanzavecchia and Sallusto, 2000; Sallusto 
et al., 1999). The second model proposes that TCM and TEM cells represent mostly separate 
lineages (Baron et al., 2003). In contrast, an alternative model indicates that TEM cells 
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convert into TCM cells over time (Wherry et al., 2003). In a study by Marzo et al it has been 
reported, that the commitment to a particular memory cell lineage was governed by the 
initial T cell precursor frequency and clonal competition (Marzo et al., 2005). 
 
 
1.4 Type I interferons  
 
Type I interferon (IFN) was first discovered by Isaacs and Lindenmann in 1957 and 
derives its name from a function to “interfere” in viral replication (Isaacs and Lindenmann, 
1957). In mammals the type I IFN genes form a large multigene family comprising the 
species , , , , and , with IFN and IFN being the best studied ones. In mice, there 
exist at least 12 different isoforms of IFN and one IFN (Kelley and Pitha, 1985a, b). 
IFN/ signal via the type I IFN receptor complex, which consists of at least two subunits, 
IFNAR1 and IFNAR2 (Stark et al., 1998). Type I IFN production is triggered upon 
recognition of viral and non-viral nucleic acids by certain PRRs, such as TLR7 and TLR3 
as well as MDA-5 and RIG-I (Uematsu and Akira, 2007; Yoneyama et al., 2005). In 
addition to their key role in antiviral immunity, type I IFNs enhance DC maturation and 
promote the activation as well as differentiation of CD8 T cells by providing signal 3 
(Curtsinger et al., 2005; Le Bon et al., 2003; Luft et al., 1998; Montoya et al., 2002). 
Furthermore, type I IFNs can elicit direct effects on CD8 T cells by promoting their 
survival and IFN production during viral infections (Cousens et al., 1999; Marrack et al., 
1999; Nguyen et al., 2002). Thus, type I IFNs are crucially involved in linking the innate 
and adaptive immune response (Uematsu and Akira, 2007). However, it has also been 
shown that type I IFNs can inhibit the production of IL-12 by DCs (Cousens et al., 1997) 
and interfere with TH1 cell differentiation (McRae et al., 1998). 
Almost all cells are capable to produce type I IFN upon viral infection. PRR stimulation 
results in the secretion of immediate-early type I IFN, especially IFN and IFN4, whose 
transcription is promoted by interferon regulatory factor 3 (IRF-3), which is constitutively 
expressed in most cell types. Rapid but low-level synthesis of IFN and IFN4 initiates a 
positive feedback loop via paracrine or autocrine stimulation of the JAK-STAT pathway 
through the type I IFN receptor. The IFNAR1 and IFNAR2 are permanently associated 
with members of the Janus protein tyrosine kinase family, specifically with 
tyrosine kinase 2 (Tyk2) and Jak1, respectively. Ligand binding stimulates the activation of 
the Janus kinases and the phosphorylation of the receptor complex. This creates the 
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phosphotyrosine-based motif, which is required for the recruitment of STAT1 and STAT2. 
Phosphorylation of STAT1 and STAT2 by the Janus kinases, results in their 
heterodimerization. The STAT1-STAT2 heterdimer translocates into the nucleus and 
associates with IRF9 to form a transcription factor complex, known as IFN-stimulated 
gene factor 3 (ISGF3). ISGF3 binds to the IFN-stimulated response element (ISRE) 
promoter sequence and induces the transcription of IRF7. In turn, IRF7 binds to the IRF-
binding site (IRFBS) and stimulates the delayed production of different IFN subtypes. 
Thus, IRF7 is a key factor in the positive feedback regulation of IFN production, thereby 
boosting IFN secretion (Figure 1.2) (Decker et al., 2005; Levy et al., 2003; Marie et al., 
1998; Sato et al., 1998; Taniguchi and Takaoka, 2001). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2   Amplification of the type I interferon response via the type I interferon receptor  
                    and the JAK-STAT pathway.  
                    (adapted from Taniguchi and Takaoka, 2001) 
 
In contrast, plasmacytoid DCs (pDCs) are capable to immediately secrete vast amounts of 
type I IFN in response to TLR stimulation (especially TLR7 and 9 stimulation) 
independent of the positive amplification loop (Asselin-Paturel et al., 2001; Asselin-Paturel 
and Trinchieri, 2005; Barchet et al., 2005a; Decker et al., 2005). Rapid IFN production 
by pDCs is ascribed to a constitutive expression of the key transcription factor IRF7 
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(Coccia et al., 2004; Dai et al., 2004; Honda et al., 2005; Kawai et al., 2004). Mouse pDCs 
are characterized by CD11c intermediate, PDCA-1 positive, B220 positive, and CD11b 
negative expression. 
 
 
1.5 The spleen 
 
The spleen is a secondary lymphoid organ that is characterized by highly organized and 
specialized structures. It functions as a blood filter that removes senescent erythrocytes 
from the circulation and it is essential for the induction of innate and adaptive immune 
responses against blood-borne pathogens. The unique architecture of the spleen comprises 
two functionally and morphologically distinct compartments, the red pulp and the white 
pulp, which are spatially separated by the marginal zone (Mebius and Kraal, 2005).  
A functional spleen is important as splenectomized patients are impaired in their ability to 
cope with several infections and most often are highly susceptible to bacterial infections 
with Streptococcus pneumoniae, Neisseria meningitides, or Haemophilus influenzae. 
Furthermore, a diminished responsiveness to certain vaccines has been observed (Jia and 
Pamer, 2009; Zandvoort and Timens, 2002). 
 
 
1.5.1 The red pulp 
 
The red pulp functions as a blood filter that removes cellular debris and senescent red 
blood cells. It is also a storage site for iron, erythrocytes, and platelets. The red pulp is 
composed of a three dimensional meshwork of splenic cords and venous sinuses allowing 
the spleen to efficiently perform its filter function. Arterial blood flows into the splenic 
cords, which consist of reticular fibers, fibroblasts, and associated macrophages. Red pulp 
macrophages are actively phagocytic and take up aging and damaged erythrocytes, which 
are incapable to pass from the cords into the sinuses due to their stiffening membranes. 
Following erythrophagocytosis, erythrocytes are degraded and iron is recycled (Cesta, 
2006; Mebius and Kraal, 2005). 
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1.5.2 The white pulp 
 
The white pulp constitutes the lymphoid compartment of the spleen, which presumably 
contains one-fourth of the body’s lymphocytes, and is thus involved in the induction of 
adaptive immunity (Cesta, 2006). The white pulp is organized by lymphoid sheaths, with 
T- and B-cell areas, also known as periarteriolar lymphoid sheaths (PALS) or follicles, 
respectively. The T- and B-cell areas are found around the branching arterial vessels and 
resemble the structure of a lymph node. The correct architecture and maintainance of the 
white pulp is controlled by specific chemokines that attract T and B cells to their respective 
sites, therby establishing distinct zones within the white pulp (Mebius and Kraal, 2005). 
The CXC-chemokine ligand 13 (CXCL13) is required for B cells to migrate to B cell 
follicles (Ansel et al., 2000; Cyster et al., 1999), whereas CCL19 and CCL21 contribute to 
the recruitment of T cells and DCs to the T cell zones (Forster et al., 1999; Gunn et al., 
1999). In the T cell zone, T cells interact with DCs and passing B cells, while clonal 
expansion of activated B cells occurs in the B cell follicles, which leads to isotype 
switching and somatic hypermutation (Mebius and Kraal, 2005). All cells that enter the 
white pulp have to pass the marginal zone, which surrounds the white pulp and separates it 
from the red pulp. As no erythrocytes and few granulocytes are present in the white pulp, it 
is believed that the entry into the white pulp is an active process, which involves signaling 
through G-protein coupled receptors (Cyster and Goodnow, 1995), chemokines and cell-
cell interactions (Johnston and Butcher, 2002; Kraal and Mebius, 2006). 
 
 
1.5.3 The marginal zone 
 
The marginal zone is involved in the induction of an innate and adaptive immune response. 
In addition to being a transit area, the marginal zone harbours many different cell types of 
lymphoid and myeloid origin. These cells not only have unique properties but also seem to 
depend on each other for their localization, thereby establishing and maintaing the integrity 
of the marginal zone (Mebius and Kraal, 2005). The thicker outer ring of the marginal zone 
(adjacent to the red pulp) is composed of marginal zone macrophages, reticular fibroblasts, 
DCs, and marginal zone B cells. The marginal sinus, which is lined by endothelial cells, 
separates the outer ring from the inner ring of the marginal zone. The inner ring consists of 
marginal zone metallophilic macrophages surrounding the white pulp. Marginal zone 
macrophages and marginal zone metallophilic macrophages can be distinguished by the 
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expression of different surface molecules. Metallophilic macrophages are characterized by 
the expression of sialic acid-binding immunoglobulin-like lectin-1 (Siglec-1, CD169, 
sialoadhesin) (Crocker and Gordon, 1989; Kraal and Janse, 1986), which serves a 
phagocytic receptor for sialylated pathogens such as Neisseria meningitides (Jones et al., 
2003). Marginal zone macrophages can be identified by the expression of the C-type lectin 
SIGNR1 mediating binding to polysaccharides on pathogens such as Streptococcus 
pneumoniae (Geijtenbeek et al., 2002; Kang et al., 2004; Lanoue et al., 2004). The type I 
scavenger receptor MARCO (Kraal et al., 2000), which is expressed on both subsets, 
recognizes a broad range of antigens, like acetylated LDL, apoptotic cells, and bacteria, 
such as Staphylococcus aureus or Neisseria meningitides (Pluddemann et al., 2006; 
Pluddemann et al., 2007; van der Laan et al., 1999). Due to the expression of these 
receptors, macrophages in the marginal zone function in trapping and elimination of blood-
borne microbes and cellular debris. Recently, it has been shown that marginal zone 
metallophilic macrophages are involved in the transfer of antigen to CD8 positive splenic 
DCs, thereby contributing to the initiation of adaptive immunity (Backer et al., in press). 
 
 
1.5.4 Dendritic cells in the spleen 
 
Most DCs of the spleen are derived from lymphoid origin and arise from local precursors 
without a monocytic intermediate (Varol et al., 2007). In contrast to macrophages, DCs are 
specialized APCs that hold a dominating role in inducing T cell responses. Murine splenic 
DCs can be divided into different subsets, based on their expression of phenotypic 
markers, localization, and function (Heath et al., 2004). CD8 positive DCs, characterized 
by the expression of DEC205, are found in the T cell zone and outer marginal zone 
(Idoyaga et al., 2009), whereas CD8 negative DCIR2 positive DCs are mainly localized in 
the marginal zone next to marginal zone B cells and marginal zone macrophages. CD8 
positive DCs are specialized in cross-presentation of antigens and in the activation as well 
as tolerization of cytotoxic T lymphocytes (Belz et al., 2005; den Haan et al., 2000; 
Dudziak et al., 2007; Schnorrer et al., 2006). Moreover, they are important for the 
generation of anti-tumor specific immune responses and elimination of tumors in vivo 
(Hildner et al., 2008). In contrast, CD8 negative DCs preferentially activate CD4 T cells 
via MHC class II presentation (Dudziak et al., 2007). Upon activation, all DC (subsets) 
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migrate into the T cell zone, where they interact with antigen-specific T cells (De Smedt et 
al., 1996). 
 
 
1.6 Virus-induced suppression of immune responses 
 
It has been known for a long time that certain viral infections result in a temporary lack in 
cell-mediated immune responses, which is frequently ascribed to the effects of virus-
induced type I IFNs (De Maeyer et al., 1975; De Maeyer-Guignard et al., 1975). Viral 
infections can elicit a negative impact on DCs. For instance, measles virus and 
lymphocytic choriomeningitis virus (LCMV) cause a profound immunosuppression by 
interfering with DC differentiation and expansion, which is dependent on type I IFN 
signaling (Hahm+Oldstone, Immunity, 2005). Furthermore, it has been reported that 
Herpes simplex virus (HSV) infection inhibits DC maturation, whereas a functional 
impairment of DCs is observed upon murine cytomegalovirus (MCMV) infection 
(Salio+Lanzavecchia, EJI, 1999; Andrews, NI, 2001). Moreover, apoptosis is induced upon 
Epstein-Barr virus (EBV) contact and DCs downregulate costimulatory molecules after 
LCMV infection (Li et al., 2002; Sevilla et al., 2004). However, not only DCs are the 
targets of virus-induced immunosuppression, as virus-induced type I IFNs are able to 
induce apoptosis in T cells and T cell proliferation is inhibited upon measles virus infection 
(Bahl et al., 2006; Hahm et al., 2003; Jiang et al., 2005; McNally et al., 2001; Sun et al., 
1998). In these ways, viruses are able to interfere with the host’s immune response, thereby 
enhancing their survival. 
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2 Aim of the thesis 
Toll-like receptors (TLRs) are important members of germ-line encoded pattern-
recognition receptors (PRRs) and recognize conserved microbial components, known as 
pathogen-associated molecular patterns (PAMPs). TLR stimulation triggers the production 
of proinflammatory cytokines, chemokines, and maturation of DCs that generally leads to 
initiation of adaptive immunity. Thus, TLRs have an immune stimulatory effect and are a 
crucial link between innate and adaptive immunity. 
However, it has been reported by our group that a systemic application of CpG, a TLR9 
ligand, inhibited subsequent antigen-specific T cell responses. In her PhD thesis, Beatrix 
Schumak showed that the suppression of cytotoxic T cell responses was not restricted to 
CpG, but rather also other systemically applied TLR ligands were capable to impede 
antigen-specific cytotoxic T cell responses. She revealed that the systemic injection of 
single-stranded RNA (ssRNA) suppressed antigen-specific cytotoxic T cell responses in a 
TLR7 and type I interferon dependent manner.  
Based on these key findings, we aimed to further elucidate the underlying mechanisms of 
ssRNA- and type I interferon-induced inhibition of adaptive immune responses.   
 
 
In this thesis, we were particularly interested in the following questions: 
 
• How does systemic ssRNA and type I interferon influence antigen-specific 
cytotoxic T cell responses in the spleen? 
 
• Does systemic ssRNA impair the expansion, activation, and cytokine production of 
CD4 and CD8 T cells? 
 
• Is there a possibility to avoid ssRNA-induced immune suppression of CD4 and 
CD8 T cell responses? 
 
• Which are the type I interferon producing and which are the responding cell types? 
Which signaling molecules downstream of the type I interferon receptor are 
involved? 
 
• What is the influence of ssRNA stimulation on phenotypic and functional 
maturation of DCs? Are ssRNA pre-activated DCs impaired in cross-priming of 
antigen-specific CD8 T cells? 
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3 Material and Methods 
 
3.1 Materials 
3.1.1 General laboratory equipment 
Autoclave Belimed, Köln 
AutoMACS Miltenyi Biotec, Bergisch Gladbach 
Balances U4100-OD2.2 and MC BA 100 (Sartorius, Göttingen)  
Beakers 5 ml, 10 ml, 25 ml, 50 ml, 100 ml, 150 ml, 250 ml, 500 ml 
(Schott, Mainz) 
Centrifuges Multifuge3 S-R, Biofuge fresco, Biofuge pico (Heraeus, 
Braunschweig) 
Counting Chamber Neubauer (Brand, Wertheim) 
Digital camera CCD-1300 (Vosskuehler, Osnabrück) 
ELISA Reader SpectraMax 250 (Molecular Devices, Sunnyvale, USA) 
Erlenmeyer flasks 50 ml, 100 ml, 250 ml, 500 ml (Schott, Mainz) 
Flow cytometers FACSCalibur, CantoII, LSRII (BD Biosciences, 
Heidelberg) 
Freezers (-20°C) Liebherr, Biberach 
Freezers (-80°C) Hera freeze (Heraeus, Braunschweig) 
Freezing container Nalge Nunc Cryo (Nunc, Wiesbaden) 
Heating block ThermoStat plus (Eppendorf, Hamburg) 
Ice machine Icematic (Scotsman, Frimont Bettolinc, Pogliano, Italy) 
Incubators HERAcell (Heraeus, Braunschweig) 
IVIS200 Xenogen, San Francisco, USA 
Magnet stirrer IKA Laboratory Equipment, Staufen 
Measuring cylinders 50 ml, 100 ml, 250 ml, 500 ml, 1l (Schott, Mainz) 
Microscopes IX71 and CKX31 (Olympus, Hamburg) 
Epifluorescence microscope Edipse TE 2000 (Nikon, 
Düsseldorf) 
Microtiter plate washing      
- device 
Nunc-Immuno
TM
 Wash12 (Nalge Nunc International, 
Thermo Fisher Scientific, Wiesbaden) 
Microwave Panasonic, Wiesbaden 
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pH-meter pH 523 (Wissenschaftlich-Technische Werkstätten, 
Weilheim) 
Pipette-Boy Pipetus (Hirschmann Labortechnik, Eberstadt) 
Pipettes Gilson, Heidelberg and Eppendorf, Hamburg 
Preparation Instruments Labotec, Göttingen 
Refrigerators (+4°C) Bosch, Stuttgart and Liebherr, Biberach 
Sieves, steel University Bonn, Department “Feinmechanik” 
Sonificator UW2070/Sonoplus (Bandeln electronic, Berlin) 
Spectrophotometers Ultrospec 3100 UV/VIS (Amersham Pharmacia, Freiburg); 
NanoDrop™ ND 1000 (NanoDrop Products, Wilmington, 
USA) 
Threaded bottles 100 ml, 250 ml, 500 ml, 1l, 2l (Schott, Mainz) 
Ultra-pure water system NANOpure Diamond, Barnstead (Werner, 
Reinstwassersysteme, Leverkusen) 
Waterbath TW8 (Julabo, Seelbach) 
Workbench, sterile HERAsafe (Heraeus, Hanau)  
 
 
 
3.1.2 Software 
Endnote X1 Thomson ISI ResearchSoft, USA 
FACS Diva V6.1.1 BD Biosciences, Heidelberg 
Flowjo V8.8.4 Tree star, Inc., USA 
Illustrator CS4 Adobe, USA 
Living Image 2.50 (IVIS) Xenogen, USA 
Microsoft Office 2008 Microsoft, USA 
Photoshop CS4 Adobe, USA 
Prism 4 for Macintosh  GraphPad Software, USA 
SPF ELISA software Molecular Devices, USA 
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3.1.3 Consumables 
Cover slides 21x46mm (Marienfeld, Lauda-Königshofen) 
Cryo vials VWR International, Darmstadt 
Cryomolds VWR International, Darmstadt 
ELISA plates Microlon, 96-well, flat-bottom, high-binding (Greiner bio-
one, Solingen) 
FACS tubes polystyrene, 12/75 mm (Sarstedt, Nümbrecht) 
FlexiPERM silicone cell culture chamber (Greiner bio-one, Solingen) 
Injection needles 27G (grey), 25G (orange), 20G (yellow) (BD Microlance, 
Heidelberg) 
Microtiter plates 96-well, round and flat bottom (Greiner bio-one, Solingen) 
Nylon wool Kisker GbR (by Labomedic GmbH, Bonn) 
Parafilm Parafilm “M” (American National Can TM, Greenwich, 
USA) 
Pasteur pipettes 150 mm and 230 mm (Roth, Karlsruhe) 
Petri dishes 10 cm (Greiner bio-one, Solingen) 
Pipette tips 10 l, 200 l, 1000 l (Greiner bio-one, Solingen) 
Plastic Pipettes 5 ml, 10 ml, 25 ml (Sarstedt, Nümbrecht) 
Polyamide tissue “Gaze” (Labomedic, Bonn) 
Polypropylene tubes sterile, 15 ml and 50 ml (Greiner bio-one, Solingen) 
Reaction tubes 0.5 ml, 1.5 ml, 2 ml (Eppendorf, Hamburg) 
Scalpel Feather (Osaka, Japan) 
Sterile filter 0.2 m (Schleicher & Schuell) 
Syringes 2 ml, 5 ml, 10 ml, 20 ml BD Discardit
TM
 (BD Bioscience, 
Heidelberg) 
Tissue culture flasks 25 cm
2
, 75 cm
2
, 150 cm
2
 (TPP, St.Louis, USA or Sarstedt, 
Nümbrecht) 
Tissue culture plates 6-, 12-, 24-, 48-, 96-well (TPP, St. Louis, USA or Sarstedt, 
Nümbrecht) 
Tuberculin syringes Omnifix-F (Braun, Melsungen) 
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3.1.4 Chemicals and reagents 
Ammonium chloride (NH4Cl) Merck, Darmstadt 
Biotin/Avidin blocking kit Vector Laboratories, Burlingame, USA  
Bovine serum albumin (BSA) Roth, Karlsruhe 
Brain Heart Infusion Broth Roth, Karlsruhe 
CFSE Molecular Probes, Leiden, Netherlandes 
Collagenase A Roche, Mannheim 
DEPC treated water (RNase free) Invitrogen, Karlsruhe 
Dimethylsulfoxide (DMSO) Merck, Darmstadt 
Disodium ethylene diamine tetraacetic acid 
(Na2EDTA) 
Merck, Darmstadt 
Disodium hydrogen phosphate (Na2HPO4)  Merck, Darmstadt 
DMEM medium Sigma Aldrich, München  
DOTAP Roth, Karsruhe 
Ethanol, absolute Merck, Darmstadt 
ethylene diamine tetraacetic acid (EDTA) Sigma Aldrich, München 
Far Red Molecular Probes, Leiden, Netherlands 
Fetal calf serum (FCS) PAA, Cölbe 
G418 sulfate PAA, Cölbe 
Golgi Plug/Stop BD Biosciences, Heidelberg 
Heparin Ratiopharm, Ulm 
Hoechst 33258 Sigma Aldrich, München 
Hoechst 33342 Molecular Probes, Leiden, Netherlands 
Hydrogen peroxide (H2O2) Merck, Darmstadt  
IMDM medium Lonza, Köln 
in vivo-jetPEI
TM 
Polyplus Transfection, Illkirch, France 
Isoflurane DeltaSelect, Pfullingen 
L-Glutamine (200 mM) PAA, Cölbe 
Liquid nitrogen Linde, Wiesbaden 
Luciferin Caliper Lifesciences, Rüsselsheim 
Lymphocyte separation medium PAA, Cölbe 
Natural silk 5.0 Catgut, Markneukirchen 
Neutralized streptavidin-peroxidase Uptima, Interchim, France 
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Normal donkey serum Jackson ImmunoResearch, West Grove, 
USA 
Normal goat serum Jackson ImmunoResearch, West Grove, 
USA 
o-Phenylenediamine dihydrochloride (OPD) Sigma Aldrich, München 
Optimem medium Gibco, BRL, Karlsruhe 
Ovalbumin (OVA) Serva, Heidelberg 
Ovalbumin (OVA), grade V Sigma Aldrich, München 
Paraformaldehyde (PFA) Fluca, Buchs 
Penicillin/Streptomycin (100x) PAA, Cölbe 
Phosphate buffered saline (PBS) Biochrom, Berlin 
Phosphate buffered saline (PBS) solution Sigma Aldrich, München 
Potassium bicarbonate (KHCO3) Merck, Darmstadt 
RPMI 1640 medium Sigma Aldrich, München 
Saponin Sigma Aldrich, München 
Sodium azide Sigma Aldrich, München 
Sodium bicarbonate (Na2HCO3) Sigma Aldrich, München 
Sodium chloride, 0.9%  B. Braun, Melsungen 
Sodium hydroxide (NaOH) Merck, Darmstadt 
Sucrose Roth, Karlsruhe 
Sulfuric acid (H2SO4), 96% Merck, Darmstadt 
Tacosil Nycomed, Konstanz 
Tissue-Tek OCT Sakura, Netherlands 
TMB substrate Uptima, Interchim, France 
Trisodium citrate (Na3C6H5O7) Sigma Aldrich, München 
Trypane blue (0.4%) Lonza, Köln 
Trypsin/EDTA Lonza, Köln 
TSA
TM
 Fluorescein System PerkinElmer, Rodgau-Jügesheim 
Tween20 Roth, Karlsruhe 
Vectashield mounting medium with DAPI Vector Laboratories, Burlingame, USA 
-mercaptoethanol Sigma Aldrich, München 
2-Methylbutane Merck, Darmstadt 
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3.1.5 Buffers, media and solutions 
DC and T cell culture medium 
RPMI 1640 medium supplemented with 10% (v/v) FCS, 2mM L-glutamine, 1% (v/v) 
penicillin/streptomycin, 50 M -mercaptoethanol. Kept under sterile conditions at 4°C. 
 
BMDC medium 
IMDM medium supplemented with 10% (v/v) FCS, 2mM L-glutamine, 1% (v/v) 
penicillin/streptomycin, 50 M -mercaptoethanol, 30% (v/v) GM-CSF supernatant. Kept 
under sterile conditions at 4°C. 
 
B16-luc melanoma cell medium 
DMEM medium supplemented with 5% (v/v) FCS, 2mM L-glutamine, 1% (v/v) 
penicillin/streptomycin. Kept under sterile conditions at 4°C. 
 
Ag8653 medium 
IMDM medium supplemented with 10% (v/v) FCS, 2mM L-glutamine, 1% (v/v) 
penicillin/streptomycin, 50 M -mercaptoethanol. Kept under sterile conditions at 4°C. 
 
FCS (fetal calf serum) 
FCS was heat-inactivated at 56°C for 30 min and stored à 50 ml aliquots at -20°C. 
 
PBS (phosphate buffered saline) 
1xPBS was adjusted to pH 7.4, aliquoted à 500 ml, autoclaved and stored at 4°C. 
 
0.5 M EDTA  
186.1g EDTA and 20g NaOH were dissolved in 1000 ml ultra-pure water and the pH was 
adjusted to 7.8 – 8.0. The solution was autoclaved and stored at room temperature. 
 
5 mM -mercaptoethanol 
178 l of 14.3 M -mercaptoethanol was added to 500 ml PBS and kept under sterile 
conditions at 4°C. 
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FACS buffer 
1x PBS containing 1% (v/v) FCS and 0.1% (v/v) NaN3. Stored at room temperature. 
 
MACS buffer 
1x PBS containing 1% (v/v) FCS and 2mM EDTA. Stored under sterile conditions at 4°C. 
 
Saponin/FACS buffer 
FACS buffer supplemented with 0.5% (w/v) Saponin, prepared freshly. 
 
ACK lysis buffer 
16.58 g NH4Cl, 2 g KHCO3, 74.4 mg Na2EDTA was dissolved in 2000 ml ultra-pure water 
and the pH was adjusted to 7.2 - 7.4. Stored under sterile conditions at room temperature. 
 
ELISA coating buffer 
0.1 M NaHCO3 in ultra-pure water, pH 8.2, autoclaved and stored at 4°C. 
 
ELISA blocking buffer 
1% BSA (w/v) in 1xPBS, prepared freshly. 
 
OPD substrate buffer 
15.6 g NaH2PO4 x 2H2O and 14.7 g Na3C6H5O7 x 2H2O were dissolved in 500 ml ultra-
pure water and the pH was adjusted to 5.0. The buffer was stored at room temperature. 
 
1M H2SO4 OPD stopping solution 
26.5 ml 96% H2SO4 was added to 500 ml ultra-pure water and kept at room temperature. 
 
0.18 M H2SO4 TMB stopping solution 
5 ml 96% H2SO4 was added to 500 ml ultra-pure water and kept at room temperature. 
 
ELISA washing buffer 
1x PBS containing 0.01% (v/v) Tween20 
 
4% (w/v) PFA solution 
8 g PFA was dissolved in 200 ml 1xPBS by gradual heating. The pH was adjusted to 7.4 
and aliquots were stored at -20°C. 
Material and Methods 
26 
30% (w/v) sucrose solution 
15 g sucrose were dissolved in 50 ml 1xPBS, freshly prepared. 
 
50 mM luciferin solution 
1 vial of luciferin (1g) was dissolved in 70 ml sterile PBS to obtain a 50 mM stock solution 
(14mg/ml). Aliquots á 2 ml were stored at -20°C. 
 
 
3.1.6 Synthetic RNA oligoribonucleotides and TLR ligands 
Synthetic RNA oligoribonucleotides (ORN) were ordered from Biomers, Dharmacon, or 
Qiagen. Lyophilized RNA was reconstituted in sterile 0.9% NaCl or Qiagen siRNA 
suspension buffer (1 g/l). Aliquots were stored at -80°C.  
ORN Sequence Target Reference 
9.2  
(dsRNA) 
5’-AGC UUA ACC UGU CCU 
UCA A dTdT-3’ (sense) 
5’-UUG AAG GAC AGG UUA 
AGC U dTdT-3’ (antisense) 
human 
TLR9 
(Hornung et al., 
2005) 
9.2s 
(ssRNA) 
5’- AGC UUA ACC UGU CCU 
UCA A-3’ (sense) 
 (Hornung et al., 
2005) 
siVEGF 5’-AUG UGA AUG CAG ACC 
AAA GAA dTdT-3’ (sense) 
5’-UUC UUU GGU CUG CAU 
UCA CAU dTdT-3’ (antisense) 
murine 
VEGF-A 
(Filleur et al., 
2003; Kornek et 
al., 2008) 
 
RNA-Al647 5’-GAA CUU CAG GGU CAG 
CUU GCC G-3’ 
 commercial 
RNA (Qiagen) 
 
 
CpG-rich oligonucleotides (ODN) were purchased from TIB MolBiol, Berlin. Lyophilized 
CpG ODN was dissolved in sterile PBS at a concentration of 1nmol/l (= 6.4 g/l) by 
incubation at 37°C for 30 min. Dissolved CpG was stored at 4°C. 
ODN Sequence Type Reference 
CpG-1668 TCC ATG ACG TTC CTG ATG CT CpG-B (Krieg et al., 1995) 
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polyI:C was ordered from Sigma-Aldrich, München, and dissolved in 0.9% NaCl at a 
concentration of 1 g/l. Aliquots were stored at -20°C. 
Substance Description Reference 
polyI:C (C10H10N4NaO7P)x • (C9H11N3NaO7P)x (Ranjith-Kumar et 
al., 2007) 
 
 
 
3.1.7  Peptides 
Peptides were obtained from Pineda, Invitrogen, or Sigma-Aldrich. They were dissolved as 
20 mM stock solutions in DMSO and stored at -20°C. 
Peptides  MHC haplotype Amino acid sequence 
OVA254-267 (S8L) H-2k
b 
SIINFEKL  
OVA265-279 (OT3p) I-A
b 
EKLTEWTSSNVMEER  
mTRP2180-188 H-2k
b 
SVYDFFVWL 
Influenza peptides H-2k
b 
ASNENMETM and SSLENFRAYV 
HSV peptide H-2k
b
 SSIEFARL 
 
 
 
3.1.8 Recombinant cytokines 
Recombinant mouse cytokines were kept at -80°C for long-term storage. Working aliquots 
of 5 g/ml were stored at -20°C.  
Cytokine Company Application 
IL-2 eBioscience, USA ELISA standard 
IL-6 eBioscience, USA ELISA standard 
IL-12p70 eBioscience, USA ELISA standard 
IL-12p70 provided by Edgar Schmitt, Mainz DC/T cell co-culture 
IFN eBioscience, USA ELISA standard 
IFN PBL Interferon Source, USA in vivo 
IFN PBL Intereron Source, USA in vivo 
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3.1.9 Antibodies 
Antibodies used in cytokine ELISA 
All antibodies used in cytokine ELISAs were purchased from eBioscience or 
BD Pharmingen. Matching antibody pairs included a primary unlabeled capture antibody 
and a biotinylated detection antibody. Each antibody was applied in previously titrated 
amounts. 
Cytokine Clone (capture antibody) Clone (detection antibody) 
IL-2 JES6-1A12 JES6-5H4 
IL-12p70 C18.2 C17.8 
IFN XMG1.2 RA-6A2 
 
 
Antibodies used for detection of antibody responses 
OVA-specific IgG antibodies were detected using a biotinylated goat anti-mouse IgG 
(Dianova, Hamburg). 
 
Antibodies coupled to magnetic beads (MACS  Beads) 
Murine anti-CD8a, anti-CD4, and anti-CD11c antibodies conjugated to magnetic beads 
(MACS Beads) were obtained from Miltenyi Biotech, Bergisch Gladbach. 
 
Immunohistology antibodies 
The following antibodies were used in immunohistology of spleens derived from 
IFN/YFP reporter mice. 
Antibody Company 
biotinylated donkey anti-rabbit Jackson Immuno Research, West Grove, USA 
goat anti-rat Cy3 Jackson Immuno Research, West Grove, USA 
monoclonal rat anti MOMA-1 BMA Biomedicals, Augst, Switzerland 
polyclonal rabbit anti-GFP Abcam, Cambridge, UK 
 
 
Fluorochrome conjugated antibodies used in FACS  
The following antibodies were purchased from eBioscience or BD Biosciences (if not 
otherwise stated) for flow cytometric analysis of murine molecules expressed at the cell 
surface or intracellularly. All antibodies were labeled with a fluorochrome (FITC, PE, PE-
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Cy7, PerCP-Cy5.5, APC, Al647, APC-Cy7, Pacific Blue, Al405) and employed at 
previously determined concentrations. 
Antigen Isotype  Clone Annotation 
B220 rat IgG2a,  RA3-6B2 = CD45R 
CD11b rat IgG2b,  M1/70 = Mac-1, integrin M chain 
CD11c hamster IgG N418 = integrin X chain 
CD16/32 rat IgG2b,  2.4G2 = anti FcR III + II 
CD19 rat IgG2a,  eBio1D3  
CD3e hamster IgG 145-2C11  
CD4 rat IgG2b,  GK1.5  
CD40 rat IgG2a,  1C10 = TNFRSF5 
CD62L rat IgG2a,  MEL-14 = L-selectin, LECAM-1, Ly-22 
CD69 hamster IgG H1.2F3  
CD80 hamster IgG 16-10A1 = B7.1 
CD86 rat IgG2b,  P03.1 = B7.2 
CD8a rat IgG2a,  53-6.7 = Ly-2 
F4/80 rat IgG2a,  BM8  
IFN rat IgG1,  XMG1.2  
IL-12p40/p70 rat IgG1 C15.6  
IL-2 rat IgG2b,  JES6-5H4  
PDCA-1 rat IgG2b JF05-
1C2.4.1 
purchased from Miltenyi Biotech 
S8L/H-2K
b
 
Pentamers 
  purchased from Proimmune 
V2 TCR rat IgG2a B20.1 = OT-I TCR 
V5 TCR mouse IgG1,  MR9-4 = OT-I TCR 
  
 
 
3.1.10 Cell lines 
B16-luc melanoma 
B16-luc is a C57BL/6-specific murine melanoma cell line expressing luciferase, OVA, and 
the green fluorescence protein (GFP). This cell line was obtained from Gunther 
Hämmerling, DKFZ, Heidelberg. 
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Ag8653 
Ag8653 is a hybridoma cell line that is used to produce GM-CSF containing supernatant 
(Karasuyama and Melchers, 1988; Stockinger et al., 1996). 
 
 
3.1.11 Viruses and bacteria 
Viruses and bacteria used in this study were kindly provided by other scientists. 
Pathogen Description Source (Reference) 
AdOVA E1 and E3 deleted recombinant 
adenoviral vector expressing 
the full length OVA protein 
under the CMV promoter 
Dr. Andreas 
Untergasser; Prof. Dr. 
Ulrike Protzer 
AdLOG E1 and E3 deleted recombinant 
adenoviral vector expressing 
luciferase, OVA-derived 
peptide SIINFEKL, and GFP 
Prof. Dr. Thomas 
Tüting  
(Schweichel et al., 
2006) 
AdmTRP2 E1 and E3 deleted recombinant 
adenoviral vector expressing 
the mTRP2-derived peptide 
SVYDFFVWL and GFP  
Prof. Dr. Thomas 
Tüting  
(Steitz et al., 2002; 
Tuting et al., 1999) 
HSV-1 Wild type Herpes simplex 
virus type 1 
Dr. Christoph Coch; 
Nico Busch 
Influenza virus Wild type Influenza A 
PR8/H1N1 virus 
Dr. Christoph Coch; 
Nico Busch 
LmOVA  Recombinant Listeria 
monocytogenes expressing the 
full length OVA protein 
Prof. Dr. Klaus Pfeffer; 
Dr. Stefanie Scheu 
(Pope et al., 2001) 
 
 
 
3.1.12 Mouse strains 
C57BL/6(N) or C57BL/6(J) wild type strains (H-2K
b
) were purchased from Charles River, 
Sulzfeld, or Janvier, France. Mice were bred under pathogen free conditions and in 
accordance to institutional animal guidelines in the animal facility (HET, House of 
Experimental Therapy) of the University of Bonn. Following knock out (ko) or transgenic 
animals backcrossed on C57BL/6 were used: 
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Strain Description Source (Reference) 
CD11c-Cre x IFNAR1
fl/fl 
DC-specific type I IFN 
receptor ko 
Prof. Dr. Ulrich 
Kalinke  
(Cervantes-
Barragan et al., 
2009) 
CD19-Cre x IFNAR1
fl/fl 
B cell-specific type I IFN 
receptor ko 
Prof. Dr. Ulrich 
Kalinke  
(Prinz et al., 2008) 
CD4-Cre x IFNAR1
fl/fl 
T cell-specific type I IFN 
receptor ko 
Prof. Dr. Ulrich 
Kalinke  
(Prinz et al., 2008) 
CD4/CD19-Cre x IFNAR1
fl/fl 
T cell/B cell-specific type I 
IFN receptor ko 
Prof. Dr. Ulrich 
Kalinke (Prinz et 
al., 2008) 
CD4 ko deficient in CD4 T cells (Rahemtulla et al., 
1991) 
I-A
b
 ko deficient in MHC class II and 
CD4 T cells 
(Cosgrove et al., 
1991; Grusby et al., 
1991) 
IFNAR1 ko deficient in the type I IFN 
receptor 
 
(van den Broek et 
al., 1995b) 
IFN ko deficient in IFN  Prof. Dr. Thomas 
Decker; Prof. Dr. 
Mathias Müller 
(Erlandsson et al., 
1998) 
IL-10 ko deficient in IL-10 Prof. Dr. Achim 
Hörauf  
(Kuhn et al., 1993) 
IRF3 ko deficient in IRF3 Prof. Dr. Thomas 
Decker; Prof. Dr. 
Mathias Müller 
(Sato et al., 2000) 
IRF7 ko deficient in IRF7 Prof. Dr. Thomas 
Decker; Prof. Dr. 
Mathias Müller 
(Honda et al., 2005) 
LysM-Cre x IFNAR1
fl/fl 
macrophage-specific type I 
IFN receptor ko  
Prof. Dr. Ulrich 
Kalinke  
(Prinz et al., 2008) 
MDA5 ko deficient in MDA5 Dr. Winfried 
Barchet (Gitlin et 
al., 2006) 
MOB IFN/YFP reporter mice Dr. Stefanie Scheu 
(Scheu et al., 2008) 
Material and Methods 
32 
 
Strain Description Source (Reference) 
OT-I/RAG transgenic CD8 T cell line 
carrying the OVA257-264 
specific TCR V2V5; lacks 
CD4 T cells and B cells 
(Hogquist et al., 
1994) 
OT-I/Thy1.1 OT-I transgenic T cell line 
expressing the congenic 
marker Thy1.1 
 
OT-II transgenic CD4 T cell line 
carrying the OVA323-339 
specific TCR 
(Barnden et al., 
1998) 
STAT1 ko deficient in STAT1 Prof. Dr. Thomas 
Decker; Prof. Dr. 
Mathias Müller 
(Durbin et al., 1996) 
TLR3 ko deficient in TLR3 (Alexopoulou et al., 
2001) 
TLR7 ko deficient in TLR7 (Hemmi et al., 
2002) 
Tyk2 ko deficient in Tyk2 Prof. Dr. Thomas 
Decker; Prof. Dr. 
Mathias Müller 
(Karaghiosoff et al., 
2000) 
 
 
 
3.2 Methods 
 
3.2.1 Experimental treatment of mice  
Pathogens, cells, and other reagents were adjusted in 0.9% NaCl or PBS for experimental 
injection of mice. Intravenous (i.v.) and intraperitoneal (i.p.) injections were performed 
with a volume of 250 l, subcutaneous (s.c.) injections with a volume of 100 l. 
 
3.2.1.1 Infection with viruses 
Mice were infected i.v. with 5x10
9
 virus particles of different recombinant adenoviruses 
(see 1.1.11).  
Mice were infected i.v. with 1x10
4
 PFU Herpes simplex virus type 1 and 1x10
5
 or 1x10
6
 
PFU Influenza A PR8/H1N1 virus.  
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3.2.1.2 Infection with recombinant Listeria monocytogenes   
Recombinant Listeria monocytogenes expressing OVA (LmOVA) were cultured overnight 
in Brain Heart Infusion Broth shaking at 37°C. Colony forming units (CFU) of LmOVA 
were quantified by OD measurement at 600 nm. Mice were infected i.v. with 5x10
3
 CFU 
bacteria. 
 
3.2.1.3 B16-luc tumor implantation 
Mice were anesthesized by inhalation of 2% isoflurane and shaved at the surgical site. An 
incision was made at the abdomen and the duodenum was carefully removed from 
peritoneum using cotton swabs to expose the portal vein. 5x10
4
 B16-luc melanoma cells 
were injected intraportally (i.po.) in 50 l volume using a tuberculin syringe with a 29G 
injection needle. The injection site was closed with a 2mm
2
 piece of Tacosil. The 
peritoneal cavity and skin was closed using natural silk.    
 
3.2.1.4 Activation of OVA-specific CD4 T cells in vivo 
Endogenous OVA-specific CD4 T cells were activated in vivo with 50 g of OVA265-279 
peptide (OT3p) (Boscardin et al., 2006) mixed with 5 g of CpG-1668 and 5 g of pI:C by 
s.c. injection into the flank. C57BL/6 mice were immunized six days before AdOVA 
infection to generate effector CD4 T cells and four weeks before AdOVA infection to 
generate OVA-specific memory CD4 T cells. 
 
3.2.1.5 CD40 stimulation in vivo 
Mice were injected i.p. with 100 g of anti-CD40 antibody (FGK-45) on the day of 
adenoviral infection. Stimulation was repeated by an additional i.v. administration of     
100 g one day after adenovirus immunization. 
 
3.2.1.6 Depletion of plasmacytoid DCs 
Plasmacytoid DCs were depleted using an anti-PDCA-1 antibody, which was given twice 
twelve hours apart. Mice were injected i.v. with 200 g each. Depletion of splenic pDCs 
was determined by flow cytometric analysis 24 hours later.  
Material and Methods 
34 
ssRNA was injected 24 hours and AdOVA 48 hours after the last anti-PDCA-1 antibody 
administration.  
 
3.2.1.7 Injection of recombinant type I interferons 
Mice were injected i.v. with 1000 U of either mouse recombinant IFNA, IFN, or IFNA 
and IFN one day prior to adenovirus infection.  
 
 
3.2.2 In vivo RNA oligoribonucleotide application 
3.2.2.1 Complexation of RNA with DOTAP 
RNA complexation using DOTAP was performed according to manufacturer’s instruction 
with some modifications for in vivo application. 10 g of single-stranded RNA or 20 g of 
double-stranded RNA was incubated with 30 l DOTAP and incubated for 20 minutes at 
room temperature under sterile and RNase-free conditions. The volume was adjusted to 
250 l with 0.9% NaCl for i.v. injection.  
 
3.2.2.2 Complexation of RNA with in vivo-jetPEI
TM
 
RNA complexation with in vivo-jetPEI
TM
 was conducted according to the manufacturer’s 
guide. Briefly, 10 g of single-stranded RNA was diluted in 40 l of 5% glucose solution 
(20 g of double-stranded RNA in 80 l of 5% glucose solution). 2 l of in vivo-jetPEITM 
was mixed with 40 l of 5% glucose solution at a N/P ratio of 10 (4 l of in vivo-jetPEITM 
was added to 80 l 5% glucose solution). The in vivo-jetPEITM solution was added to the 
RNA solution, mixed thoroughly, and incubated for 20 minutes at room temperature under 
sterile and RNase-free conditions (Important: Do not mix the solutions in the reverse 
order). The volume was adjusted to 250 l with 5% glucose solution for i.v. injection. 
 
 
3.2.3 Ex vivo analysis of splenic DCs  
Splenic DCs were enriched by collagenase digestion. Spleens were perfused ex vivo using 
a syringe with 0.04% collagenase A, cut into small pieces, and incubated for 30 minutes at 
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37°C in a waterbath. Afterwards, digestion was stopped by adding MACS buffer and 
spleens were homogenized by passing through a metal sieve (mesh size 250 m). 
Splenocytes were immediately used for antibody staining of surface molecules to 
determine the maturation status by flow cytometry. For intracellular IL-12p70 staining, 
splenocytes were resuspended in DC/T cell medium. 5x10
6
 splenocytes were plated in 
100 l per well of a 48-well plate and Golgi-Plug/Stop was added in 200 l medium with a 
final concentration of 1 l/ml. Cells were collected after four hours of incubation at 37°C 
and applied to an intracellular cytokine staining. 
 
 
3.2.4 Peptide-specific restimulation of T cells ex vivo 
Splenocytes were isolated five days post AdOVA or ssRNA/AdOVA immunization and 
resuspended in DC/T cell medium. 2x10
6
 splenocytes were plated in 100 l per well of a 
96-well plate. OVA-specific CD8 T cells were restimulated by addition of 1 M S8L 
peptide, whereas OVA-specific CD4 T cells were restimulated using 100 g/ml OT3p 
peptide (each added in 100 l). IFN and IL-2 production by T cells was determined after 
overnight incubation at 37°C by flow cytometric analysis of intracellular cytokines or in 
supernatants by ELISA. 
 
 
3.2.5 Ex vivo cross-priming assay 
C57BL/6 wild type and IFNAR1 deficient mice were immunized with AdOVA or 
ssRNA/AdOVA and splenic DCs were purified using the AutoMACS based separation.  
20 hours after adenovirus injection, mice were sacrifized and spleens were digested by ex 
vivo perfusion with 0.04% collagenase A, cut into small pieces, and incubated for 
30 minutes at 37°C in a water bath. Upon digestion, spleens were homogenized by passing 
through a metal sieve. Cells were washed once and the cell suspension was filtered. After 
another centrifugation step for 10 minutes at 486 x g, splenocytes were resuspended in cold 
MACS buffer (0.5 ml per spleen) and anti-CD11c MACS beads were added (30 l per 
spleen). Cells were incubated for 15 minutes at 4°C, washed once in MACS buffer, and 
CD11c positive DCs were purified by positive selection (Possel) using the AutoMACS cell 
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separation system. Subsequently, CD11c positive cells were adjusted to 3x10
6
 cells per ml 
in DC/T cell medium and 3x10
5 
DCs were plated in 100 l per well of a 96-well plate.  
OVA-specific CD8 T cells were prepared from spleens and lymph nodes of naive          
OT-I/RAG mice using nylon wool. Organs were homogenized by passing through a metal 
sieve and the cell suspension was centrifuged for 10 minutes at 486 x g. Erythrocytes were 
lysed by addition of 1 ml ACK lysis buffer and incubation for 2 minutes at room 
temperature. Tubes were filled with PBS to stop lysis reaction and cells were centrifuged 
again for 10 minutes at 486 x g. Afterwards, the cell pellet was resuspended in DC/T cell 
medium and applied to a sterile 10 ml syringe filled with 0.6 g nylon wool (The nylon 
wool containing syringe had been previously blocked with 2% (v/v) FCS/PBS at 37°C for 
at least 45 minutes). Cells were incubated for 60 minutes at 37°C to allow macrophages 
and DCs to adhere to the nylon wool. Afterwards, T cells were washed off by carefully 
adding 20 ml of warm DC/T cell medium. Eluted T cells were counted and 1x10
5           
OVA-specific CD8 T cells were added in 100 l to the pre-plated splenic DCs. Co-culture 
supernatants were collected after 24 hours. IFN and IL-2 production by T cells was 
determined by ELISA or flow cytometric analysis of intracellular cytokines. In addition, 
CD69 expression was analyzed by antibody staining and subsequent flow cytometry. 
 
 
3.2.6 Collection of serum for cytokine analysis 
Blood was collected from the portal vein using a heparinized syringe and allowed to 
coagulate. Blood samples were centrifuged for 15 minutes at 3835 x g and serum was 
transferred to a clean tube and stored at -20°C until cytokine analysis. 
 
 
3.2.7 Expansion and activation of transgenic OT-I T cells in vivo 
The spleen was taken from one NK/NKT cell-depleted OT-I/Thy1.1 transgenic mouse and 
homogenized using a metal sieve. The homogenate was centrifuged for 10 minutes at 
486 x g and the cell pellet was resuspended in 10 ml MACS buffer for filtration. After 
another centrifugation, cells were resuspended in 0.5 ml cold MACS buffer and 30 l of 
anti-CD8a MACS beads were added. Cells were incubated with MACS beads for 
15 minutes at 4°C, washed once, and purified by positive selection (Possel) using the 
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AutoMACS cell separation system. Purified OT-I T cells were counted and 5x10
4
         
OT-I T cells were injected i.v. into recipient mice. One day upon transfer, mice were either 
left untreated or injected i.v. with complexed ssRNA. 24 hours later, mice were infected 
with AdOVA. The expansion and activation of transgenic OT-I T cells was determined in 
spleens five days post infection by flow cytometric analysis for CD8a, Thy1.1, and 
CD62L. In addition, an intracellular cytokine staining was performed in order to analyze 
IFN production by OT-I T cells upon overnight S8L-specific restimulation.  
 
 
3.2.8 CFSE proliferation assay of CD4 T cells in vivo 
OVA-specific CD4 T cells were isolated from spleens of OT-II transgenic donor mice. 
Organs were homogenized by passing them through a metal sieve and homogenates were 
centrifuged for 10 minutes at 486 x g. The cell pellet was resuspended in 10 ml cold 
MACS buffer and filtered to remove residual tissue and debris. After another 
centrifugation, cells were resuspended in cold MACS buffer (0.5 ml per spleen) and anti-
CD4 MACS beads (30 l per spleen) were added. Cells were incubated with MACS beads 
for 15 minutes at 4°C, washed once in MACS buffer, and CD4 T cells were isolated by 
positive selection (Possel) using the AutoMACS cell separation system. Purity of          
OT-II T cells was assessed by flow cytometric analysis of CD4, V5, and V2. 
Afterwards, CD4 T cells were labeled with 2 M CFSE in PBS by incubation at 37°C for 
20 minutes. The reaction was stopped by adding ice cold PBS and cells were washed 
extensively. Finally, purified CD4 T cells were counted and 2x10
6
 CFSE-labeled 
CD4 T cells were injected i.v. per recipient mouse. Two days upon adoptive transfer, mice 
were immunized with AdOVA alone or were previously injected i.v. with DOTAP- or in 
vivo-jetPEI
TM
- complexed ssRNA one day prior to AdOVA infection. Proliferation of 
splenic OT-II T cells was assessed three days after AdOVA immunization by a CFSE 
dilution assay using flow cytometry.   
 
 
3.2.9 Flow cytometric analysis (FACS) 
 
Flow cytometry (fluorescence activated cell sorting, FACS) was used to investigate the 
expression of different surface molecules, to detect intracellular cytokines, and to 
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determine the generation of endogenous OVA-specific CD8 T cells by S8L/H-2K
b
 
pentamer staining. Data were acquired using a FACS Calibur, LSR II, or Canto II and 
subsequently analyzed using the FlowJo software.  
 
3.2.9.1 Surface staining of molecules 
Cells were transferred into a 96-well round bottom plate for antibody staining for flow 
cytometric analysis (approximately 1x10
6
 cells/well) and washed once in FACS buffer. 
The staining was performed in a volume of 50 l per sample. A mastermix was prepared 
containing the desired antibodies and anti-CD16/CD32 (blocking of FcR, “Fc block”). 
Upon centrifugation for 3 minutes at 486 x g, cells were resuspended in 50 l of the 
mastermix and incubated for 20 minutes on ice protected from light. Cells were washed 
twice in FACS buffer and afterwards analyzed by flow cytometry. Hoechst-33258 
(1 g/ml) was added to cells shortly before acquisition to exclude dead cells from analysis.  
 
3.2.9.2 Intracellular staining of cytokines 
To prevent secretion of cytokines, cells were incubated in the presence of 1 l/ml Golgi-
Plug/Stop for four to five hours at 37°C. Afterwards, cells were harvested and transferred 
into a 96-well round bottom plate. At first, a surface staining was performed as described 
in 1.2.9.1. Afterwards, stained cells were fixed for ten minutes at room temperature by 
incubation in 2% (v/v) PFA/FACS buffer. PFA was immediately washed off by 
centrifugation at 486 x g for 3 minutes. Cells were permeabilized by adding 100 l of 
Saponin/FACS buffer and incubated for 20 minutes at room temperature (protected from 
light). Plates were centrifuged for 3 minutes at 486 x g and a mastermix containing the 
cytokine antibodies (1:100 dilution) and anti-CD16/CD32 was prepared in 
Saponin/FACS buffer. Cells were resuspended in 50 l of the antibody mastermix and 
incubated protected from light for 30 minutes at room temperature (after 20 minutes 
another 100 l of Saponin/FACS buffer was added to allow unbound antibody to diffuse 
out of the cell). Afterwards, cells were washed twice in FACS buffer and applied to flow 
cytometry.    
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3.2.9.3 S8L/H-2K
b
 specific pentamer staining 
The generation of endogenous OVA-specific CD8 T cells was determined in spleens of 
mice five days post AdOVA or AdLOG infection using S8L/H2-K
b
 pentamers. The 
staining was conducted on a 96-well round bottom plate. Isolated splenocytes were washed 
once in FACS buffer and centrifuged for 3 minutes at 486 x g. Cells were resuspended in 
30 l FACS buffer containing 5 l S8L/H-2Kb pentamers as well as anti-CD16/CD32 and 
were incubated for 20 minutes at room temperature (light-protected). Afterwards, 20 l of 
a CD8a antibody was directly added (without centrifugation), which had been diluted in 
FACS buffer. Cells were incubated for further 20 minutes on ice and washed twice in 
FACS buffer before flow cytometric analysis. Hoechst-33258 (1 g/ml) was added to the 
cells immediately before data acquisition to discriminate between viable and dead cells. 
 
 
3.2.10 Analysis of antigen-specific cytotoxic CD8 T cells  
(in vivo cytotoxicity assay) 
 
Cytotoxic activity of endogenous antigen-specific CD8 T cells was measured in spleens 
five days post pathogen infection by performing an in vivo cytotoxicity assay (Feuerer et 
al., 2003). Briefly, splenocytes from syngeneic donor mice were divided into two fractions. 
One fraction was pulsed with 1 M of the specific H-2Kb peptides SIINFEKL (OVA), 
SVYDFFVWL (mTRP2), ASNENMETM/SSLENFRAYV (Influenza virus), or 
SSIEFARL (HSV-1 virus) for 20 minutes at 37°C. Subsequently, peptide-loaded cells were 
labeled with 1 M of CFSE or Far Red by incubation for 15 minutes at 37°C (CFSEhigh or 
Far Red, target cells). The second fraction was not pulsed with peptide and labeled with 
0.1 M CFSE (CFSElow, reference cells). Upon labeling, cells were washed extensively 
and counted. Both populations were mixed in a 1:1 ratio (CFSE
high
/Far Red:CFSE
low
) and 
1x10
7
 cells were injected i.v. into recipient mice. Unless otherwise stated, spleens were 
removed four hours later and homogenized by passing through a metal sieve. After 
centrifugation for 10 minutes at 486 x g, splenocytes were resuspended in 5 ml 
MACS buffer. Lysis of peptide-loaded cells was measured by flow cytometric analysis. 
Unimmunized naive mice served as a control. The percentage of specific lysis was 
calculated using the following formula: 
% specific cytotoxicity = 100 – [(CFSE
high
/CFSE
low
)sample / (CFSE
high
/CFSE
low
)control] x100  
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3.2.11 Cytokine ELISA (enzyme linked immunosorbent assay) 
ELISA microtiter plates were coated with 50 l per well of the primary capture antibody, 
which was diluted to 1 g/ml in ELISA coating buffer, and incubated overnight at 4°C. 
Unbound antibody was removed by extensive washing with ELISA washing buffer. To 
prevent unspecific binding, the ELISA plate was blocked by addition of 100 l blocking 
buffer and incubated for two hours at 37°C. After washing the plate thoroughly, 50 l of 
each sample (supernatants or sera in triplicates) and the recombinant cytokine standard 
(1 to 3 dilution series starting at 80 ng/ml, 8 steps) was added and incubated overnight at 
4°C. The plate was washed extensively and 50 l of the biotinylated detection antibody 
was added, which had been diluted to 0.5 g/ml in blocking buffer. The plates were 
incubated for two hours at room temperature and afterwards washed thoroughly again. The 
streptavidin-conjugated peroxidase was diluted to 1 g/ml in blocking buffer and 
50 l were added per well. After incubation for 30 minutes at 4°C and extensive washing, 
50 l of TMB substrate was applied to each well and the absorbance was immediately 
measured at 650 nm in a ELISA plate reader. Afterwards, the enzymatic reaction was 
stopped by addition of 50 l 0.18M H2SO4 stopping solution. The absorbance was 
measured at 450 nm again. The standard curve was plotted as a sigmoidal curve, as 
peroxidase is an allosteric enzyme.   
 
 
3.2.12 OVA IgG ELISA 
Mice were injected with AdOVA, with or without previous ssRNA injection. Serum titers 
of OVA-specific IgG were quantified 25 days post infection by ELISA. ELISA plates were 
coated with 100 l of 50 g/ml OVA (grade V), which was diluted in ELISA coating 
buffer. Plates were incubated overnight at 4°C and afterwards washed extensively in 
washing buffer to remove any unbound OVA. After blocking of ELISA plates 
(150 l blocking buffer, two hours at 37°C), sera were applied in a volume of 100 l per 
well. Sera were consecutively diluted 1:1 in blocking buffer on the plate (5 dilution steps) 
and incubated overnight at 4°C. After a thorough washing step, 100 l of biotinylated goat 
anti-mouse IgG antibody was added (1:10000 dilution in blocking buffer) and the plate 
was incubated for one hour at room temperature. Unbound detection antibody was 
removed by extensive washing before 100 l of streptavidin-conjugated peroxidase was 
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added at a concentration of 1 g/ml and incubated for one hour at room temperature. In the 
meantime, the OPD substrate solution was freshly prepared. 5 mg OPD was dissolved in    
5 ml OPD substrate buffer and supplemented with 5 l of 30% H2O2. After washing off the 
peroxidase, 50 l of the OPD substrate solution was applied per well and incubated until a 
color change to yellow was clearly visible. The enzymatic reaction was stopped by 
addition of 50 l 1M H2SO4. The absorbance was measured at 490 nm using the ELISA 
reader. OVA-specific IgG titers were quantified by plotting the serum dilution (y-axis) 
against the measured OD values (x-axis) to obtain a linear equation. The serum dilution 
was read at a fixed OD value for all samples (e.g. 0.5) and the titer corresponded to the 
reciprocal value of the serum dilution. 
 
 
3.2.13 Type I interferon bioassay 
Type I interferon (IFN) production was assayed in sera and splenocyte supernatants with 
the help of Prof. Dr. Rainer Zawatzky, DKFZ, Heidelberg.  
Biological activity of type I IFN was measured in a standard cytopathic effect inhibition 
assay using a modified 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide test, 
which was described previously (Nickolaus et al., 1998). Briefly, monolayers of murine L-
929 cells (15000 cells in 100l per well) were incubated overnight with twofold dilutions 
of the test samples and then infected with mouse encephalomyocarditis virus at a 
multiplicity of infection of 0.1. After 20 hours, methylthiazolyldiphenyl-
tetrazoliumbromide was added for four hours at a final concentration of 1 mg/ml. The 
virus-induced cytopathic effect was quantified by ELISA. A twofold dilution of an internal 
laboratory standard preparation of mouse IFN based on the NIH mouse reference IFN/ 
preparation was included in each test. One laboratory unit corresponded to one 
international unit (IU) defined as the concentration of type I IFN resulting in a 50% 
protection against viral lysis. Colorimetric analysis of the alcohol-soluble dye was 
performed at 570 nm using an ELISA reader. IFN activity was excluded by using an IFN 
blocking antibody.  
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3.2.14 Immunohistology of IFN  expression 
IFN expression was investigated in vivo in spleens upon ssRNA stimulation using IFN 
knockin reporter mice, which express the yellow fluorescence protein (YFP) under the 
IFN promoter (Scheu et al., 2008). Immunohistological analysis was performed with the 
help of Philipp Dresing and Dr. Stefanie Scheu, Uni Düsseldorf. 
Organs were fixed in 4% PFA at room temperature for two hours, incubated in 
30% sucrose solution overnight at 4°C, then embedded in OCT-TissueTek, and frozen in 
methylbutane on dry-ice. After blocking of endogenous peroxidases and biotin, 7-m 
sections were stained by using a rabbit anti-GFP antibody (cross-reacts with YFP) 
followed by a biotinylated donkey anti-rabbit antibody. After a repeated biotin and 
peroxidase blocking, sections were counterstained with a rat anti-MOMA-1 antibody 
followed by a goat anti-rat-Cy3 antibody. Signal amplification with TSA fluorescein or 
biotin kits was performed according to manufacturer’s instruction. Sections were mounted 
with Vectashield containg DAPI. Images were captured on an epifluorescence microscope 
with a digital camera and overlaid by using Photoshop software. 
 
 
3.2.15 In vivo imaging of bioluminescence 
Mice were analyzed at indicated time points after injection of recombinant AdLOG or 
B16-luc melanoma cells. Immediately before measurement of bioluminescence using the 
real-time IVIS Imaging System, mice were injected i.p. with 200 l luciferin solution. 
Analysis was performed under inhalational anesthesia with isoflurane. Data were aquired 
using the Living Image 2.50 software. 
 
 
3.2.16 Production of GM-CSF supernatant 
The GM-CSF producing cell line Ag8653 was thawed, added to 10 ml cold IMDM 
medium, and centrifuged at 486 x g for 10 minutes in order to remove DMSO. Afterwards, 
cells were resuspended in 10 ml warm IMDM medium and cultured in a T25 flask for 
24 hours at 37°. 1 mg/ml of G418 sullfate was added to select for GM-CSF producing cells 
and the cells were incubated for another 48 hours. Cells were splitted into three T75 flasks 
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containing 30 ml medium supplemented with 1 mg/ml G418 sulfate and grown until 
confluency. Then, cells were passaged into two T175 flasks containing 40-50 ml medium 
supplemented with 1 mg/ml G418 sulfate and incubated until they were confluent and the 
medium had turned orange. Ag8653 cells were harvested, counted and plated with 1.5x10
6
 
cells per dish (150x20 mm culture dish) in 30 ml medium without G418 sulfate. After three 
days of incubation, supernatants were collected in 50 ml tubes and centrifuged at 486 x g 
for 10 minutes and for further 20 minutes at 2683 x g. Supernatants were pooled in a sterile 
Erlenmeyer flask. Aliquots à 45 ml were stored at -20°C. 
 
 
3.2.17 Generation of bone-marrow derived DCs (BMDCs) 
Hind legs of C57BL/6 mice were cut at the pelvis and put into sterile PBS. Feet, skin, and 
muscle tissue were removed and blank bones were shortly dipped into ethanol. The 
femoral and the shank bones were separated and cut at the ends with a scissor. The bone 
marrow was eluted into a petri dish using a syringe filled with PBS. Afterwards, the bone 
marrow was homogenized by pipetting up and down several times. The cell suspension 
was centrifuged at 486 x g for 10 minutes and resuspended in IMDM medium 
supplemented with 30% GM-CSF supernatant. Cells were plated in 20 ml medium onto 
three petri dishes (10 cm) and incubated at 37°. After three to four days in culture, cells 
were passaged onto six petri dishes in fresh IMDM medium containing 30% GM-CSF 
supernatant and incubated for three further days. Differentiated BMDCs were used to 
identify the intracellular localization of DOTAP- or in vivo-jetPEI
TM
- complexed RNA 
(see 1.2.18). 
 
 
3.2.18 Intracellular localization of RNA in BMDCs 
1x10
5
 BMDCs were plated on microscopy glass slides using flexiPERM cell culture 
chambers and incubated for 30 to 45 minutes at 37°C to let BMDCs become attached. In 
the meantime, RNA-Al647 was complexed with either DOTAP or in vivo-jetPEI
TM
. 
500 ng RNA-Al647 was dissolved in 25 l of Optimem medium and 2 l DOTAP was 
mixed with 25 l Optimem medium. The DOTAP solution was added to the RNA solution, 
mixed, and incubated for 20 minutes at room temperature. For complexation with in vivo-
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jetPEI
TM
, 500 ng RNA-Al648 was added to 25 l of Optimem medium. A 1:10 pre-
dilution of in vivo-jetPEI
TM
 was prepared and 0.5 l of the dilution was added to 25 l 
Optimem medium. The in vivo-jetPEI
TM
 Optimem solution was mixed with the RNA 
solution and incubated for 20 minutes at room temperature. Upon incubation, further 
200 l of Optimem medium was added and the RNA complexes were given onto the 
BMDCs after the medium had been removed. To identify endosomal compartments, OVA-
FITC was added simultaneously at a concentration of 20 g/ml. Fluorescence microscopy 
was performed 20 minutes after RNA addition. Hoechst 33342 was added to cells shortly 
before microscopical analysis in order to identify cell nuclei. 
 
 
3.2.19 Determination of cell number 
The cell suspension was diluted 1:10 or 1:100 in 0.04% trypane blue to discriminate 
between live and dead cells. 10 l of this suspension was applied to a Neubauer counting 
chamber and living cells were counted in all four large squares. The cell count was 
calculated using the following formula: 
Cell number/ml = counted viable cells/4 x dilution x 10
4
 
 
 
3.2.20 Statistics 
Results are depicted as mean +/- standard error of the mean (SEM). Statistical significance 
was calculated by an unpaired two-tailed Student’s t test using the Prism software. 
p values of 0.01 to 0.05 were considered as significant (*), p values of 0.001 to 0.01 as 
highly significant (**) and p of <0.001 as extremely significant (***). 
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4 Results 
4.1 Suppression of adaptive immune responses by the TLR7 Ligand 
single-stranded RNA (ssRNA) 
4.1.1 ssRNA suppresses antigen-specific CTL responses in a TLR7- 
dependent manner  
 
Recognition of Toll-like receptor (TLR) ligands by their respective TLRs triggers the 
activation of the vertebrate’s immune system and generally results in immunity (Iwasaki 
and Medzhitov, 2004; Janeway, 1992; Kawai and Akira, 2005; Medzhitov and Janeway, 
2002). It is well established, that the local application of synthetic CpG oligonucleotides, a 
TLR9 ligand, enhances the immunogenicity of co-administered antigens (Klinman et al., 
2004; Krieg, 2006). However, we and other groups have shown that the systemic injection 
induces immunoregulatory mechanisms that cause the suppression of subsequent antigen-
specific adaptive immune responses (Mellor et al., 2005; Wilson et al., 2006; Wingender et 
al., 2006).  
In the present study, we investigated how a systemic administration of a TLR7 ligand 
affected antigen-specific T cell responses in the spleen against subsequent infections by 
viral or bacterial pathogens. As a synthetic TLR7 ligand we used a RNA 
oligoribonucleotide (ORN), termed 9.2, which is complementary to the human TLR9 
mRNA and recognized by murine TLR7 (Hornung et al., 2005). To study antigen-specific 
CTL responses, we infected mice i.v. with recombinant adenoviruses expressing OVA only 
(AdOVA) or luciferase, OVA, and GFP (AdLOG), respectively. The OVA-derived MHC 
class I peptide SIINFEKL (S8L) is presented on H-2K
b
 and recognized by peptide-specific 
T cells, which results in the expansion and activation of S8L-specific CTLs. Here, mice 
were immunized i.v. with 5x10
9
 virus particles of AdLOG alone or they received 20 g of 
9.2 (duplex RNA) or 10 g of the single-stranded RNA (ssRNA) 9.2s (sense strand of 9.2) 
i.v. one day prior to AdLOG administration. OVA-specific cytotoxicity was analyzed in 
spleens of mice five days post AdLOG infection using an in vivo cytotoxicity assay. CTL 
activity was completely inhibited in 9.2-injected mice, while AdLOG-infected mice 
generated a strong CTL response. Furthermore, 9.2-mediated suppression of the CTL 
response was dependent on the recognition of the single-strand RNA motif, in this case the 
sense strand of 9.2 (Figure 4.1 A, key finding by Beatrix Schumak). An influence of the 
antisense strand on the CTL response could be excluded, as it has been already reported by 
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Hornung et al. that the sense strand and not the antisense strand of 9.2 is recognized by 
TLR7 (Hornung et al., 2005). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1   RNA oligoribonucleotides suppressed adeno-specific CTL responses in a TLR7  
                    dependent manner.   
OVA-specific cytotoxic CD8 T cell responses were determined in spleens of mice five days post 
AdLOG infection. (A) Inhibition of the CTL response was dependent on the recognition of single-
strand RNA motifs. C57BL/6 wild type mice were injected i.v. with 5x10
9
 virus particles AdLOG 
alone or received 20 g of 9.2 (duplex RNA) or 10 g 9.2s (ssRNA, sense strand of 9.2) i.v. one 
day prior to AdLOG immunization. (B, C) RNA oligoribonucleotides suppressed CTL responses in 
a TLR7 dependent manner. C57BL/6 wild type, TLR3 ko, TLR7 ko, or MDA5 ko were immunized 
i.v. with AdLOG alone or were previously injected with 9.2s (sense, B) or 9.2 (duplex, C). OVA-
specific cytotoxicity is shown as mean +/- SEM (n=3 mice per group). Data of one representative 
experiment out of at least two independent experiments are depicted. 
 
 
Single-stranded RNA has been identified as a physiological ligand of TLR7 (Diebold et al., 
2004; Heil et al., 2004), whereas double-stranded RNA is recognized by endosomal TLR3 
(Alexopoulou et al., 2001) or by the cytoplasmic receptors MDA5 or RIG-I (Gitlin et al., 
2006; Hornung et al., 2006; Schlee et al., 2009; Yoneyama et al., 2005). In order to 
confirm, that 9.2-mediated CTL suppression required the recognition by TLR7 and not 
other nucleic acid receptors, we performed immunization experiments in TLR3 ko, TLR7 
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ko, and MDA5 ko mice. 9.2 and 9.2s ORN injection still impeded the generation of 
AdLOG-specific CTL responses in TLR3 and MDA5 ko mice, respectively. However, the 
OVA-specific cytotoxic activity was not impaired in TLR7 ko mice, proving that RNA-
mediated CTL inhibition depended on the recognition by endosomal TLR7 (Figure 4.1 B 
and C; Figure 4.1 C was kindly provided by Beatrix Schumak). All following experiments 
were performed with the single-stranded RNA oligoribonucleotide 9.2s if not otherwise 
stated. 
To identify the mechanisms underlying the CTL suppression, we first examined the 
possibility that innate immune stimulation by 9.2s triggered antiviral effects that led to a 
fast elimination of the virus, which might have resulted in a substantial reduction in 
antigen load in the organism. We infected C57BL/6 wild type mice either with AdLOG 
alone or injected mice i.v. with 10 g of 9.2s either one day before, simultaneously with, or 
one day after AdLOG administration. We assessed the adenoviral burden by in vivo 
imaging of bioluminescent luciferase expression two days post AdLOG immunization. In 
addition, OVA-specific lysis was quantified in spleens of mice five days post AdLOG 
injection.  
 
 
 
 
 
Figure 4.2   ssRNA-induced CTL suppression was not due to a reduced adenoviral burden. 
C57BL/6 wild type mice were infected with 5x10
9
 virus particles of AdLOG alone or they received 
i.v. 10 g of 9.2s either one day before, simultaneously with, or one day after AdLOG injection. 
(A) Adenoviral burden was quantified by in vivo imaging of bioluminescent luciferase expression 
two days post AdLOG immunization. (B) OVA-specific cytotoxicity was determined in spleens 
five days post AdLOG administration. Representative data are shown as mean +/- SEM (n=3 mice 
per group) of two independent experiments. 
 
 
In all 9.2s injected groups, an approximately tenfold reduction in luciferase expression was 
observed in comparison to mice injected with AdLOG alone, which indicated a diminished 
viral load due to innate immune stimulation by 9.2s (Figure 4.2 A). Nevertheless, the 
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OVA-specific CTL response was only compromised if 9.2s was given before AdLOG 
immunization. A simultaneous administration had only a minor influence on CTL activity, 
whereas a subsequent 9.2s injection did not impair the CTL response against AdLOG 
(Figure 4.2 B). In conclusion, these results demonstrated that the suppressive effect of 9.2s 
was not a consequence of a reduced viral burden but rather involved a regulatory 
mechanism. 
In further experiments we examined how a repetitive systemic administration of the ORN 
9.2s affected subsequent adenoviral-specific CTL responses. Here, three consecutive i.v. 
injections of 9.2s (d-3; d-2; d-1) prior to AdLOG infection also clearly inhibited the 
generation of an efficient CTL response (Figure 4.3 A). Even a second administration one 
day after AdLOG immunization did not rescue the CTL response (Figure 4.3 A). 
Moreover, we analyzed how long a previous injection with 9.2s interfered with the 
establishment of an AdLOG-specific CTL response. To this end, mice were injected i.v. 
with 10 g of 9.2s one day (d-1), three days (d-3) or five days (d-5) before AdLOG 
infection. OVA-specific CTL activity was suppressed regardless of whether 9.2s was given 
one day or three days before adenoviral infection. If mice received 9.2s already five days 
in advance, an antigen-specific CTL response was established, although it was less 
efficient (circa 50% reduction) in comparison to mice that were immunized with AdLOG 
alone (Figure 4.3 B). Furthermore, 9.2s-mediated suppression of CTL activity was dose-
dependent, as only the highest dose of 10 g clearly impeded an antigen-specific CTL 
response against a subsequent AdOVA infection. 1 g of 9.2s induced only a partial 
suppression of the CTL response (approximately 23% reduction), whereas a low dose of 
0.1 g 9.2s rather enhanced the cytotoxic activity (Figure 4.3 C). In conclusion, these 
results showed that ssRNA suppressed CTL responses in a time- and dose-dependent 
manner. 
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Figure 4.3   Time kinetics and dose dependency of ssRNA-mediated CTL suppression. 
Analysis of OVA-specific CTL responses in spleens of C57BL/6 wild type mice five days post 
AdLOG or AdOVA immunization. (A, B) 10 g 9.2s was administered i.v. at different time points 
with regard to AdLOG infection. (C) Wild type mice were injected i.v. with varying amounts of 
9.2s (0.1; 1, or 10 g) one day before infection with AdOVA. OVA-specific lysis is shown as mean 
+/- SEM with n=3 mice per group. 
 
 
To investigate if the observed suppressive impact induced by systemic 9.2s was restricted 
to adenoviral vectors, we performed experiments, in which C57BL/6 wild type mice were 
infected with other viral or bacterial pathogens. Mice were infected with 1x10
4
 PFU 
Herpes simplex virus type I (HSV-1), 1x10
5
 PFU Influenza A PR8/H1N1 virus, or 
5x10
3
 CFU OVA-expressing Listeria monocytogenes (LmOVA). Indicated groups received 
10 g of 9.2s i.v. one day prior to infection. Antigen-specific CTL responses were 
determined in spleens of mice five days post infection by performing in vivo cytotoxicity 
assays. We detected potent CTL responses against HSV-1 (Figure 4.4 A), Influenza virus 
(Figure 4.4 B), and LmOVA (Figure 4.4 C), which were significantly compromised when 
mice were previously injected with 9.2s. Thus, these results clearly showed that a systemic 
injection of ssRNA not only abrogated a CTL response against adenoviral vectors, but 
rather caused a general immune suppression against subsequent infections with various 
pathogens. 
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Figure 4.4   ssRNA impeded antigen-specific CTL responses against various pathogens. 
C57BL/6 wild type mice were infected with 1x10
4
 PFU HSV-1 (A), 1x10
5
 PFU Influenza 
A PR8/H1N1 virus (B), or 5x10
3
 CFU LmOVA (C). Indicated groups received 10 g of 9.2s i.v. 
one day prior to infection. Antigen-specific CTL responses were determined in spleens five days 
post infection and are illustrated as mean +/- SEM (n=3 mice per group). Representative data of 
two independent experiments are shown. 
 
 
 
 
4.1.2 Cytoplasmic targeting of ssRNA prevents suppression of antigen-
specific CTL responses 
 
Unlike immunostimulatory DNA sequences, naked RNA molecules are highly susceptible 
to degradation by RNases. Thus, a complexation with different carriers, like cationic 
liposomes or polyethylene imines is necessary (Diebold et al., 2004; Heil et al., 2004; 
Hornung et al., 2005). Data that have been presented in the previous chapter were obtained 
with 9.2s that had been stabilized with cationic liposomes (DOTAP). DOTAP not only 
protects RNA from degradation but also increases the uptake into cells and targets RNA to 
the endosomal compartment containing TLR7 (Almofti et al., 2003; Yasuda et al., 2005). 
A different complexing agent termed in vivo-jetPEI
TM
, which is a linear polyethylene 
imine, facilitates the delivery into the cytoplasm after osmotic rupture of the endosome and 
enhances the entry into the nucleus (Boussif et al., 1995; Brunner et al., 2002; Kichler et 
al., 1995). Therefore, we analyzed whether CTL suppression was associated with the 
subcellular distribution of RNA oligoribonucleotides and whether inhibition of subsequent 
antigen-specific immune responses could be prevented when ssRNA was complexed with 
the carrier in vivo-jetPEI
TM
, thereby circumventing endosomal recognition by TLR7. To 
this end, we infected C57BL/6 wild type mice i.v. with AdLOG, HSV-1, Influenza A 
PR8/H1N1 virus, or LmOVA. Indicated groups were previously injected with 10 g 9.2s, 
which had been complexed with either DOTAP (9.2s/DOTAP) or in vivo-jetPEI
TM
 
(9.2s/PEI). Antigen-specific CTL responses were quantified in spleens of mice five days 
post infection. Only 9.2s/DOTAP caused suppression of antigen-specific CTL responses 
against AdLOG (Figure 4.5 A), HSV-1 (Figure 4.5 B), Influenza virus (Figure 4.5 C), and 
LmOVA (Figure 4.5 D) as already shown in Figure 4.4. However, if 9.2s was stabilized by 
in vivo-jetPEI
TM
, antigen-specific CTL responses were not impeded but were comparable 
to mice that had been exposed to the pathogen alone (Figure 4.5). Thus, ssRNA-induced 
immune suppression was avoided by complexation with the carrier in vivo-jetPEI
TM
.  
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Figure 4.5   ssRNA delivery into the cytoplasm abolished suppression of antigen-specific CTL 
responses.   
C57BL/6 wild type mice were infected with 5x10
9 
virus particles of AdLOG (A), 1x10
4
 PFU   
HSV-1 (B), 1x10
5
 PFU Influenza A PR8/H1N1 virus (C), or 5x10
3
 CFU LmOVA (D). Indicated 
groups were injected i.v. with 10 g 9.2s, which had been complexed with either DOTAP 
(9.2s/DOTAP) or in vivo-jetPEI
TM 
(9.2s/PEI), one day prior to pathogen infection. Antigen-specific 
CTL responses were quantified in spleens five days post infection and are displayed as mean       
+/- SEM with n=3 mice per group. Representative data of at least two independent experiments are 
shown. 
 
 
Furthermore, we aimed to confirm that RNA complexation with in vivo-jetPEI
TM
 
circumvented the suppression of CTL responses due to a distinct intracellular localization 
and not due to a difference in the in vivo distribution of ssRNA. Therefore, we made use of 
Alexa647-labeled RNA that was complexed with either the carrier DOTAP or in vivo-
jetPEI
TM
. Regardless of whether this RNA was stabilized with DOTAP or in vivo-jetPEI
TM
, 
an overall in vivo distribution was seen upon systemic injection (Figure 4.6 A). To study 
the intracellular localization of DOTAP-versus in vivo-jetPEI
TM
- complexed RNA, we 
incubated bone marrow-derived DCs (BMDCs) with 500 ng of RNA-Alexa647 that had 
been stabilized with either DOTAP or in vivo-jetPEI
TM
. Endosomes were identified by 
coincubation with 20 g/ml FITC-labeled OVA known to be directed into endosomes upon 
receptor-mediated uptake (Burgdorf et al., 2007). Fluorescence microscopic analysis was 
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performed 20 minutes after RNA addition. In accordance to other studies, we detected an 
endosomal localization of DOTAP-complexed RNA, while RNA was distributed in the 
cytoplasm and nucleus when stabilized with in vivo-jetPEI
TM
 (Figure 4.6 B). 
 
 
 
 
 
 
 
 
 
Figure 4.6  Complexation of RNA with DOTAP or in vivo-jetPEI
TM
 targeted RNA to     
distinct intracellular compartments. 
(A) In vivo distribution of Alexa647-labeled RNA, complexed with either the carrier DOTAP or in 
vivo-jetPEI
TM
, was analyzed upon i.v. injection using the NightOWL Scanner applying a Cy5 filter. 
One representative mouse out of two is depicted. (B) Intracellular localization of RNA was 
investigated in BMDCs by fluorescence microscopy. BMDCs were incubated with 500 ng of RNA-
Alexa647, which had been complexed to either DOTAP or in vivo-jetPEI
TM
. Endosomes were 
identified by coincubation with 20 g/ml FITC-labeled OVA. Fluorescence microscopic analysis 
was performed 20 minutes after RNA addition. Representative pictures of at least three 
independent experiments are shown. 
 
 
In conclusion, our data revealed that ssRNA-induced immune suppression was avoided by 
complexation with the carrier in vivo-jetPEI
TM
, which promoted the delivery of RNA to the 
cytoplasm thereby circumventing endosomal TLR7 recognition. 
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4.1.3 Differential regulation of AdOVA-specific effector CD8 T cell 
responses by distinct intracellular targeting of ssRNA 
 
Based on our findings that systemic ssRNA induced a TLR7 dependent suppression of 
subsequent CTL responses, we wondered whether the lack of cytotoxic activity was due to 
tolerization (Steinman et al., 2003) or rather due to an absent generation of antigen-specific 
effector CD8 T cells. To address this question, mice were either left untreated or injected 
i.v. with 10 g of 9.2s/DOTAP or 9.2s/PEI one day prior to AdOVA infection. The 
generation of endogenous OVA-specific CD8 T cells was assayed five days post AdOVA 
infection in spleens by flow cytometric analysis of S8L/H-2K
b
 specific pentamers and the 
total number of OVA-specific CD8 T cells per spleen was calculated. A massive expansion 
of pentamer-positive OVA-specific CD8 T cells was detected in mice that had been 
immunized with AdOVA alone, whereas the previous injection of DOTAP-complexed 9.2s 
avoided the generation of OVA-specific CD8 T cells and the number of pentamer-positive 
CD8 T cells was comparable to those observed in naive mice. In contrast, a significant 
increase in endogenous OVA-specific CD8 T cells was also noticed if 9.2s was stabilized 
using the carrier in vivo-jetPEI
TM
 (Figure 4.7 A and B).  
Moreover, we monitored the activation status of OVA-specific CD8 T cells by staining for 
CD62L on S8L/H-2K
b
 pentamer-positive cells. CD62L expression on naive T cells is 
required for their
 
efficient homing to lymph nodes. It is rapidly downregulated upon T cell 
activation, which then gain access to peripheral tissues (Butcher and Picker, 1996; 
Mascarell and Truffa-Bachi, 2004). In AdOVA immunized mice, most OVA-specific 
CD8 T cells (74.0% ± 1.8) showed an activated phenotype, as evidenced by a low 
expression level of CD62L. If mice received a pre-injection of 9.2s/DOTAP, only 
37% ± 1.8 of OVA-specific CD8 T cells exhibited a low expression of CD62L, whereas 
68.3% ± 2.9 of pentamer-positive CD8 T cells downregulated CD62L, if 9.2s was 
stabilized with in vivo-jetPEI
TM
 (Figure 4.7 D). Furthermore, just like in naive mice, 
almost no activated OVA-specific CD8 T cells were present in spleens after AdOVA 
immunization, if mice had been pretreated with 9.2s/DOTAP. Comparable total numbers 
of activated pentamer-positive CD8 T cells were present in mice, which had been infected 
with AdOVA alone or received 9.2s/PEI prior to AdOVA administration (Figure 4.7 C). 
In addition to activation and cytotoxic activity of OVA-specific CD8 T cells, we 
determined how effector cytokine production was affected by a preceding administration 
of 9.2s in response to AdOVA immunization. Splenocytes were isolated from AdOVA or 
9.2s/AdOVA injected mice and restimulated for 24 hours with the OVA-derived peptide 
Results 
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S8L. IFN production was measured by intracellular cytokine staining and flow cytometric 
analysis or in cell culture supernatants by ELISA. IFN was produced by 2.7% ± 0.3 of 
CD8 T cells in response to AdOVA infection. However, IFN production was almost 
absent if mice had been injected with 9.2s/DOTAP before (0.2% ± 0.1). In contrast, 
effector cytokine production was rescued, if 9.2s was directed into the cytoplasm by 
stabilization with in vivo-jetPEI
TM
 (1.9% ± 0.3) (Figure 4.7 E and F). The same result was 
obtained, when IFN secretion was quantified in culture supernatants of S8L-restimulated 
splenocytes (Figure 4.7 G). In summary, suppression of antigen-specific CTL responses by 
DOTAP-complexed ssRNA was accompanied by an impaired expansion, activation, and 
IFN production of OVA-specific CD8 T cells. 
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Figure 4.7   DOTAP-stabilized ssRNA interfered with the expansion, activation, and cytokine 
secretion of OVA-specific CD8 T cells.  
C57BL/6 wild type mice were immunized i.v. with 5x10
9
 virus particles of AdOVA alone or mice 
received i.v. 10 g of 9.2s/DOTAP or 9.2s/PEI one day prior to infection. (A) The generation of 
endogenous OVA-specific CD8 T cells was assayed by flow cytometry five days post AdOVA 
infection by S8L/H-2K
b
 pentamer staining of splenocytes and (B) the total number of OVA-
specific CD8 T cells per spleen was calculated. (C, D) Expression of CD62L was examined on 
S8L/H-2K
b
 pentamer positive endogenous OVA-specific CD8 T cells (D) and the total count of 
CD62
low
 OVA-specific CD8 T cells in the spleen was determined (C). (E-G) Splenocytes, isolated 
from AdOVA or 9.2s/AdOVA immunized mice, were restimulated with the OVA-specific peptide 
S8L. IFN production of OVA-specific CD8 T cells was measured by intracellular cytokine 
staining and flow cytometric analysis (E, F) or in splenocyte supernatants by ELISA (G). 
Representative dot plots or histograms of one mouse out of three are shown. Data presented in bar 
graphs show mean +/- SEM (n=3 mice per group). 
 
 
Furthermore, we investigated if a preceding i.v. injection of ssRNA also suppressed 
transgenic OVA-specific OT-I T cells in response to AdOVA immunization (Hogquist et 
al., 1994). To this end, we adoptively transferred 5x10
4
 OT-I T cells expressing the 
congenic marker Thy1.1 into naive C57BL/6 wild type recipient mice. Afterwards, mice 
were either left untreated or injected i.v. with 10 g of 9.2s/DOTAP or 9.2s/PEI one day 
before AdOVA immunization. Five days post infection, expansion of transgenic            
OT-I T cells was examined in spleens by flow cytometric analysis of CD8a and Thy1.1 
double-positive lymphocytes. A massive accumulation of OT-I T cells was detected in 
mice that had been infected with AdOVA alone (2.6% ± 0.14% of splenocytes) and in 
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those that had received 9.2s/PEI prior to AdOVA administration (2.21% ± 0.16% of 
splenocytes). Again, only a moderate increase in OT-I T cells was evident (0.45% ± 0.04% 
of splenocytes), if mice had been pre-injected with 9.2s that had been targeted to the 
endosome by complexation with DOTAP (Figure 4.8 A). Additionally, we analyzed the 
activation of OT-I T cells by staining of CD62L. Most OT-I T cells revealed an activated 
phenotype as reflected by low CD62L expression, if mice had been immunized with 
AdOVA alone (72.8% ± 0.7) or pre-injected with 9.2s/PEI (57.1% ± 4.9). In contrast, 
administration of 9.2s/DOTAP prior to AdOVA infection interfered with T cell activation 
as the majority of OT-I T cells still expressed high levels of CD62L (Figure 4.8 B). 
Finally, we determined whether OT-I T cells were impaired in IFN production upon 
antigen-specific restimulation. Here, splenocytes were isolated five days post AdOVA or 
9.2s/AdOVA administration and restimulated with the OVA-specific peptide S8L. The 
percentage of IFN secreting OT-I T cells was quantified by intracellular cytokine staining 
and subsequent flow cytometric analysis. Regardless of whether mice were immunized 
with AdOVA alone or had been previously injected with 9.2s, similar percentages of IFN 
producing OT-I T cells were detected upon restimulation (Figure 4.8 C). In conclusion, 
these data clearly demonstrate that 9.2s/DOTAP-mediated CTL suppression was not a 
result of T cell tolerization but rather due to an impaired activation and expansion of 
antigen-specific CD8 T cells.  
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Figure 4.8   Targeting of ssRNA to the endosomes inhibited expansion and efficient activation 
of transgenic OT-I T cells in response to AdOVA infection. 
C57BL/6 wild type mice received 5x10
4
 transgenic OT-I/Thy1.1
+ 
T cells. Subsequently, mice were 
infected i.v. with AdOVA alone or were injected i.v. with 10 g of 9.2s/DOTAP or 9.2s/PEI one 
day before adenoviral immunization. (A) Expansion and total number of transgenic OT-I/Thy1.1
+
 
cells was determined in spleens five days post AdOVA administration. (B) CD62L expression was 
monitored on OT-I/Thy1.1
+
 cells and the percentage of CD62L
low
 OT-I/Thy1.1
+
 cells is depicted. 
(C) Splenocytes were isolated from AdOVA or 9.2s/AdOVA immunized mice and IFN production 
by OT-I/Thy1.1
+
 CD8 T cells was analyzed by intracellular cytokine staining upon S8L 
restimulation. Representative dot plots or histograms of one mouse out of three are shown. Data 
presented in bar graphs are illustrated as mean +/- SEM (n=3 mice per group). 
 
 
 
 
 
 
4.1.4 Antigen-specific CD4 T cell responses are impeded by endosomal 
targeting of ssRNA 
 
It is known, that cognate CD4 T cell help is indispensable to establish an efficient and 
long-lasting CD8 T cell response. CD4 T cell help was also essential for a strong CTL 
response against AdOVA, since the cytotoxic activity was significantly impaired in mice 
that lack CD4 T cells and MHC class II molecules (Figure 4.9 A and B, data kindly 
provided by Beatrix Schumak). 
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Figure 4.9   Efficient AdOVA-specific CTL response required CD4 T cell help. 
OVA-specific CTL responses were examined in spleens of C57BL/6 wild type mice ± CD4 
depleting antibody, in CD4 ko (A), and I-A
b
 ko mice (B) five days post AdOVA infection. 500 g 
of CD4 depleting antibody was given i.p. two days before AdOVA challenge (A). Data are shown 
as mean +/- SEM with n=3 mice per group. 
 
 
Based on these findings, we asked the question whether systemic injection of ssRNA 
oligoribonucleotides also affected antigen-specific CD4 T cell responses. First, we 
investigated if proliferation of OVA-specific CD4 T cells was impaired in response to 9.2s 
and AdOVA immunization. Here, we adoptively transferred 2x10
6
 CFSE-labeled 
transgenic OVA-specific CD4 T cells (OT-II) into naive C57BL/6 mice. Two days upon 
transfer, mice were immunized i.v. with AdOVA alone or indicated groups received 10 g 
of 9.2s/DOTAP or 9.2s/PEI one day prior to adenoviral challenge. Proliferation was 
monitored three days post AdOVA infection by a CFSE dilution assay.  
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Figure 4.10    DOTAP-complexed ssRNA impaired proliferation and expansion of OVA-
specific CD4 T cells. 
2x10
6
 CFSE-labeled transgenic OVA-specific CD4 T cells (OT-II) were adoptively transferred into 
naive C57BL/6 wild type mice. Two days upon transfer, mice were immunized i.v. with AdOVA 
alone or indicated groups received 10 g of 9.2s/DOTAP or 9.2s/PEI i.v. one day prior to 
adenovirus administration. (A) Proliferation of OT-II cells was monitored three days post AdOVA 
challenge by a CFSE dilution assay. In (B) the percentage of proliferated OT-II cells is depicted 
and the total number of OT-II cells per spleen is shown in (C). The experiment was performed with 
n=3 mice per group. 
 
 
 
Strong proliferation of OT-II T cells was detected in mice that had been infected with 
AdOVA alone or those that had received a preceding injection of 9.2s/PEI. Although the 
percentage of proliferated OT-II T cells was similar in AdOVA (97.1% ± 0.9) or 9.2s/PEI 
and AdOVA (80.7 ± 4.6) immunized mice, obviously less OT-II T cells were counted in 
spleens of 9.2s/PEI and AdOVA injected mice. However, neither proliferation (Figure 4.10 
A and B) nor expansion (Figure 4.10 C) of OT-II T cells was observed in mice that had 
received DOTAP-complexed 9.2s. 
 
Furthermore, we assayed how systemic RNA oligonucleotides influenced the production of 
effector cytokines like IFN and IL-2 in response to AdOVA immunization. C57BL/6 wild 
type mice were either left untreated or injected i.v. with 9.2s/DOTAP or 9.2s/PEI one day 
prior to AdOVA challenge. Splenocytes were isolated five days later and endogenous 
OVA-specific CD4 T cells were restimulated using an MHC class II restricted OVA-
specific peptide (OVA 265-279; OT3p). IFN production by splenic CD4 T cells was 
investigated by intracellular cytokine staining and subsequent flow cytometric analysis. In 
addition, the release of IFN and IL-2 was measured by ELISA in splenocyte culture 
supernatants.  
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Figure 4.11    DOTAP-stabilized ssRNA impeded effector cytokine production by CD4 T cells 
upon AdOVA challenge. 
C57BL/6 wild type mice were either left untreated or injected i.v. with 10 g of 9.2s/DOTAP or 
9.2s/PEI one day before AdOVA infection. Splenocytes were isolated five days post AdOVA 
challenge and endogenous OVA-specific CD4 T cells were restimulated using an MHC class II 
restricted OVA-specific peptide (OVA265-279; OT3p). IFN production by CD4 T cells was 
investigated by intracellular cytokine staining and flow cytometric analysis (A). Secretion of IFN 
and IL-2 was measured in splenocyte culture supernatants by ELISA (B). Representative data in 
bar graphs are shown as mean +/- SEM. A representative dot plot of one mouse is depicted (n=3 
mice per group). 
 
 
 
Targeting of 9.2s into the endosome by DOTAP complexation impeded effector cytokine 
production in response to AdOVA stimulation, as no IFN producing CD4 T cells were 
detected (Figure 4.11 A). Moreover, no IFN and only little amounts of IL-2 was secreted 
in splenocyte cultures (Figure 4.11 B). As expected, IFN and IL-2 were produced if 9.2s 
was directed into the cytoplasm by stabilization with in vivo-jetPEI
TM
. 
Thus, these data clearly indicated that the systemic injection of RNA oligoribonucleotides 
impeded the expansion and effector cytokine production of antigen-specific CD4 T cells, if 
ssRNA was targeted to the endosome by complexation with DOTAP.  
 
T helper cell function is important to ensure an optimal Ig isotype class switch to IgG 
antibodies (Grewal and Flavell, 1996; Hollenbaugh et al., 1994). Thus, we quantified 
OVA-specific IgG antibody titers in sera of wild type mice that had been infected with 
AdOVA alone or had been pre-injected with 9.2s/DOTAP. OVA-specific IgG titers were 
IFNγ
C
D
4
naive AdOVA
9.2s (DOTAP)
AdOVA
9.2s (PEI)
AdOVA
0.027 1.31 0.034 1.25
0.0
0.5
1.0
1.5 *** ***
*
IF
N
γ p
ro
du
ci
ng
 C
D
4 
T 
ce
lls
 (%
)
0
5
10
15
20
25
30
35
n.d.
**
***
IF
N
γ (
ng
/m
l)
0.00
0.05
0.10
0.15
0.20
0.25
0.30
0.35
n.d.
***
***
IL
-2
 (n
g/
m
l)
naive Ø
AdOVA
9.2s
(DOTAP)
AdOVA
9.2s
(PEI)
AdOVA
naive Ø
AdOVA
9.2s
(DOTAP)
AdOVA
9.2s
(PEI)
AdOVA
naive Ø
AdOVA
9.2s
(DOTAP)
AdOVA
9.2s
(PEI)
AdOVA
A
B
Results 
 61 
remarkably diminished (ca. fourfold reduction) in 9.2s/AdOVA treated mice indicating that 
CD4 T cell help was compromised (Figure 4.12). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.12    Systemic injection of ssRNA interfered with the generation of OVA-specific IgG 
antibodies. 
Titers of OVA-specific IgG antibodies were quantified in sera of C57BL/6 wild type mice 25 days 
post AdOVA infection. Mice were either left untreated or injected with 10 g of 9.2s/DOTAP one 
day prior to AdOVA immunization. Each bar represents the mean +/- SEM with n=5 mice per 
group. Representative data out of three independent experiments are illustrated. 
 
 
 
So far, we have demonstrated that targeting of ssRNA to the endosome interfered with the 
generation of an antigen-specific CD4 T cell response, thus presumably leading to an 
impaired CD4 T cell help. Based upon this assumption, we examined whether it might be 
possible to overcome ssRNA-mediated CTL suppression by providing CD40-CD40L 
signals. CD40 and CD40L interactions are known to mediate CD4 T cell help and have 
been implicated in the generation of CTL responses against adenovirus (Bennett et al., 
1998; Schoenberger et al., 1998; Toes et al., 1998; Yang et al., 1996). To this end, 
C57BL/6 wild type mice were immunized i.v. with AdOVA alone or pre-injected i.v. with 
10 g of 9.2s/DOTAP. Indicated groups were injected twice with 100 g of an anti-CD40 
antibody (FGK-45) and OVA-specific lysis was determined in spleens of mice five days 
post adenoviral challenge. Surprisingly, CD40 stimulation was not sufficient to overcome 
ssRNA-induced immune suppression (Figure 4.13).  
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Figure 4.13   CD40 stimulation did not prevent ssRNA-induced CTL suppression. 
C57BL/6 wild type mice were immunized i.v. with AdOVA alone or received i.v. 10 g of 
9.2s/DOTAP one day before adenovirus challenge. Indicated groups were injected twice with 
100 g of an anti-CD40 antibody (one injection i.p. on the day of and one injection i.v. one day 
after AdOVA infection). OVA-specific cytotoxicity was analyzed five days post AdOVA infection 
in spleens of mice. Data are presented as mean +/- SEM (n=3 mice per group). 
 
 
 
 
Furthermore, we addressed the question, if it was possible to prevent ssRNA-induced 
CTL suppression in the presence of activated and memory antigen-specific CD4 T cells, 
which provide not only CD40-CD40L signals, but license the DCs in an antigen-specific 
manner through binding of the TCR to MHC class II molecules and/or by secretion of 
cytokines. Endogenous OVA-specific CD4 T cells were activated in vivo by s.c. 
immunization with 50 g of OVA265-279 peptide (OT3p) in adjuvants six days (for effector 
CD4 T cells) or four weeks (for memory CD4 T cells) before AdOVA infection. Indicated 
groups were additionally injected i.v. with 9.2s/DOTAP one day before adenovirus 
challenge. OVA-specific cytotoxic activity and expansion of OVA-specific CD8 T cells 
was analyzed in spleens five days post AdOVA infection. Importantly, ssRNA-induced 
abrogation of an AdOVA-specific CD8 T cell response was prevented in the presence of 
antigen-specific effector (Figure 4.14 A and C) and memory CD4 T cells (Figure 4.14 B 
and D). Thus, suppression of the CD8 T cell response might be overcome in the presence 
of CD4 T cell help provided by effector or memory CD4 T cells. 
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Figure 4.14    Presence of activated and memory antigen-specific CD4 T cells prevented   
ssRNA-mediated suppression of the CTL response. 
Endogenous OVA-specific CD4 T cells were activated in vivo by s.c. immunization with 50 g of 
OVA265-279 peptide, mixed with 5 g of CpG-1668 and 5 g of pI:C, six days before AdOVA 
infection (A, C). For OVA-specific memory CD4 T cell generation, the peptide mixture was given 
s.c. four weeks before AdOVA challenge (B, D). Indicated groups were injected i.v. with 10 g 
9.2s/DOTAP one day before AdOVA immunization. OVA-specific cytotoxicity (A, B) and the 
generation of OVA-specific CD8 T cells (C, D) was investigated in spleens of mice five days post 
AdOVA infection. In bar graphs the mean +/-SEM (with n=3 mice per group) is displayed. 
Representative S8L/H-2K
b 
- pentamer dot plots of one mouse out of three are presented. Two 
independent experiments were performed. 
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4.1.5 IL-10 is not involved in ssRNA-mediated suppression of the 
CTL response 
 
IL-10 is an anti-inflammatory cytokine, which plays a role in the suppression of immune 
responses. It is expressed by a variety of immune cells, such as TH2 cells, 
T regulatory cells, macrophages, or DCs and suppresses the production of pro-
inflammatory cytokines like IL-12, which is important for an efficient T cell response 
(Fiorentino et al., 1989; Fiorentino et al., 1991; Maynard and Weaver, 2008; Mosser and 
Zhang, 2008). As we observed suppression of CTL responses upon RNA 
oligoribonucleotide administration, we speculated whether IL-10 production might be 
stimulated upon systemic ssRNA administration. To address this question, we used 
C57BL/6 wild type and IL-10 ko mice, which were infected with AdOVA alone or had 
been injected i.v. with 10 g 9.2s/DOTAP one day before adenovirus infection. OVA-
specific CTL responses were assessed in spleens five days post infection. 9.2s-induced 
suppression of an AdOVA-specific CTL response was still observed in IL-10 ko mice, 
implying that IL-10 was not involved (Figure 4.15). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.15   ssRNA-mediated CTL suppression was independent of IL-10. 
C57BL/6 wild type and IL-10 ko mice were immunized i.v. with either AdOVA alone or injected 
i.v. with 10 g of 9.2s/DOTAP one day before adenovirus infection. OVA-specific lysis was 
measured in spleens five days post AdOVA infection. Data are presented as mean +/- SEM (n=3 
mice). 
 
 
 
4.1.6 ssRNA-induced CTL suppression depends on type I interferon  
 
It has been reported that detection of viral and non-viral nucleic acids by pattern-
recognition receptors results in the induction of type I interferons (IFN), which play a 
0
25
50
75
100
O
VA
-s
pe
ci
fic
 c
yt
ot
ox
ic
ity
 (%
)
wild type IL-10 ko
AdOVA 9.2s; AdOVA
n.d.
** *
Results 
 65 
crucial role in linking innate and adaptive immunity. Type I IFN serves as a signal 3 (in 
addition to TCR stimulation (signal 1) and costimulation (signal2) to obtain an efficient 
cytotoxic CD8 T cell response (Curtsinger et al., 2005; Decker et al., 2005; Diebold et al., 
2004; Hornung et al., 2005; Lund et al., 2004; Uematsu and Akira, 2007).  
Thus, we investigated if systemic administration of 9.2s triggered the release of 
type I IFNs. To this end, C57BL/6 wild type mice were injected i.v. with 10 g of 
9.2s/DOTAP and type I IFN secretion was monitored at different time points post injection 
in sera and in splenocyte culture supernatants using a type I IFN bioassay (Nickolaus et al., 
1998).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.16   DOTAP-complexed ssRNA induced the production of type I interferons. 
10 g of DOTAP-stabilized 9.2s was administered i.v. into mice. (A, B) Type I interferon secretion 
was analyzed in sera (A) and splenocyte supernatants (B) of C57BL/6 wild type mice at indicated 
time points post 9.2s injection. (C) Type I interferon production was quantified in sera of wild type, 
TLR7 ko, and TLR3 ko mice six hours after i.v. injection of DOTAP or in vivo-jetPEI
TM 
complexed 
9.2s. 
 
 
Type I IFN was detected as early as three hours post 9.2s injection both in sera 
(Figure 4.16 A) and splenocyte culture supernatants (Figure 4.16 B). Highest levels of 
type I IFN secretion was recorded six hours after 9.2s challenge, which declined 
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progressively until almost no type I IFN was measured 24 hours post 9.2s injection (Figure 
4.16 A and B). In order to analyze if the initiation of type I IFN required endosomal 
recognition of 9.2s by TLR7, we performed the experiment in TLR7 ko mice or complexed 
9.2s to the carrier in vivo-jetPEI
TM
, which targets 9.2s to the cytoplasm. As expected, we 
did not detect type I IFN secretion in TLR7 ko mice nor in mice that had received in vivo-
jetPEI
TM
-stabilized 9.2. High amounts of type I IFN were found in sera of TLR3 ko mice 
in response to 9.2s/DOTAP, which was consistent with the result that ssRNA-mediated 
CTL suppression did not involve TLR3 (Figure 4.16 C).  
 
As 9.2s stimulated the production of type I IFNs, we addressed the question whether the 
generation of antigen-specific CTL responses was inhibited through the induction of 
type I IFNs despite their well-described immune-activating properties (Akira et al., 2006; 
Curtsinger et al., 2005; Uematsu and Akira, 2007). Here, we used IFNAR1-deficient mice, 
which cannot respond to type I IFNs due to a lack of the receptor (van den Broek et al., 
1995a; van den Broek et al., 1995b). C57BL/6 wild type and IFNAR1 ko mice were either 
left untreated or injected i.v. with 10 g of 9.2s/DOTAP one day prior to AdLOG 
immunization. Five days post infection, OVA-specific cytotoxicity was quantified in 
spleens of mice. Additionally, the generation of OVA-specific CD8 T cells was determined 
by flow cytometry analysis of S8L/H-2K
b
 pentamers. Interestingly, 9.2s did not impair the 
cytotoxic activity (Figure 4.17 A; data kindly provided by Beatrix Schumak) and 
generation of OVA-specific CD8 T cells (Figure 4.17 B) in IFNAR1 deficient mice, 
supporting the notion that 9.2s-induced type I IFNs caused the inhibition of subsequent 
CTL responses.  
To further strengthen the hypothesis that type I IFNs act in an immunosuppressive way on 
adaptive immune responses, we analyzed the influence of recombinant type I IFNs on 
AdLOG-specific cytotoxic activity in wild type mice. Mice were injected i.v. with 1000U 
IFN, IFN, or IFN/ one day before AdLOG immunization. As a positive control, mice 
received 9.2s/DOTAP. The cytotoxic activity of OVA-specific CD8 T cells was 
remarkably decreased (reduction in cytotoxic activity of about 50%) in the presence of 
type I IFN in comparison to mice that had been challenged with AdLOG alone. However, 
the inhibition of the CTL response was not as severe as if 9.2s was applied, which might be 
due to lower levels of circulating recombinant type I IFN compared to the amount that was 
induced by 9.2s administration (Figure 4.17 C). 
Results 
 67 
Finally, we revealed that 9.2s-mediated CTL suppression was not exclusively dependent 
on IFN, as 9.2s administration did not interfere with the OVA-specific CTL response in 
IFN deficient mice (Figure 4.17 D). 
Taken together, our results demonstrate that systemic ssRNA application induced the 
production of type I IFNs, which inhibited antigen-specific CTL responses in the spleen 
despite its well-known immune stimulatory property.  
 
 
 
 
 
 
 
 
 
 
 
Figure 4.17   ssRNA-mediated inhibition of the CTL response was type I interferon  
                      dependent. 
(A, B) C57BL/6 and IFNAR1 ko mice were immunized i.v. with AdLOG alone or received an i.v. 
administration of 10 g 9.2s/DOTAP one day prior to AdLOG infection. OVA-specific 
cytotoxicity (A) and the generation of OVA-specific CD8 T cells (B) was determined in spleens 
five days post AdLOG immunization. (C) The influence of recombinant type I interferon on 
AdLOG-specific cytotoxic activity was analyzed by i.v. injection of  1000U of IFN, IFN, or 
IFN/IFN one day before AdLOG administration in wild type mice. As a positive control, mice 
received 10 g of 9.2s/DOTAP i.v. before AdLOG vaccination. (D) C57BL/6 and IFN ko mice 
were infected with AdLOG alone or were previously injected i.v. with 10 g of 9.2s/DOTAP.     
(C, D) OVA-specific lysis was assayed in spleens of mice five days post adenovirus immunization. 
Data are shown as mean +/- SEM with n=3 mice per group. (A, B, D)  Representative results of at 
least two independent experiments are depicted. 
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4.1.7 Plasmacytoid DCs produce type I interferon in response to ssRNA 
stimulation 
 
It has been reported that a wide variety of cell types are capable of producing type I IFN by 
using a feed-forward amplification loop that is initiated by paracrine or autocrine binding 
of secreted IFN/ to the type I IFN receptor (Bogdan et al., 2004; Decker et al., 2005). 
Plasmacytoid DCs (pDCs) are known to rapidly release vast quantities of early type I IFN 
in response to TLR stimulation (especially TLR7 and 9 stimulation) independent of the 
positive amplification loop (Asselin-Paturel and Trinchieri, 2005; Decker et al., 2005; 
Honda et al., 2005).  
In the following experiment, we sought after the cell type secreting type I IFN in response 
to 9.2s stimulation. In order to identify the cell population in vivo we made use of IFN 
knockin reporter mice, which produce YFP when IFN is induced (Scheu et al., 2008). 
IFN-YFP reporter mice were injected i.v. with 10 g 9.2s/DOTAP and six hours later 
YFP expression was assayed by flow cytometry of splenocytes. YFP signals, which 
corresponded to IFN production, were detected in splenic pDCs, which were identified by 
CD11c
int
PDCA-1
pos
B220
pos
CD11b
neg
 expression. No other cell type, such as T or B cells, 
released IFN after 9.2s injection (Figure 4.18 A). Moreover, histological staining was 
performed on spleen sections to localize IFN expression. YFP positive signals were 
evident in the marginal zone, which had been visualized by counterstaining for MOMA-1 
(Figure 4.18 B).  
As pDCs were identified to respond rapidly to 9.2s stimulation by releasing type I IFN, we 
further characterized the role of pDCs in ssRNA-mediated suppression of antigen-specific 
CTL responses. We depleted pDCs in C57BL/6 wild type mice by using an anti-PDCA-1 
antibody and the elimation of pDCs (CD11c
int
PDCA-1
pos
B220
pos
 cells) in the spleen was 
determined 24 hours later by flow cytometry. Depletion of pDCs was only partially 
efficient as residual cells were still present (approximately 0.2 - 0.3%) (Figure 4.18 C). 
Thereafter, we investigated if ssRNA-mediated suppression of an antigen-specific CTL 
response was circumvented if pDCs were depleted. C57BL/6 wild type mice were injected 
or not with the anti-PDCA-1 depleting antibody. Subsequently, mice were either left 
untreated or received an i.v. administration of 10 g 9.2s/DOTAP one day prior to AdOVA 
infection. OVA-specific cytotoxic activity was quantified in spleens five days post 
adenoviral infection. If mice had been pretreated with the anti-PDCA-1 antibody, the 
OVA-specific cytotoxic activity was augmented by approximately 25% in comparison to 
mice that were injected with 9.2s/DOTAP and AdOVA (Figure 4.18 D). We assume that 
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the moderate increase in the CTL response might be attributed in part to an incomplete 
elimination of pDCs (Figure 4.18 C).  
In summary, these data demonstrate that pDCs responded to TLR7-mediated recognition of 
ssRNA in vivo by releasing early IFN and contributed to the suppression of an antigen-
specific CTL response. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.18    Splenic pDCs produced IFN  in response to ssRNA stimulation and were 
involved in suppression of the CTL response. 
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(A, B) IFN-YFP reporter mice were injected i.v. with 10 g of 9.2s/DOTAP. Six hours post 
injection mice were sacrifized. (A) YFP expression was examined by flow cytometric analysis of 
splenocytes. pDCs were identified by CD11c
int
PDCA-1
pos
B220
pos
CD11b
neg
 expression (Gate G1), 
whereas T and B cells were distinguished by CD3e
pos
 and CD19
pos
 expression, respectively. (B) 
YFP expression was analyzed on histological sections of the spleen, which were counterstained 
with anti-MOMA-1 and DAPI to visualize the marginal zone and the T/B cell zone. Representative 
dot plots and histology of one mouse out of three mice of two independent experiments are shown. 
(D) pDC depletion in spleens was assessed by using an anti-PDCA-1 antibody, which was given 
i.v. twice (200 g each). 24 hours after the last injection, pDC depletion efficiency was determined 
in spleens by staining for CD11c, PDCA-1, and B220 and using flow cytometry. Representative 
dot plots of one mouse out of two mice are presented. (E) pDCs were depleted as described in D. 
Subsequently, wild type and pDC-depleted mice were injected i.v. with either AdOVA alone or 
received i.v. 10 g 9.2s/DOTAP prior to AdOVA immunization. OVA-specific cytotoxicity was 
quantified in spleens five days post AdOVA injection. Representative data are shown as mean +/- 
SEM (n=3 mice per group) out of two independent experiments.  
 
 
 
4.1.8 Macrophages and DCs are targets of ssRNA-induced 
type I interferon 
 
So far, we identified pDCs as one initial cellular source of type I IFN in response to 9.2s 
stimulation. Thereafter, we were interested in unveiling the cell type that was responding 
to type I IFNs and contributed to ssRNA-mediated CTL suppression by using Cre-
mediated cell-specific IFNAR1 deficient mice (Clausen et al., 1999; Prinz et al., 2008; 
Stockinger et al., 2009; Varol et al., 2007). C57BL/6 wild type, B cell-specific, T cell-
specific, T cell/B cell-specific, macrophage, and DC-specific IFNAR1 deficient mice were 
immunized i.v. with AdLOG alone or received a preceding i.v. injection of 10 g 
9.2s/DOTAP. As a positive control, complete IFNAR1 ko mice were used in all 
experiments. OVA-sepcific lysis was determined in spleens five days post AdLOG 
immunization. 9.2s still caused an abrogation of the CTL response in T cell-specific and/or 
B cell-specific IFNAR1 deficient mice, indicating that type I IFNs did not act on these cell 
types (Figure 4.19 A). However, antigen-specific cytotoxic activities were unaffected by 
systemic ssRNA injection in mice that lack the IFNAR1 receptor on macrophages (LysM-
cell) and DCs (Figure 4.19 B and C). Consistent with these results, OVA-specific 
CD8 T cells were generated in macrophage-specific and DC-specific IFNAR1 ko mice in 
response to 9.2s and AdLOG injection, while no expansion of S8L/H-2K
b
 pentamer-
positive CD8 T cells was observed in spleens of wild type mice (Figure 4.19 D and E). In 
conclusion, these results demonstrate that ssRNA-induced type I IFNs acted on 
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macrophages and DCs, which seem to be modulated in their ability to stimulate an efficient 
CTL response.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.19    Macrophages and DCs were identified to respond to ssRNA-stimulated 
type I interferons. 
Cell-specific IFNAR1 deficient mice were generated by Cre-mediated deletion. (A) C57BL/6 wild 
type, complete IFNAR1 ko, B cell-specific, T cell-specific, and T cell/B cell-specific IFNAR1 ko 
were immunized with AdLOG alone or were injected i.v. with 10 g of 9.2s/DOTAP one day prior 
to adenoviral challenge. OVA-specific lysis was determined in spleens five days post AdLOG 
injection. (B, C) Wild type, complete IFNAR1 ko, LysM-specific, and DC-specific IFNAR1 ko 
were treated as described in A and OVA-specific cytotoxicity was analyzed. (D, E) The generation 
of OVA-specific CD8 T cells was determined by flow cytometric analysis of S8L/H-2K
b
 
pentamers. OVA-specific cytotoxicity is depicted as mean +/- SEM and a representative pentamer 
dot plot of one mouse is shown (n=3 mice per group). At least two independent experiments were 
performed. 
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4.1.9 ssRNA-mediated CTL suppression involves type I interferon 
signaling via STAT1 and IRF7 
 
Robust type I IFN production requires a positive feedback amplification, which is initiated 
through autocrine or paracrine binding of secreted type I IFN to the type I IFN receptor. 
This receptor is associated with the Janus protein tyrosine kinases JAK1 and Tyk2 that 
target the STAT transcription factors STAT1 and STAT2 for phoshorylation. Upon 
phosphorylation, STAT1 and STAT2 heterodimerize, translocate to the nucleus and 
interact with the DNA-binding protein IRF9. This complex is known as the transactivation 
complex ISGF3, which initiates the transcription of immediate-early target genes, such as 
IRF7 and IRF3 which control the production of type IFNs (Decker et al., 2005; Honda and 
Taniguchi, 2006; Levy et al., 2003; Prakash et al., 2005). 
To investigate which signaling molecules downstream of the type I IFN receptor were 
involved in ssRNA-mediated suppression of the CTL response, we used STAT1, Tyk2, 
IRF3, and IRF7 deficient mice.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.20   ssRNA-mediated CTL suppression involved signaling via STAT1 and IRF7. 
OVA-specific cytotoxic activity was determined in spleens of C57BL/6 wild type (A-C), STAT1 
ko (A), Tyk2 ko (B), IRF3 ko, and IRF7 ko (C) mice upon i.v. administration of AdLOG alone or 
after i.v. pre-injection of 9.2s/DOTAP. Representative data are illustrated as mean +/- SEM of at 
least two independent experiments (n=3 mice per group). 
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OVA-specific cytotoxicity was assessed in spleens of mice upon i.v. administration of 
AdLOG alone or after i.v. pre-injection of 9.2s/DOTAP. 9.2s-induced OVA-specific 
CTL suppression was still observed in Tyk2 ko (Figure 4.20 B) and IRF3 ko 
(Figure 4.20 C) mice, whereas a CTL response was generated in STAT1 (Figure 4.20 A) 
and IRF7 ko (Figure 4.20 C) mice. Consequently, these results imply that type I IFN 
production might require a positive amplification by signaling through STAT1 and IRF7 
downstream of the IFNAR receptor. 
 
 
 
 
4.1.10 ssRNA stimulated DC maturation but impaired IL-12 secretion 
 
Up to here, we have shown that systemic ssRNA affected CD8 and CD4 T cell responses 
against subsequent infections in a TLR7 and type I IFN dependent manner. In the 
following, we investigated if systemic ssRNA stimulation interfered with the phenotypic 
and functional maturation of DCs, which is essential for T lymphocyte activation and 
differentiation into TH1 cells, TH2 cells as well as into cytotoxic effector T lymphocytes 
(Akira et al., 2006; Banchereau and Steinman, 1998; Iwasaki and Medzhitov, 2004; Kawai 
and Akira, 2005).  
We injected i.v. 10 g 9.2s/DOTAP into C57BL/6 wild type mice and evaluated the 
surface expression of activation markers on splenic CD11c
high
CD8a
pos
 DCs, which are 
known to cross-present antigen, 24 hours post 9.2s injection. Flow cytometric analysis 
revealed a moderate but significant reduction (ca. 27%) in the percentage of splenic 
CD11c
high
CD8a
pos
 DCs in comparison to naive mice (Figure 4.21 A). Furthermore, 
costimulatory molecules like CD40, CD80, and CD86 were upregulated on splenic 
CD11c
high
CD8a
pos
 DCs in response to ssRNA treatment. Interestingly, we noticed a 
reduced expression of MHC class II molecules, which was in line with the observation that 
antigen-specific CD4 T cell responses were impaired by a preceding injection of ssRNA 
(Figure 4.21 B).  
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Figure 4.21    DOTAP-complexed ssRNA induced the upregulation of costimulatory 
molecules but downregulation of MHC class II molecules expressed by splenic 
DCs. 
C57BL/6 wild type mice were injected i.v. with 10 g 9.2s/DOTAP. 24 hours later, the percentage 
of splenic CD11c
high
CD8a
pos
 DCs was determined (A) and splenic CD11c
high
CD8a
pos
 DCs were 
examined for their expression of maturation markers CD40, CD80/86, and MHC class II by flow 
cytometry (B). The bar graph shows the mean +/- SEM and one representative histogram for each 
staining is depicted. Two independent experiments were performed with n=3 mice per group. 
 
 
 
Pathogen recognition and TLR stimulation leads to the production of pro-inflammatory 
cytokines, such as IL-12, which is mainly produced by phagocytes and DCs. IL-12, as a 
“third signal”, is a crucial cytokine required for the generation of an efficient and long-
lasting T cell response (Curtsinger et al., 2003a; Curtsinger et al., 2003b; Curtsinger et al., 
1999; Schmidt and Mescher, 1999; Trinchieri, 1995, 2003). Therefore, we examined 
whether IL-12 secretion in response to a pathogen was negatively affected by pre-injection 
of ssRNA. To mimic pathogen infection, we injected mice i.v. with 100 g CpG-1668. 
Indicated groups received a preceding injection of 10 g of 9.2s/DOTAP, which was given 
i.v. 24 hours prior to CpG administration. IL-12p70 secretion was analyzed in sera of mice 
by ELISA or by intracellular cytokine staining using flow cytometry. The percentage of 
IL-12 producing splenic CD11c
high
CD8a
pos
 DCs was significantly diminished by 45% in 
mice that had been pre-injected with 9.2s compared to mice that were stimulated with CpG 
alone (Figure 4.22 A). In addition, also the level of systemic IL-12 was considerably 
reduced (ca. 85% reduction) in sera of 9.2s and CpG treated mice (Figure 4.22 B). 
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Figure 4.22    ssRNA pre-activated DCs were impaired in IL-12 secretion in response to CpG 
stimulation. 
C57BL/6 wild type mice received i.v. either 100 g of CpG-1668 alone or were injected with 
10 g of 9.2s/DOTAP one day prior to CpG administration. Two hours upon CpG injection, IL-12 
production by splenic CD11c
high
CD8a
pos
 DCs was analyzed by intracellular cytokine staining and 
flow cytometric analysis (A). IL-12 secretion was quantified in sera of mice by ELISA (B). 
Representative data of two independent experiments are depicted. Results in bar graphs are 
presented as mean +/- SEM and one representative dot plot of one mouse is shown (n= 3 mice per 
group). 
 
 
In conclusion, systemic application of 9.2s induced on the one hand a phenotypic 
maturation of splenic DCs, which was characterized by the upregulation of costimulatory 
molecules. On the other hand, MHC class II expression was reduced and IL-12 production 
was impaired in response to a subsequent pathogenic stimulus. 
 
 
 
 
4.1.11 Impaired cross-priming of antigen-specific CD8 T cells by ssRNA 
pre-activated splenic DCs 
 
DCs possess the capability to cross-present exogenous antigen, which offers a mechanism 
for priming of CD8 T cells specific for viruses that do not directly infect DCs. In order to 
fully activate CD8 T cells by cross-priminig, DCs need to become licensed by appropriate 
activation signals, which are provided by TLR stimulation, CD4 T cell help through CD40-
CD40L interaction, and/or virus-induced type I IFNs (Bennett et al., 1998; Bennett et al., 
1997; Iwasaki and Medzhitov, 2004; Le Bon et al., 2003; Schoenberger et al., 1998).  
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Therefore, we asked whether a preceding injection of ssRNA influenced cross-priming of 
OVA-specific CD8 T cells (OT-I) by splenic DCs upon AdOVA challenge. C57BL/6 wild 
type mice were immunized i.v. with AdOVA alone or in combination with 10 g 
9.2s/DOTAP which was given i.v. one day before AdOVA infection. Splenic CD11c 
positive DCs were purified 20 hours post AdOVA challenge and co-cultured for 24 hours 
with naive OT-I T cells. Cross-priming of OT-I T cells was monitored by measuring IFN 
and IL-2 secretion in co-culture supernatants by ELISA or by intracellular cytokine 
staining of OT-I T cells and subsequent flow cytometric analysis. In addition, 
T cell activation was assayed by investigating CD69 surface expression. Splenic DCs, that 
had been isolated from AdOVA immunized mice, induced obvious CD8 T cell activation 
as evidenced by the upregulation of CD69 (Figure 4.23 C) and IL-2 as well as 
IFN production by OT-I T cells (Figure 4.23 A and B). However, CD8 T cell activation 
and effector cytokine release was compromised if DCs had been pre-activated by systemic 
ssRNA application prior to AdOVA infection (Figure 4.23).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.23    Systemic pre-activation of DCs with ssRNA impeded ex vivo cross-priming and 
activation of OVA-specific CD8 T cells. 
C57BL/6 wild type mice were immunized i.v. with AdOVA alone or in combination with 10 g 
9.2s/DOTAP given i.v. one day before AdOVA injection. Splenic CD11c positive DCs were 
MACS-purified 20 hours post AdOVA challenge and co-cultured with naive OVA-specific 
CD8 T cells (OT-I) for 24 hours. IFN and IL-2 production was analyzed in co-culture supernatants 
by ELISA (A) and by intracellular cytokine staining of OT-I T cells (B). CD8 T cell activation was 
assayed by staining for CD69 and flow cytometric analysis (C). Representative data of at least three 
independent experiments with n=3 mice per group are shown. 
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4.1.12 Impaired cross-priming of antigen-specific CD8 T cells is 
type I interferon dependent and circumvented by exogenous IL-12 
 
We have shown that systemic injection of ssRNA induced the suppression of the 
CTL response against a subsequent AdOVA infection through the induction of type I IFNs, 
which were ultimately acting on DCs (Figure 4.16, 4.17 and 4.19). Thus, we next 
investigated if the cross-priming ability of ssRNA pre-activated splenic DCs was restored 
in type I IFN receptor deficient mice. Wild type and IFNAR1 ko mice were treated as 
described in the previous chapter (see 4.1.11). Indeed, ex vivo cross-priming of OVA-
specific CD8 T cells (OT-I) by ssRNA pre-activated DCs was unaffected in response to 
AdOVA infection if DCs were isolated from IFNAR1 deficient mice, as a release of IFN 
was detected in co-culture supernatants (Figure 4.24 A). This observation was in 
accordance with the results obtained in DC-specific IFNAR1 deficient mice, in which 
ssRNA-induced CTL suppression was prevented (Figure 4.19).  
 
 
 
 
 
 
 
 
 
 
 
Figure 4.24  Impaired cross-priming of OVA-specific CD8 T cells by ssRNA pre-activated 
DCs was dependent on type I interferons and was abolished in the presence of 
IL-12. 
(A) C57BL/6 wild type and IFNAR1 ko mice were immunized i.v. with AdOVA alone or in 
combination with 10 g 9.2s/DOTAP given i.v. one day before AdOVA injection. Splenic CD11c 
positive DCs were MACS-purified 20 hours post AdOVA challenge and co-cultured with naive 
OVA-specific CD8 T cells (OT-I) for 24 hours. IFN production was quantified in co-culture 
supernatants by ELISA. (B) Wild type mice were treated and splenic DCs were isolated as 
described in A. Co-culture with OT-I T cells was performed in the absence or presence of 
1.25 ng/ml or 5 ng/ml recombinant IL-12p70. IFN secretion was determined in co-culture 
supernatants after 24 hours by ELISA. Representative results of at least two independent 
experiments are shown with n=3 to 4 mice per group. 
 
 
As ssRNA pretreatment interfered with the production of IL-12 in response to a subsequent 
CpG injection, we speculated whether it might be possible to rescue AdOVA-specific 
cross-priming of OT-I T cells by ssRNA pre-activated DCs in the presence of exogenous 
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IL-12. Addition of increasing concentrations of recombinant IL-12p70 resulted in an 
overall enhancement in IFN production by OT-I T cells that had been stimulated by 
splenic DCs isolated from AdOVA only immunized mice (Figure 4.24 B). Importantly,  
IL-12 supplementation also induced T cell activation by 9.2s pre-activated splenic DCs, as 
IFN secretion by OT-I T cells was comparable to the levels that were secreted, if T cells 
were primed by DCs from AdOVA immunized mice in the absence of IL-12 
(Figure 4.24 B). 
Thus, impaired cross-priming of OVA-specific CD8 T cells by ssRNA-preactivated DCs 
was dependent on type I IFN and was circumvented by provision of exogenous IL-12. 
 
 
4.1.13 Summary of chapter 4.1 
Our data presented so far showed that the systemic application of ssRNA suppressed 
subsequent antigen-specific cytotoxic CD8 T cell responses against viral and bacterial 
pathogens in a TLR7 dependent manner. The absence of antigen-specific cytotoxicity was 
associated with an impaired expansion and activation of antigen-specific CD8 T cells. 
Furthermore, we detected that the proliferation and cytokine production of antigen-specific 
CD4 T cells was impeded, which was associated with a downregulation in MHC class II 
molecule expression on ssRNA-preactivated splenic DCs. The suppression of T cell 
responses was avoided if ssRNA was targeted to the cytoplasm by complexation with the 
carrier in vivo-jetPEI
TM
, thus preventing endosomal recognition by TLR7. Interestingly, we 
revealed that ssRNA-induced inhibition of an adenovirus-specific CTL response depended 
on the secretion of type I IFNs, which are generally accepted to have immune stimulatory 
properties. Furthermore, we identified pDCs to be one initial cellular source of type I IFNs, 
which then affected macrophages and DCs by modulating their ability to stimulate an 
efficient CTL response. In addition, we demonstrated that ssRNA-preactivated splenic DCs 
were impeded in their ability to cross-prime OVA-specific CD8 T cells in response to an 
AdOVA infection, although they had matured in response to ssRNA stimulation. Finally, 
we assume that systemic ssRNA interfered with the generation of CD4 T cell help, as the 
presence of activated as well as memory antigen-specific CD4 T cells circumvented 
ssRNA-induced CTL suppression. Taken together, ssRNA-induced type I IFNs could also 
inhibit antigen-specific immune responses in the spleen, despite their well-established 
immune stimulatory properties. 
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4.2 Relevance of RNA- and type I interferon-mediated suppression of 
adaptive CD8 T cell responses 
 
 
4.2.1 Small-interfering RNA application interferes with an adenoviral-
based tumor vaccination in a model of combinatorial anti-tumor 
therapy  
 
Based on recent insights that small interfering RNA (siRNA) is recognized by TLR7 and 
induces innate immune stimulation (Judge et al., 2005; Robbins et al., 2008; Robbins et al., 
2009; Rossi, 2009; Sioud, 2005, 2006) together with our findings that ssRNA, recognized 
by TLR7, was capable to interfere with the generation of subsequent CTL responses 
through the induction of type I IFNs, we speculated what would happen if a siRNA-
mediated knockdown approach would be combined with an adenoviral based-tumor 
vaccintion. To mimic a combinatorial anti-tumor therapy of siRNA application and 
adenoviral vaccination, we implanted intraportally (i.po.) 5x10
4
 luciferase expressing B16 
melanoma cells (B16-luc) into C57BL/6 mice. Four days later, tumor bearing mice were 
vaccinated i.v. with a recombinant adenovirus expressing the melanocyte-specific antigen 
murine tyrosine-related protein 2 (AdmTRP2). Indicated groups received an i.v. 
administration of 20 g DOTAP or in vivo-jetPEITM complexed siRNA specific for VEGF 
(siVEGF) (Filleur et al., 2003; Kornek et al., 2008) one day before adenoviral 
immunization. Tumor growth was monitored by in vivo imaging of bioluminescent 
luciferase expression (IVIS200) (Figure 4.25). 
 
 
 
 
 
 
 
 
 
Figure 4.25    Time schedule of melanoma implantation, subsequent siRNA application, and 
adenoviral vaccination.    
 
 
Adenoviral therapy alone led to an almost complete tumor regression, whereas tumor 
expansion was not inhibited in mice pre-injected with siVEGF/DOTAP prior to AdmTRP2 
vaccination. As tumors grew so fast in non-treated as well as siVEGF/AdmTRP2 treated 
mice, they were sacrifized due to ethical reasons (Figure 4.26 A). If siVEGF was stabilized 
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using the carrier in vivo-jetPEI
TM
 (siVEGF/PEI) and injected i.v. one day before 
AdmTRP2 immunization, adenoviral based tumor therapy was not impaired 
(Figure 4.26 B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.26    DOTAP-complexed siRNA specific for VEGF abrogated adenoviral tumor 
vaccination due to lack of a tumor-specific CTL response. 
(A, B) 5x10
4
 luciferase expressing B16 melanoma cells (B16-luc) were implanted intraportally into 
C57BL/6 mice. Four days later, tumor bearing mice were vaccinated with AdmTRP2 alone or 
indicated groups received an i.v. administration of 20 g DOTAP-complexed siVEGF 
(siVEGF/DOTAP) (A) or in vivo-jetPEI
TM
 complexed siVEGF (siVEGF/PEI) (B). Tumor growth 
was monitored by in vivo imaging of bioluminescent luciferase expression (IVIS200). 
(C) TRP2 tumor-specific cytotoxicity was examined in spleens of wild type mice five days post 
AdmTRP2 injection. Indicated groups were pre-injected i.v. with 20 g of siVEGF/DOTAP or 
siVEGF/PEI. Tumor growth is expressed as photons/sec/cm
2
 and is presented as mean +/- SEM  
(n=4-5 mice per group). † Mice were sacrifized due to massive tumor burden.  
OVA-specific lysis is depicted as mean +/- SEM with n=3 mice per group. 
 
 
Moreover, we determined the mTRP2-specific cytotoxicity in spleens of mice five days 
post AdmTRP2 immunization and confirmed that the anti-tumor vaccination failed due to a 
lack of a tumor-specific CTL response when DOTAP-complexed siVEGF was used. In 
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contrast, an efficient tumor-specific CD8 T cell response was established by AdmTRP2 
immunization if siVEGF was stabilized using in vivo-jetPEI
TM
 (Figure 4.26 C).  
 
 
4.2.2 Influenza infection inhibits the CTL response against a subsequent 
adenovirus infection 
 
It has been known for a long time that a temporary lack of cell-mediated immune reactions 
may occur upon certain viral infections, which is frequently attributed to the effects of 
virus-induced type I IFNs (De Maeyer et al., 1975; De Maeyer-Guignard et al., 1975; 
Hahm et al., 2005; Trifilo et al., 2006). 
Here, we investigated how an influenza infection, known to trigger type I IFN production 
(Barchet et al., 2005b; Diebold et al., 2004), influenced the CD8 T cell response against a 
subsequent adenoviral infection. We infected C57BL/6 wild type mice with 1x10
6
 PFU 
Influenza A PR8/H1N1 virus one day before infection of those mice with AdLOG. The 
generation of OVA-specific CD8 T cells and their cytotoxic activity was measured in 
spleens five days post adenovirus administration. Interestingly, mice that had been infected 
with Influenza virus were not able to elicit a cytotoxic T cell response against a subsequent 
adenoviral infection (Figure 4.27 A). The lack of OVA-specific cytotoxic activity was 
attributed to the absence of OVA-specific CD8 T cells, which were determined by    
S8L/H-2K
b
 pentamer staining (Figure 4.27 B). Furthermore, Influenza-mediated inhibition 
of the AdLOG-specific CTL response was dependent on type I IFNs, as cytotoxic 
CD8 T cell responses were equally strong in IFNAR1 deficient mice infected with AdLOG 
alone or those that had been infected with Influenza before (Figure 4.27 A). Therefore, it 
seems likely that Influenza virus suppressed subsequent adaptive immune responses in a 
similar manner as we observed with the TLR7 ligand ssRNA.     
 
    
 
 
 
 
 
Figure 4.27    Influenza infection suppressed a subsequent adenovirus-specific CD8 T cell  
                       response in a type I interferon dependent manner. 
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C57BL/6 wild type and IFNAR1 ko mice were injected i.v either with AdLOG alone or were 
infected with 1x10
6
 PFU Influenza A PR8/H1N1 virus one day before AdLOG challenge. (A) 
OVA-specific CTL response was measured in spleens of wild type and IFNAR1 ko mice five days 
post adenovirus infection. (B) The generation of endogenous OVA-specific CD8 T cells was 
investigated in spleens of wild type mice by flow cytometric analysis of S8L/H-2K
b
 pentamers. 
OVA-specific lysis is illustrated as mean +/- SEM (with n=3 mice per group). Representative data 
of at least two independent experiments are depicted. 
 
 
 
 
4.2.3 Summary of chapter 4.2 
In this chapter we addressed the relevance of RNA- and type I IFN-mediated immune 
suppression. We investigated in a model of a combinatorial anti-tumor therapy how siRNA 
application might interfere with the generation of tumor-specific CTL responses induced 
by adenoviral-based vaccination. Vaccination with an adenovirus expressing the melanoma 
antigen TRP2 triggered an efficient tumor-specific CTL response and consequently led to 
an almost complete melanoma regression. If mice received an additional injection of 
DOTAP-complexed siRNA (specific for VEGF) before AdmTRP2 administration, tumor 
expansion was not prevented due to an impaired CTL response. However, if siRNA was 
complexed with the carrier in vivo-jetPEI
TM
 instead of DOTAP, AdmTRP2 vaccination 
induced a strong tumor-specific CTL response which led to a regression of tumor growth. 
In conclusion, our data demonstrate that a therapeutic application of siRNA might have 
off-target effects due to the recognition of siRNA by nucleic acid receptors such as TLR7, 
thus leading to immune stimulation and production of type I IFNs, which might impair 
subsequent adaptive immune responses. 
Furthermore, we described that not only systemic exposure to synthetic ssRNA, but also an 
Influenza virus infection impaired the generation of a cytotoxic CD8 T cell response 
against a subsequent adenovirus infection in a type I IFN dependent manner. 
Consequently, these results imply that viruses, which trigger type I IFNs, might inhibit 
adaptive immune responses towards following infections in a similar fashion as we 
observed with the TLR7 ligand ssRNA. 
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5 Discussion 
Toll-like receptors (TLRs) are canonical pattern-recognition receptors (PRRs), which 
recognize conserved molecular structures of microorganisms. It is known that stimulation 
of TLRs results in the activation of innate immunity, which is essential for the initiation of 
an adaptive immune response (Akira et al., 2006; Iwasaki and Medzhitov, 2004; Kawai 
and Akira, 2005). However, our group has shown that the systemic injection of CpG, a 
TLR9 ligand, induces immunoregulatory mechanisms that cause suppression of subsequent 
antigen-specific adaptive immune responses (Wingender et al., 2006), which contradicts 
the general assumption that stimulation of TLRs results in the induction of host immunity. 
Furthermore, Beatrix Schumak demonstrated in her PhD thesis, that the suppression of 
cytotoxic T cell (CTL) responses was not only restricted to CpG, but also other 
systemically applied TLR ligands impeded antigen-specific CTL responses. She revealed 
that the systemic injection of single-stranded RNA (ssRNA) oligonucleotides suppressed 
antigen-specific CTL responses in a TLR7 and type I interferon (IFN) dependent manner 
(Schumak, 2008). Based on these key findings, we aimed to further unravel the underlying 
mechanism and relevance of ssRNA- and type I IFN-mediated inhibition of adaptive 
immune responses. 
 
The results presented in this thesis show that systemic administration of ssRNA leads to 
the suppression of CTL responses against subsequent infections by viral and bacterial 
pathogens. The absence of cytotoxicity was associated with impaired expansion and 
activation of antigen-specific CD8 T cells as well as an impaired proliferation and cytokine 
production of antigen-specific CD4 T cells. Suppression of adaptive T cell responses was 
avoided if ssRNA was targeted to the cytoplasm by complexation with the carrier in vivo-
jetPEI
TM
, thus preventing endosomal recognition by TLR7. TLR7-mediated recognition of 
ssRNA triggered the production of type I IFNs, which played a central role in ssRNA-
induced CTL suppression. Furthermore, we identified plasmacytoid dendritic cells (pDCs) 
to respond immediately to ssRNA stimulation by releasing type I IFN. This cytokine then 
affected macrophages and dendritic cells (DCs) by modulating their capacity to stimulate 
an efficient CTL response. DCs from ssRNA-pretreated mice were impaired in their ability 
to cross-prime antigen-specific CD8 T cells upon an adenovirus infection, although they 
had matured in response to ssRNA stimulation. In addition, ssRNA-induced CTL 
suppression was circumvented in the presence of activated as well as memory antigen-
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specific CD4 T cells, indicating that systemic ssRNA interfered with the generation of 
CD4 T cell help. This interpretation was supported by the observation that MHC class II 
expression was downregulated on splenic DCs upon systemic application of ssRNA, 
thereby impeding CD4 T cell activation.  
 
The second part of this thesis dealt with the relevance and potential risks of RNA- and 
type I IFN-induced CTL suppression.  
In the last decade new strategies in anti-cancer treatment have emerged which aim at the 
induction of tumor-specific cytotoxic T cell responses and suppression of tumorigenicity 
by directed post-transcriptional gene silencing using small interfering RNA (siRNA). 
Mimicking such a combinatorial approach, we reported that, depending on the carrier used, 
systemic in vivo siRNA injection abrogated an adenoviral-based melanoma vaccination 
due to the lack of a tumor-specific CTL response. In conclusion, our data indicate that a 
therapeutic application of siRNA might have off-target effects due to the recognition by 
nucleic acid receptors such as TLR7, thus leading to immune stimulation and production of 
type I IFNs, which might impair subsequent adaptive immune responses. 
Moreover, we could demonstrate that CTL suppression was not restricted to the application 
of synthetic RNA oligoribonucleotides but rather seems to be true for infections with 
type I IFN inducing viruses in general. We pointed out that the infection with Influenza 
virus impeded the generation of the CTL response against a subsequent adenovirus 
infection in a type I IFN dependent manner. Consequently, these results imply that viruses, 
known to trigger type I IFN, might inhibit adapative immune responses towards following 
infections in a similar fashion as we described for systemic ssRNA.   
 
 
5.1 Mechanisms of ssRNA and type I interferon-mediated suppression 
of adaptive immune responses 
 
5.1.1 Targeting of ssRNA into the endosome suppresses antigen-specific 
CD8 T cell responses in a TLR7 dependent manner 
 
In this study, we reported that the systemic application of the TLR7 ligand ssRNA 
suppressed subsequent antigen-specific CTL responses in the spleen. This result is in line 
with several reports showing that the systemic exposure to TLR ligands, such as CpG, 
LPS, or polyI:C can inhibit adaptive T cell immunity despite their well known immune 
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stimulatory properties (Mellor et al., 2005; Wilson et al., 2006; Wingender et al., 2006). 
We observed that ssRNA-mediated suppression was not only restricted to adenovirus 
infection, but impaired CTL responses against various viral and bacterial pathogens 
(Figure 4.4), indicating a general suppressive effect of systemic ssRNA on the generation 
of adaptive immunity.  
RNA can be recognized by endosomally located TLR3 and TLR7 (Alexopoulou et al., 
2001; Diebold et al., 2004; Heil et al., 2004) or by the cytoplasmic receptors MDA5 and 
RIG-I (Gitlin et al., 2006; Hornung et al., 2006; Schlee et al., 2009; Yoneyama et al., 
2005). The RNA oligoribonucleotide used in our studies, namely 9.2, is recognized by 
TLR7 if complexed to the carrier DOTAP (Hornung et al., 2005). Indeed, the suppression 
of the CTL response strictly depended on the detection by endosomal TLR7 and was based 
on the recognition of the single-strand motif of the sense strand (Figure 4.1). In order to 
circumvent detection by TLR7, we employed an alternative carrier for complexation of 
RNA. Instead of DOTAP, a cationic liposome, which not only protects RNA from 
degradation but targets RNA to the endosome (Almofti et al., 2003; Yasuda et al., 2005), 
we used in vivo-jetPEI
TM
 to stabilize RNA for in vivo application. In vivo-jetPEI
TM
 is a 
linear polyethylene imine, which facilitates the delivery into the cytoplasm after osmotic 
rupture of the endosome (Boussif et al., 1995; Brunner et al., 2002; Kichler et al., 1995). In 
agreement with these studies, we could show that complexation of our RNA using in vivo-
jetPEI
TM
 promoted the delivery of RNA into the cytoplasm (Figure 4.6 B). TLR7-mediated 
recognition of ssRNA was thereby prevented, and thus CTL responses against subsequent 
viral and bacterial infections were not suppressed (Figure 4.5). Moreover, an involvement 
of RIG-I stimulation in our experiments could be excluded, as the RNA oligonucleotides 
used lack 5’-triphosphates and blunt ends, which are prerequisites for recognition by   
RIG-I (Hornung et al., 2006; Schlee et al., 2009). 
It is known that TLR stimulation triggers the activation of the innate immune system in 
order to prevent pathogen spread before the intervention of the adaptive immune system 
(Akira et al., 2006; Pichlmair and Reis e Sousa, 2007). Therefore, we first investigated 
whether DOTAP-complexed ssRNA stimulated the innate immune system to induce a fast 
elimination of the virus, and thereby results in a substantial reduction in antigen load in the 
organism. However, we could exclude this possibility as ssRNA diminished the viral 
burden irrespective of whether it was given before, simultaneously with, or one day after 
adenovirus infection. Importantly, the CTL response was only impaired if ssRNA was 
given prior to adenovirus infection, indicating that the suppressive impact of ssRNA is not 
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a consequence of a reduced viral burden but rather involves a regulatory mechanism. 
Moreover, these data demonstrated that also the timing of ssRNA application played an 
important role, as only a preceding injection impeded subsequent CTL responses (Figure 
4.2). Remarkably, systemic ssRNA interfered with the generation of CTL responses if 
applied as early as five days prior to an adenovirus infection. 
Furthermore, we revealed that systemic injection of DOTAP-complexed ssRNA inhibits 
the expansion and activation of endogenous antigen-specific CD8 T cells in response to 
AdOVA infection (Figure 4.7). In spite of an impaired expansion and activation of 
adoptively transferred OT-I T cells, comparable amounts of IFN producing OT-I T cells 
were detected upon restimulation in mice that had been treated with AdOVA alone or those 
that had received DOTAP-stabilized ssRNA and AdOVA (Figure 4.8). These results 
provide evidence that the lack of antigen-specific cytotoxicity is associated with a 
defective priming of antigen-specific CD8 T cells and not due to tolerization (Steinman et 
al., 2003) or control of effector CD8 T cells by T regulatory cells (Sakaguchi et al., 1995; 
Shevach, 2009). However, in order to exclude a definitive role of T regulatory cells in 
ssRNA-mediated CTL suppression, immunization experiments need to be performed in 
Foxp3-DTR mice, where T regulatory cells can be selectively depleted by diptheria toxin 
injection (Hämmerling, unpublished). Furthermore, we could rule out a role of IL-10 in 
ssRNA-induced CTL suppression (Figure 4.15), which is consistent with the assumption 
that the absence of cytotoxicity resulted from a defect in CD8 T cell priming by DCs and 
was not due to a control of effector CD8 T cells by anti-inflammatory cytokines, such as 
IL-10 or TGF (Akdis and Blaser, 2001; Maynard and Weaver, 2008; Shevach, 2009).    
In conclusion, our data cleary demonstrate that a preceding systemic injection of ssRNA 
inhibits subsequent antigen-specific CTL responses against various pathogens in a TLR7- 
dependent manner. The lack of antigen-specific cytotoxicity is not the consequence of a 
diminished viral burden due to the stimulation of innate immunity, but is rather accounted 
for by an impaired priming and activation of naive antigen-specific CD8 T cells.  
 
 
 
5.1.2 ssRNA-induced inhibition of antigen-specific CD4 T cell responses 
results in impaired CD4 T cell help 
 
Cognate CD4 T cell help is essential to establish a strong CD8 T cell response against 
various pathogens (Bennett et al., 1997; Bevan, 2004; Cardin et al., 1996; Castellino and 
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Germain, 2006; Keene and Forman, 1982; von Herrath et al., 1996). DCs are licensed by 
ligation of CD40 and CD40L expressed on CD4 T helper cells, which enhances the DCs 
ability to stimulate an efficient cytotoxic CD8 T cell response (Bennett et al., 1998; 
Schoenberger et al., 1998; Toes et al., 1998). Indeed, the data presented in this thesis 
indicate that CD4 T cell help is impeded by systemic exposure to ssRNA upon TLR7-
mediated recognition. This was concluded from observations that injection of DOTAP-
complexed ssRNA interfered with the expansion and cytokine production of antigen-
specific CD4 T cells upon AdOVA infection (Figure 4.10 and 4.11). Again, impairment of 
the CD4 T cell response was avoided if ssRNA was targeted to the cytoplasm by 
complexation with in vivo-jetPEI
TM
. In addition, OVA-specific IgG titers were remarkably 
diminished in mice that had received DOTAP-complexed ssRNA before AdOVA infection 
(Figure 4.12). This finding further emphasizes that CD4 T cell help is negatively affected 
by systemic ssRNA, as T helper cell function is important to ensure an optimal Ig isotype 
switch to IgG antibodies (Grewal and Flavell, 1996; Hollenbaugh et al., 1994). Moreover, 
we detected a downregulation in MHC class II expression on splenic DCs upon systemic 
ssRNA stimulation, which most likely results in a lack of antigen presentation and 
activation of CD4 T cells. These results coincide with the findings by Young et al, which 
demonstrate that the systemic activation of DCs by CpG, a TLR9 ligand, inhibits the 
induction of CD4 T cell responses against subsequently encountered antigens, which is 
attributed to a downregulation of MHC class II/peptide complex formation (Young et al., 
2007). 
CD40 and CD40L interactions are known to mediate CD4 T cell help and have been 
implicated in the induction of cytotoxic T cell responses against adenovirus (Bennett et al., 
1998; Schoenberger et al., 1998; Toes et al., 1998; Yang et al., 1996). However, it was 
impossible to overcome ssRNA-mediated CTL suppression by mimicking CD4 T cell help 
through CD40 stimulation of DCs (Figure 4.13), indicating that additional signals by 
CD4 T cells are necessary to prevent inhibition of the CTL response. Indeed, the 
suppressive effect of DOTAP-complexed ssRNA was avoided in the presence of effector 
and memory antigen-specific CD4 T cells (Figure 4.14), which not only provide CD40-
CD40L signals, but license DCs in an antigen-specific manner through binding of the 
T cell receptor (TCR) to MHC class II molecules and/or secretion of cytokines. Future 
experiments are required to elucidate the exact mechanism and signals provided by 
CD4 T helper cells, which prevent ssRNA-induced suppression of cytotoxicity. A 
preliminary ex vivo DC/T cell coculture experiment already indicated, that activated 
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CD4 T cells have to be present during priming of CD8 T cells by DCs, as no OT-I T cell 
activation was observed, if splenic DCs were isolated from mice, that had been immunized 
with ssRNA and AdOVA in the presence of activated OVA-specific effector CD4 T cells. 
Based on our findings that intravenous injection of DOTAP-complexed ssRNA interfered 
with the induction of CD4 T cell help together with the fact that CD4 T cell help is crucial 
for the generation of long-lived and functional CD8 T cell memory (Janssen et al., 2003; 
Shedlock and Shen, 2003; Sun and Bevan, 2003; Williams and Bevan, 2007), it will be 
interesting to investigate if systemic TLR ligand treatment prior to the primary infection 
results in an impaired memory response upon re-encounter with the pathogenic antigen. 
We observed in a preliminary experiment that mice suffered from a high bacterial burden 
in response to OVA-expressing Listeria monocytogenes (LmOVA) rechallenge, if they had 
received DOTAP-complexed ssRNA prior to the primary infection with AdOVA. In 
contrast, mice that were immunized with AdOVA alone or had received in vivo-jetPEI
TM
- 
complexed ssRNA prior to AdOVA infection, had a lower bacterial burden, implying that 
the memory response was impaired in ssRNA/DOTAP-treated mice. However, further 
experiments have to be designed in order to characterize how systemic TLR ligands affect 
the generation of antigen-specific memory responses.  
 
 
5.1.3 ssRNA-induced CTL suppression requires type I interferon 
signaling 
 
Detection of viral nucleic acids by PRRs results in the induction of type I IFNs, which play 
a crucial role in directing antiviral defense as well as in linking the innate and adaptive 
immune response (Lund et al., 2004; Uematsu and Akira, 2007). Furthermore, the 
recognition of nonviral single-stranded RNA and siRNA by TLR7 leads to the production 
of type I IFNs (Diebold et al., 2004; Hornung et al., 2005; Judge et al., 2005). In agreement 
with these publications we detected a TLR7-dependent production of type I IFNs in sera 
and splenocyte supernants upon systemic injection of ssRNA (Figure 4.16).   
Moreover, we revealed that the suppression of the CTL response was ascribed to the 
induction of type IFNs (Figure 4.17 A-C). This finding constrasts the general association 
of type I IFNs with immune stimulation, as type I IFNs enhance DC maturation and 
promote the activation as well as differentiation of CD8 T cells by providing signal 3 
(Curtsinger et al., 2005; Le Bon et al., 2003; Luft et al., 1998; Montoya et al., 2002; 
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Nguyen et al., 2000; Nguyen et al., 2002). Despite their well-described stimulatory 
properties, also anti-inflammatory functions of type I IFNs have been described in several 
models of autoimmunity, such as multiple sclerosis or systemic lupus erythematosus (Hron 
and Peng, 2004; Karp et al., 2000; Katakura et al., 2005; Touil et al., 2006; Yarilina et al., 
2007). Furthermore, a negative regulation of CTL responses has been reported by the 
groups of Welsh and Reimann (Bahl et al., 2006; Bochtler et al., 2008; Dikopoulos et al., 
2005).  
As type I IFNs played an important role in ssRNA-induced suppression of the immune 
response, we aimed to further elucidate the underlying mechanisms. Using IFN-reporter 
mice (Scheu et al., 2008), we identified pDCs to immediately respond to TLR7-mediated 
recognition of ssRNA in vivo (Figure 4.18 A). Nevertheless, it is likely that pDCs 
additionally secrete IFN, as they express high constitutive levels of IRF7, a transcription 
factor described to initiate IFN production (Barchet et al., 2002; Coccia et al., 2004; Dai 
et al., 2004; Kawai et al., 2004). Our observation is in line with several studies reporting 
that pDCs produce vast amounts of early type I IFNs upon TLR stimulation, especially 
TLR7 and 9 (Asselin-Paturel et al., 2001; Asselin-Paturel and Trinchieri, 2005; Barchet et 
al., 2005b). Moreover, we could show that the elimination of pDCs augmented the CTL 
response in ssRNA and AdOVA immunized mice (Figure 4.18 C and D). These results 
substantiate the contribution of pDCs in ssRNA-induced suppression of antigen-specific 
CTL responses. However, pDC depletion did not result in a full recovery of the CTL 
response, which we assume is attributed at least in part to an incomplete depletion of 
pDCs. In addition, we cannot exclude that also other splenic cell populations, such as 
TLR7-expressing macrophages, react to ssRNA stimulation and produce early type I IFNs, 
especially IFN and IFN4 through activation of pre-existing IRF3, which is 
constitutively expressed (Applequist et al., 2002; Barchet et al., 2005b; Hassan et al., 
2009). We failed to detect IFN-producing macrophages in IFN-reporter mice, which 
might be due to low levels of IFN secreted by macrophages or due to production of 
IFN4, which cannot be detected in IFN-reporter mice.   
Next, we were interested in unveiling the cell types responding to ssRNA-induced 
type I IFNs. Several studies report a severe lymphopenia in early stages upon virus 
infection, which is ascribed to virus-induced type I IFNs (Bahl et al., 2006; Jiang et al., 
2005; McNally et al., 2001). Using Cre-mediated cell-specific type I IFN receptor deficient 
mice we could exclude a direct inhibitory effect of type I IFN on T cells. Rather, we 
revealed that ssRNA-induced CTL suppression was prevented in CD11c-specific as well as 
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LysM-specific IFNAR1 deficient mice (Figure 4.19). In the spleen, LysM expression is 
restricted to monocyte-derived macrophages. Therefore, LysM-specific IFNAR1 deficient 
mice lack the type I IFN receptor on splenic macrophages but not on DCs, which do not 
differentiate from monocyte precursors but rather develop from lymphoid origin 
(Jakubzick et al., 2008; Prinz et al., 2008; Stockinger et al., 2009; Varol et al., 2007). Thus, 
these results clearly showed that type I IFNs affected splenic macrophages and DCs.  
In addition, we analyzed which signaling molecules downstream of the type I IFN receptor 
were involved in the transmission of type I IFN-mediated inhibition of CTL responses. We 
detected that STAT1 and IRF7 played a crucial role, as CTL responses were present in 
STAT1 and IRF7 deficient mice in response to systemic DOTAP-stabilized ssRNA 
injection and adenovirus infection (Figure 4.20 A and C). Synthesis of early type I IFNs, 
presumably low levels of IFN4 and IFN, initiates a positive feedback loop via paracrine 
or autocrine stimulation of the JAK-STAT pathway through the type I IFN receptor. 
Signaling via STAT1 results in the induction and activation of the transcription factor 
IRF7, which in turn binds to the promoter regions of many IFN genes and induces the 
production of several delayed IFN isoforms (Levy et al., 2003; Marie et al., 1998; 
Prakash et al., 2005; Sato et al., 1998). Based on our result that CTL suppression was 
absent in LysM-specific type I IFN receptor deficient mice, we assume that the synthesis 
of IFN subtypes occurs via this amplification loop in splenic macrophages, which 
subsequently mediate the suppression of the CTL response. A role of splenic macrophages 
in type I IFN amplification is underlined by a recent study showing that type I IFNs in 
response to Listeria monocytogenes are amplified by a splenic cell type with the cell 
surface markers characteristic of macrophages (Stockinger et al., 2009). Nevertheless, 
further experiments are required to prove the involvement of splenic macrophages in the 
amplification of type I IFN in our studies. In future experiments, we will determine 
type I IFN levels upon systemic ssRNA stimulation in complete IFNAR1 deficient and 
LysM-specific IFNAR1 deficient mice. If the amplification of the type I IFN response 
depends on a feed-forward loop through the type I IFN receptor expressed by 
macrophages, low levels of systemic type I IFN, especially IFN, are expected in LysM-
specific IFNAR1 deficient mice. In addition, we will monitor MxA expression, which is 
induced by type I IFNs (Arnheiter et al., 1996; Roers et al., 1994; Staeheli et al., 1993), by 
histological stainings performed on spleen sections. A visible ring of MxA expression 
upon ssRNA stimulation in the marginal zone, where most splenic macrophages are 
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located (Mebius and Kraal, 2005; Mebius et al., 2004), would be a further indication that 
splenic macrophages are important for the amplication of the type I IFN response. 
A dominant role of IFN in ssRNA-induced immune suppression is substantiated by the 
observation that injection of ssRNA did not impede the CTL response in IFN and IRF3 
deficient mice. Strinkingly, the systemic injection of recombinant IFN (subtype ) did 
not result in a complete inhibition of the CTL response. We suppose that the moderate 
suppression of the CTL response might be either due to lower levels of circulating 
type I IFN compared to the amount that is stimulated by i.v. injection of ssRNA or due to a 
different subtype of IFN that is produced through the amplification loop. As there exist 
several IFN isoforms, it will be difficult to identify which specific IFN subtype 
mediates the suppressive effect on adaptive immunity.  
 
 
5.1.4 ssRNA-induced type I interferons impair IL-12 secretion and 
cross-priming of antigen-specific CD8 T cells by splenic DCs 
 
Phenotypic and functional maturation of DCs is essential for T lymphocyte activation and 
differentiation into T helper as well as into cytotoxic T lymphocytes (Akira et al., 2006; 
Banchereau and Steinman, 1998; Iwasaki and Medzhitov, 2004; Kawai and Akira, 2005). 
Our data obtained in transgenic mice lacking the type I IFN receptor on DCs, where CTL 
suppression by ssRNA was prevented, cleary demonstrated that ssRNA-induced type I IFN 
acted on DCs, which were negatively modulated in their ability to generate CTL responses.  
Although a slight decrease in splenic CD11c
high
CD8a
pos 
DCs, those known to cross-present 
antigens in vivo (den Haan et al., 2000), was detected upon ssRNA treatment, we assume 
that this had a minor influence on the lack of the CTL response as the number of DCs was 
still sufficient to stimulate a CD8 T cell response. Activation of T cells requires the 
maturation of DCs, which is characterized by the upregulation of costimulatory molecules 
CD80/86 and expression of CD40 on DCs. The latter is necessary to receive CD4 T cell 
help via CD40 and CD40L interactions. We observed that a systemic injection of ssRNA 
induced the upregulation of CD80, CD86, and CD40 on splenic CD11c
high
CD8a
pos
 DCs 
(Figure 4.21 B). Thus, we could rule out that an impaired DC maturation contributed to the 
inhibition of the CTL response. This is in agreement with recent studies reporting that 
systemic TLR ligands or type I IFN impede the generation of T cell responses despite a 
maturation of DCs (Longman et al., 2007; Wilson et al., 2006; Young et al., 2007). 
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Interestingly, we noticed a downregulation in MHC class II molecule expression on splenic 
DCs in response to ssRNA injection, which is in line with our finding that the induction of 
antigen-specific CD4 T cell responses was impeded.  
In addition to antigen presentation (signal 1) and costimulation by DCs (signal 2), the 
production of IL-12, as a signal 3, is crucial for the generation of an efficient and long-
lasting CD8 T cell response (Curtsinger et al., 2003a; Curtsinger et al., 2003b; Curtsinger 
et al., 1999; Schmidt and Mescher, 1999; Trinchieri, 1995, 2003). Indeed, IL-12 secretion 
by ssRNA pre-activated DCs was considerably diminished in response to CpG stimulation 
(Figure 4.22), which is consistent with reports describing that type I IFNs inhibit IL-12 
secretion by murine and human DCs (Cousens et al., 1997; McRae et al., 1998). It is likely 
that the reduction in IL-12 production after CpG stimulation is mediated by ssRNA-
induced type I IFNs. To confirm this assumption, we will analyze IL-12 secretion in 
IFNAR1 deficient mice upon systemic administration of DOTAP-complexed ssRNA and 
CpG administration.  
Beside the downregulation in MHC class II molecule expression and the reduction in IL-12 
production, we revealed that ssRNA pre-activated splenic DCs were impaired in their 
ability to cross-prime antigen-specific CD8 T cells ex vivo (Figure 4.23), which was 
overcome by exogenous provision of recombinant IL-12 (Figure 4.24 B). Again, the 
inability to activate antigen-specific CD8 T cells was dependent on type I IFNs, as cross-
priming of CD8 T cells by ssRNA pre-activated DCs isolated from IFNAR1 deficient mice 
was unaffected in response to AdOVA infection (Figure 4.24 A). These results strengthen 
the finding that ssRNA-induced type I IFN acts on DCs, thereby modulating their capacity 
to activate CD8 T cells. Our findings are supported by observations of Longman et al, 
showing in an in vitro system that immature human DCs exposed to type I IFNs are 
impaired in their ability to activate CD8 T cells via the cross-presentation pathway. In 
contrast, already matured DCs enhance T cell activation in the presence of type I IFNs 
(Longman et al., 2007). Likewise, the injection of DOTAP-complexed ssRNA after 
adenovirus infection did not inhibit the generation of a CTL response in our experiments. 
Our results and the findings by Longman et al suggest, that type I IFNs can exert 
contrasting effects on adaptive immunity depending on the timepoint. The opposing effects 
of type I IFN are not attributed to a differential expression of the type I IFN receptor 
(Longman et al., 2007), but rather seem to be mediated by distinct intracellular signaling 
pathways downstream of the type I IFN receptor. It has been demonstrated that inhibitory 
effects of type I IFN on immature DCs are mediated by signaling via STAT1, whereas the 
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immune stimulatory effects on mature DCs are triggered through signaling via STAT4 
(Longman et al., 2007). This view was supported by the observation that type I IFNs 
negatively regulate IFN expression in mice by activation of STAT1 (Nguyen et al., 2000), 
whereas STAT4 is involved in the transmission of stimulatory effects of type I IFNs and 
triggers the production of IFN in response to viral infections (Nguyen et al., 2002). 
Whether the suppressive effect of type I IFN on splenic DCs in our experiments is indeed 
transmitted via STAT1 will be difficult to investigate, as STAT1 deficient mice lack the 
positive feedback loop, which is essential to ensure the production of IFN, which leads to 
the suppression of the CTL response. In order to address this question, it will be necessary 
to use Cre-mediated DC-specific STAT1 deficient mice, which are not available at present.  
The inhibitory effect of ssRNA-induced type I IFN might be additionally attributed to 
differences in antigen uptake. So far, we have not examined whether antigen capture as 
such or time-kinetics of antigen uptake are altered. However, the absence of a CD8 T cell 
response cannot be soley ascribed to a substantial decrease in antigen uptake in ssRNA-
preactivated DCs, as we were able to circumvent ssRNA-induced CTL suppression in the 
presence of antigen-specific effector or memory CD4 T cells. Furthermore, 
supplementation of recombinant IL-12 in ex vivo DC/T cell coculture experiments induced 
T cell activation by ssRNA pre-activated splenic DCs. These results imply that the amount 
of antigen presented on MHC class I must have been sufficient for T cell activation at least 
in the presence of CD4 T cell help. Nevertheless, it will be interesting to compare antigen 
uptake and the amount of antigen cross-presented by immature or ssRNA-activated splenic 
DCs in response to AdOVA infection. 
 
 
5.1.5 ssRNA- and type I interferon-mediated suppression of antigen-
specific T cell responses – Summary and conclusion 
 
In Figure 5.1, our findings are summarized and we suggest a potential mechanism how 
systemic ssRNA stimulates the production of type I IFNs, which mediates the suppression 
of subsequent antigen-specific T cell responses in the spleen.  
(A) Upon systemic injection, DOTAP-complexed ssRNA is recognized in the endosome 
by TLR7-expressing pDCs in the spleen, which leads to the production of immediate-early 
IFN/ (1). Secreted IFN/ binds in a paracrine manner to the type I IFN receptor 
expressed by splenic macrophages, which initiates a positive feeback amplification loop 
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through the JAK-STAT pathway (2, 3). Signaling via STAT1 induces the formation of the 
transactivation complex ISGF3, which translocates to the nucleus and induces the 
transcription factor IRF7, which in turn stimulates the transcription and production of 
delayed IFN subtypes (4). Amplified IFN binds to the type I IFN receptor expressed on 
splenic DCs, thereby stimulating on the one hand the upregulation of costimulatory 
molecules CD80/86 as well as CD40, and on the other hand the downregulation of MHC 
class II expression (5). Upon encounter with a pathogen (e.g. adenovirus, HSV-1, 
Influenza virus, Listeria monocytogenes), ssRNA-activated DCs are impaired in IL-12 
production, in their ability to activate CD4 T cells, and to cross-prime CD8 T cells (6), 
which ultimately results in the lack of an antigen-specific CTL response (7). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
           Figure 5.1   Summary and mechanisms of ssRNA- and type I interferon-mediated  
                               CTL suppression in the spleen. 
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(B) In the presence of CD4 T cell help, provided by activated antigen-specific effector or 
memory CD4 T cells, ssRNA-induced inhibition of CTL responses is circumvented. We 
suppose that effector or memory CD4 T cells provide CD40-CD40L signals, but also 
license the DC in an antigen-specific manner through binding of the TCR to MHC class II 
molecules and trigger the secretion of important cytokines, such as IL-12 or IL-2. 
However, we do not know, which additional signals might be provided by activated 
CD4 T cells, that prevent ssRNA-induced CTL suppression. Possible candidates might be 
chemokines, which are secreted to recruit CD8 T cells to the site, where antigen-specific 
DC/CD4 T cell interaction occurs (Castellino et al., 2006). How exactly activated 
CD4 T cells help to prevent ssRNA-induced suppression of cytotoxicity remains to be 
determined. 
 
 
 
5.2 Relevance of RNA- and type I interferon-mediated suppression of 
adaptive CD8 T cell responses 
 
5.2.1 Therapeutic application of siRNA harbors the risk of immune 
suppression – Interference of siRNA application with induction of 
tumor-specific CTL responses 
 
Traditional ways of anti-cancer treatment include surgery, irradiation, and chemotherapy. 
However, recent studies offer a successful suppression of tumorigenicity by using siRNA 
mediated post-transcriptional gene silencing. For instance, it has been recently published 
that mitosis in cancer cells is disrupted by targeting of cell cycle proteins, such as KSP or 
PLK1 (Judge et al., 2009), and that apoptosis of cancer cells is initiated by silencing the 
anti-apoptotic protein Bcl-2 (Poeck et al., 2008). Another promising target that has come 
into the focus of cancer therapy is the vascular endothelial growth factor (VEGF), which is 
involved in tumor angiogenesis. Indeed, several studies have used gene silencing targeting 
VEGF-A mRNA in distinct tumor models in order to block angiogenesis (Filleur et al., 
2003; Jia et al., 2007; Kim et al., 2006; Kornek et al., 2008; Mulkeen et al., 2006; Shen et 
al., 2007; Shen et al., 2006; Takei et al., 2004). Recently, a dual function of siRNA 
application in tumor therapy has been discussed, which aims at the induction of innate 
immune stimulation in addition to a target-specific gene knockdown (Poeck et al., 2008). 
Indeed, numerous reports have revealed that unmodified siRNAs are recognized by nucleic 
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acid receptors, such as TLR7, and stimulate the innate immune system to produce pro-
inflammatory cytokines, like type I IFNs, TNF, and IL-6 (Judge et al., 2005; Robbins et 
al., 2008; Rossi, 2009; Sioud, 2005, 2006). 
Moreover, the induction of tumor-directed CTL responses constitutes a promising strategy 
for the prevention and treatment of malignancies. Induction of an effective tumor-specific 
CTL response can be achieved by vaccination with antigen-loaded DCs or with 
recombinant adenoviruses expressing tumor-associated antigens (Chen et al., 2003; Gallo 
et al., 2005; Gallo et al., 2007; Steitz et al., 2002; Steitz et al., 2001a; Steitz et al., 2001b; 
Steitz et al., 2006; Toes et al., 1997; Tuting et al., 1999). 
Owing to their plasticity, tumors tend to evade single-targeted therapeutic approaches. 
Therefore, it is reasonable that a combinatorial tumor-directed approach using siRNA-
mediated gene-silencing and innate immune stimulation together with an adenoviral-based 
vaccination would provide an efficient opportunity in tumor therapy.  
Importantly, we observed in a model of a combinatorial anti-tumor therapy that, depending 
on the carrier used, systemic in vivo siRNA injection (Filleur et al., 2003; Kornek et al., 
2008) abrogated a subsequent adenoviral-based tumor vaccination due to the lack of a 
tumor-specific CTL response, indicating that systemic siRNA application might result in 
undesired off-target effects (Figure 4.26). Positive off-target effects of siRNA application 
due to innate immune stimulation have been recently described in the study of Kleinman 
which shows, that siRNA targeting VEGF reduces choroidal neovascularization, a 
hallmark of age-related macula degeneration (AMD), which was not ascribed to gene 
silencing but was rather a consequence of TLR3-mediated recognition of siRNA and 
induction of IFN (Kleinman et al., 2008). In order to avoid unwanted off-target effects of 
siRNA we propose to use a carrier, such as in vivo-jetPEI
TM
, which targets siRNA to the 
cytoplasm and therby prevents recognition of siRNA by endosomally located TLR3 and 
TLR7. Another opportunity to prevent the failure of the adenovirus-based tumor 
vaccination would be to inject DOTAP-complexed siRNA after adenovirus immunization, 
as we have shown that the timing of systemic RNA oligonucleotide injection plays a 
crucial role whether a CTL response is generated or not. A preliminary experiment already 
revealed that systemic siRNA application post adenovirus injection promoted tumor 
regression. Nevertheless, this strategy may offer only limited success and is questionable, 
as the application temporally after the adenovirus immunization would eliminate the 
tumor, but may occur before a subsequent unknown infection, and thus is likely to cause 
immune suppression again. Recent publications offer another elegant possibility to 
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circumvent siRNA-mediated stimulation of the innate immune system by making use of 
chemically modified siRNAs, where 2’-O-methyl residues are incorporated into the 
siRNA’s backbone (Judge and MacLachlan, 2008; Judge et al., 2006; Robbins et al., 2007; 
Sioud et al., 2007). 
However, as mentioned above, new strategies are currently emerging where innate immune 
stimulation is desired in addition to gene silencing. In a study by Poeck et al a bifunctional 
siRNA was designed, which silenced Bcl-2 and additionally activated RIG-I (Poeck et al., 
2008), due to triphosphates attached to the 5’end (Hornung et al., 2006). Systemic 
treatment with this triphosphate-siRNA (pppsiRNA) resulted in a significant reduction in 
metastatic growth of a melanoma, which was attributed to the synergistic effects of RIG-I-
mediated innate immune stimulation and siRNA-mediated Bcl2 silencing that provoked 
massive apoptosis in tumor cells (Poeck et al., 2008). A major drawback of a systemic 
application of pppsiRNA, which was not considered in this publication, is that the 
intravenous injection of pppsiRNA results in the suppression of subsequent cytotoxic 
T cell responses due to the induction of type I IFNs by RIG-I activation (unpublished 
observation). Therefore, we attempt to circumvent a suppression of adaptive immune 
responses by targeting pppsiRNA exclusively to the liver. Indeed, it has been shown that 
LDL-cholesterol-modified siRNA is efficiently taken up in the liver and silences apoB 
protein expression in vivo (Wolfrum et al., 2007). Using similar approaches, we intend to 
induce a local production of type I IFNs, which may result in a synergistic effect of innate 
immune stimulation and target-specific gene knockdown, without interfering with 
subsequent adaptive immune responses, offering a powerful treatment of liver tumors or 
chronic viral liver infections.    
Taken together, we demonstrate that systemic siRNA application might lead to undesired 
off-target effects such as immune suppression. In order to avoid these unwanted side 
effects we suggest to carefully consider how to use siRNA in therapeutic applications.  
 
 
5.2.2 Influenza virus infection inhibits the CTL response against a 
subsequent adenovirus infection in a type I interferon dependent 
manner 
 
It is known that certain viral infections result in a temporary lack in cell-mediated immune 
responses, which is frequently ascribed to the effects of virus-induced type I IFNs (De 
Maeyer et al., 1975; De Maeyer-Guignard et al., 1975). Several reports demonstrate, that 
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viral infections can elicit negative impacts on DCs by interfering with their differentiation, 
expansion, and maturation or by induction of apoptosis (Andrews et al., 2001; Hahm et al., 
2005; Li et al., 2002; Salio et al., 1999; Sevilla et al., 2004). However, not only DCs are 
the targets of virus-induced immunosuppression, as virus-induced type I IFNs are able to 
induce apoptosis in T cells or inhibit T cell proliferation upon measles virus infection (Bahl 
et al., 2006; Hahm et al., 2003; Jiang et al., 2005; McNally et al., 2001; Sun et al., 1998). 
We could show that an infection with Influenza virus inhibited the generation of a 
cytotoxic T cell response against a subsequent adenovirus infection in a type I IFN 
dependent manner (Figure 4.27). Consequently, these results imply that viruses, known to 
trigger type I IFNs, might inhibit adaptive immune responses towards following infections 
in a similar fashion as we have described for systemic ssRNA injection. It remains to be 
determined, whether Influenza virus infection impedes subsequent adaptive immune 
responses due to an impaired cross-priming of CD8 T cells and CD4 T cell help.  
 
 
 
5.3 Concluding Remarks 
 
The findings presented within this thesis demonstrate that ssRNA- and virus-induced 
type I IFNs cannot only stimulate, but also inhibit antigen-specific T cell responses in the 
spleen, depending on the timing of administration. Although immune suppression is 
generally not desired, it might be that the induction of immune suppression represents a 
type of “emergency shutdown” that is initiated when circumstances of TLR activation or 
infection poses a serious danger by excessive inflammation for the host. Furthermore, 
immune suppression against a subsequent infection may enable the immune system to cope 
with the initial infection first before fighting against the following one.  
In addition, we indicate that a therapeutic application of siRNA, which can be recognized 
by nucleic acid receptors, might have off-target effects that result in immune suppression. 
Our findings will contribute to a better understanding how to design and apply siRNA in 
the clinics in order to avoid undesired off-target effects.  
Moreover, we think that TLR-dependent induction of immune suppression by recognition 
of endogenous ligands, as it has been observed for immunocomplexed “self” RNA or DNA 
by TLR7/8 or TLR9, respectively, represents an ongoing physiological mechanism to 
prevent potentially undesired or even harmful immune responses.  
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